



US 20180282701A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2018/0282701 A1**

Kim et al. (43) **Pub. Date: Oct. 4, 2018**

(54) **METHOD TO REDUCE ONCOGENIC POTENTIAL OF INDUCED PLURIPOTENT STEM CELLS FROM AGED DONORS**

(71) Applicant: **MEMORIAL SLOAN-KETTERING CANCER CENTER**, New York, NY (US)

(72) Inventors: **Kitai Kim**, New York, NY (US); **Maria Skamagki**, New York, NY (US); **Yildirim Dogan**, New York, NY (US)

(21) Appl. No.: **15/517,014**

(22) PCT Filed: **Oct. 6, 2015**

(86) PCT No.: **PCT/US2015/054319**

§ 371 (c)(1),

(2) Date: **Apr. 5, 2017**

Related U.S. Application Data

(60) Provisional application No. 62/060,532, filed on Oct. 6, 2014, provisional application No. 62/121,463, filed on Feb. 26, 2015, provisional application No. 62/121,460, filed on Feb. 26, 2015.

Publication Classification

(51) **Int. Cl.**
C12N 5/074 (2010.01)
C12N 15/85 (2006.01)
C07K 14/47 (2006.01)


(52) **U.S. Cl.**
CPC *C12N 5/0696* (2013.01); *C12N 15/85* (2013.01); *C07K 14/4702* (2013.01); *C12N 2501/71* (2013.01); *C12N 2501/608* (2013.01); *C12N 2501/606* (2013.01); *C12N 2501/605* (2013.01); *C12N 2501/603* (2013.01); *C12N 2501/602* (2013.01); *C12N 2501/50* (2013.01); *C12N 2501/998* (2013.01); *C12N 2510/00* (2013.01); *C12N 2501/604* (2013.01)

(57) **ABSTRACT**

Disclosed are findings that: (a) induced pluripotent stem cells derived from aged donors (A-iPSC) show increased genomic instability, a defect in apoptosis, a defect in glucose metabolism, and a blunted DNA damage response are compared to those derived from young donors (Y-iPSC); and (b) inhibition of excessive glutathione-mediated H₂O₂ scavenging activity, found to be associated with A-iPSC and in turn inhibiting DNA damage response and apoptosis, substantially rescues these defects and reduces the oncogenic potential of A-iPSC. Supplementation of pluripotency factor ZSCAN10 (shown to be poorly activated in A-iPSC and to act upstream of glutathione involvement), e.g., by expression as an adjunct to the four Yamanaka iPSC reprogramming factors, led to substantial recovery of genomic stability, DNA damage response, and apoptosis in A-iPSC through enhancing GLUT3 and normalizing homeostasis of glutathione/H₂O₂; GLUT3 (a pluripotent stem cell-specific glucose transporter acting upstream of glutathione and also poorly activated in A-iPSC) has similar effects, indicating that inhibition of glutathione/H₂O₂ notably through delivery of ZSCAN 10 and/or GLUT3 and/or an exosome subunit will be clinically useful, resulting in A-iPSC of improved properties and reduced oncogenic potential.

Specification includes a Sequence Listing.

FIGURES 1A and 1B



FIGURES 1C and 1D





FIGURE 1E



FIGURES 1F AND 1G




FIGURE 2




FIGURE 3






FIGURE 4




FIGURES 5A-5E


A




ESC (n=6)




Y-IPSC (n=12)




A-IPSC (n=28, 48%)



A-IPSC (n=30, 52%)



FIGURES 6A-6C



Figures 6D-6E










FIGURE 7A-7B




FIGURES 8A-8B




FIGURES 9A-9B






FIGURES 9C-9D



FIGURES 10A-10B




FIGURES 10C-10E



FIGURES 10F-10G

F



G




FIGURE 11




FIGURE 12




FIGURE 13 A-D




FIGURE 13 E-H







FIGURE 13 I



FIGURES 14A-14D



FIGURES 14E-14F







FIGURE 14G

FIGURES 15A-15C



**METHOD TO REDUCE ONCOGENIC
POTENTIAL OF INDUCED PLURIPOTENT
STEM CELLS FROM AGED DONORS**

CROSS REFERENCE TO RELATED
APPLICATIONS

[0001] This application claims priority to the following three U.S. Provisional Patent Applications: No. 62/060,532 filed Oct. 6, 2014; No. 62/121,460 and No. 62/121,463 both filed Feb. 26, 2015. The contents of each application are incorporated by reference herein.

GOVERNMENT SPONSORED RESEARCH OR
DEVELOPMENT

[0002] The work described in this disclosure was funded in part by grants from the National Institutes of Health, 5R00HL093212-04; and P30 CA008748 and RO1 5R01AG043531-02. The U.S. government may have certain rights in this disclosure.

SEQUENCE LISTING

[0003] The present application includes a sequence listing in electronic form as a txt file in ascii format titled "7704-0021-PCT_ST25[3].txt" and having a size of 133.7 kb. The contents of this txt file are incorporated by reference herein.

BACKGROUND OF THE DISCLOSURE

Field of the Disclosure

[0004] This disclosure relates to improvements in induced pluripotent stem cells and more specifically to induced pluripotent stem cells having reduced oncogenic potential and/or improved apoptosis response, and/or improved DNA damage response and/or improved genomic stability.

Description of the Related Art

[0005] Direct reprogramming of somatic cells, for example with the transcription factors Oct4, Sox2, Klf4, and c-Myc1 (also known as the Yamanaka protocol), yields induced pluripotent stem cells (iPSC) with remarkable similarity to embryonic stem cells (Takahashi et al. *Cell* 126: 663-676, 2006). Other protocols for making iPSC are known, as described for example in González, F. et al. *Nature Reviews Genetics* 12: 231-242 (Apr. 1, 2011). Analogous to ES cells, iPSC form teratomas, differentiated tumors with tissues from all three embryonic germ layers, and contribute to all tissues when injected into murine blastocysts.

[0006] Derivation of patient-specific iPSC for several disorders has been reported (Part et al. *Cell* 134:877-86, 2008; Dimos et al. *Science* 321: 1218-21, 2008). Development of iPSC provides opportunities for disease modeling using patient derived iPSC and directed differentiation methods. Additional areas that can greatly benefit from iPSC are drug development and drug screening. Finally, considering that iPSC resemble ESC in the pluripotency potential, but circumvent the histo-incompatibility issues associated with ESC-based therapies, iPSC hold enormous potential for generating histo-compatible transplantable tissue using a patient's own somatic cells.

[0007] According to the United Network for Organ Sharing (UNOS), approximately 120,000 Americans are currently waiting to receive organ transplants, but only 24,000 transplants were performed between January and October of 2013. UNOS estimates that 18 patients die each day while waiting for an immune-matched organ from a small number of donors.

[0008] iPSC are useful in many different ways: first, as research tools, they enable otherwise inaccessible experiments to link gene function to tissue formation; second, they offer a new approach to drug discovery and development including both screening and toxicity testing as iPSC can be differentiated into human cells of different tissues and organs. But the most important utility of iPSC is in organ and tissue generation for engraftment, to replace missing or nonfunctioning organs and tissues and to treat degenerative diseases, including without limitation those associated with an aging population.

[0009] While iPSC offer great opportunities, there are still many unexplored questions and hindrances related to their application in clinical setting. For example, different tissues show variable susceptibility to reprogramming (Maherli et al. *Cell Stem Cell* 3:340-345, 2008; Aoi et al. *Science* 321: 699-702, 2009). Additionally, recent studies have shown that iPSC contain a residual epigenetic signature depending on the tissue type of the donor tissue used (Kim et al. *Nat Biotechnol* 29(12): 1117-1119, 2011) and that iPSC from aged donors (A-iPSC) retain an aging-specific epigenetic memory (Kim et al. *Nature* 467(7313):285-290, 2010). Furthermore, while Yamanaka and others identified four iPSC reprogramming factors required for generating iPSC using young donor tissue (Y-iPSC), it is not clear whether the same four factors would be sufficient for reprogramming iPSC from aged donor tissue (A-iPSC).

[0010] Prigione, A. et al *PLoS One*. 2011; 6(11):e27352. doi: 10.1371/journal.pone.0027352 also reported the presence of karyotype aberrations in aged-iPSC from humans although in their experiment they did not find resistance to apoptosis. These investigators measured micro-nuclei formation which is an indicator of a cell under apoptotic process as opposed to the fact of cell death (apoptosis) itself. Also lactate dehydrogenase was used for normalization which would not permit detection of already dead cells. Lastly, the time interval between DNA damage infliction and measurement may have been too long. Nevertheless, these authors also stressed the importance of developing reprogramming protocols that preserve the genomic stability of aged somatic cells.

[0011] As older patients are more likely to benefit from the clinical application of iPSC in tissue regeneration and both heterologous and autologous transplantation, and because iPSC are already being studied in clinical trials of a number of aging-related degenerative diseases, such as macular degeneration and Parkinson's disease, there is a significant need to comprehensively evaluate A-iPSC and determine how to reverse the negative effects of aging in these cells in order to improve their quality and consequently their function upon differentiation and transplantation.

[0012] One of the recognized drawbacks of iPSC has been their potential oncogenicity. This has been variously putatively ascribed to the use of oncogenes to generate them and possibly to the use of integrating viral-based vectors. As a result, efforts have been devoted to avoiding the use or integration of oncogenes and to avoiding the use of viral

vectors. See, for example Nakagawa, M. et al *Nat Biotechnol.* 2008 January; 26(1):101-6 for reprogramming without MYC. Other researchers have turned to nonintegrative viruses such as Sendai virus to generate iPSC: Chen I P et al (2013) Induced Pluripotent Stem Cell Reprogramming by Integration-free Sendai Virus Vectors from Peripheral Blood of Patients with craniometaphyseal dysplasia, *Cell Reprogram.* 2013 December; 15(6):503-13; and Lieu P T et al (2013) Generation of Induced Pluripotent Stem Cells with CytoTune, a Non-Integrating Sendai Virus, *Methods Mol. Biol.* 2013; 997:45-56 (from blood cells or fibroblasts). Yet others use RNA-based (vector-free) methods and tools for this purpose (such as B18R protein) are commercially available: see, e.g., Affymetrix eBioscience <http://www.ebioscience.com/knowledge-center/cell-type/induced-pluripotent-stem-cells.htm#benefits%20of%20ma>; or Warren, L. et al Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA, *Nature Scientific reports*, 2:#657 (Sep. 14, 2012). Yet others have used protein: Kim, D. et al, Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins, *Cell Stem Cell.* 2009 Jun. 5; 4(6):472-6. However, these methods may suffer from low reprogramming efficiency while oncogenicity can persist. Moreover, prior reprogramming efforts did not take into account age of donor cells in considering oncogenicity. Nor have there been proposals to use any additional factor as an adjunct to the reprogramming protocol.

SUMMARY OF THE DISCLOSURE

[0013] In one aspect, the disclosure provides a method for improving at least one of DNA damage response, apoptosis response, genomic stability and glucose metabolism of A-iPSC, the method comprising supplementing A-iPSC with at least one of (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter GLUT3; and (iii) an exosome subunit, each as an adjunct to reprogramming of the A-iPSC to substantially restore said at least one of DNA damage response, apoptosis response, glucose metabolism and genomic stability to levels approximating those of Y-iPSC.

[0014] In some embodiments, excessive expression of GSS or GPX2 is inhibited by at least one of the following:

[0015] supplementing A-iPSC with pluripotency factor ZSCAN10; and/or

[0016] supplementing A-iPSC with pluripotent stem cell-specific glucose transporter 3 GLUT3; and

[0017] supplementing A-iPSC with an exosome subunit.

wherein the supplementation is an adjunct to reprogramming pluripotency factors and is in an amount effective to accomplish total or partial rescue in one or more of DNA damage response, apoptosis, and genomic stability in said A-iPSC.

[0018] In another aspect, the disclosure provides a method for reducing the oncogenic potential of induced pluripotent stem cells (iPSC) said cells having one or more of genomic instability, a defect in apoptosis, a defect in DNA damage response and a defect in glucose metabolism and exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to embryonic stem cells or induced pluripotent stem cells from young donors (Y-iPSC), the method comprising:

[0019] inhibiting glutathione-mediated H₂O₂ scavenging activity in said iPSC to partially or totally restore

homeostasis in said iPSC by directly and/or indirectly inhibiting excessive expression of glutathione peroxidase 2 (GPX2) in said iPSC.

[0020] In yet another aspect, the disclosure provides a method for reducing the oncogenic potential of induced pluripotent stem cells derived from aged donors (A-iPSC) said A-iPSC exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to induced pluripotent stem cells derived from young donors (Y-iPSC), the method comprising:

[0021] inhibiting glutathione-mediated H₂O₂ scavenging activity in said A-iPSC to partially or completely restore glutathione/H₂O₂ homeostasis in said A-iPSC by directly and/or indirectly inhibiting excessive expression of glutathione peroxidase 2 (GPX2) in said A-iPSC.

[0022] In still another aspect, the disclosure provides a method for reducing the oncogenic potential of induced pluripotent stem cells (iPSC) said cells having one or more of genomic instability, a defect in apoptosis, a defect in DNA damage response and a defect in glucose metabolism, and exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to embryonic stem cells or induced pluripotent stem cells from young donors (Y-iPSC), the method comprising supplementing A-iPSC with at least one of (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter GLUT3; and (iii) an exosome subunit, each as an adjunct to reprogramming to substantially restore said at least one of DNA damage response, apoptosis response, glucose metabolism and genomic stability to levels substantially the same as those of Y-iPSC or ESC.

[0023] In some embodiments, the supplementation is carried out by adding ZSCAN 10 and/or GLUT3 and/or an exosome subunit to a culture medium in which said A-iPSC are maintained.

[0024] In some embodiments, the supplementation is carried out by increasing the expression of ZSCAN10 and/or GLUT3 and/or an exosome subunit in said cells.

[0025] In some embodiments, the supplementation is sufficient to restore ZSCAN 10 and/or GLUT3 and/or exosome subunit levels in said A-iPSC to about 50% or more of the respective levels of embryonic stem cells (ESC).

[0026] In some embodiments, the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to within the range from about 80% to about 120% of that of ESC.

[0027] In some embodiments, the supplementation is sufficient to restore genomic stability of said A-iPSC to approximately that of Y-iPSC.

[0028] In some embodiments, genomic stability is measured by incidence of aneuploid clones.

[0029] In some embodiments, the apoptosis rate is measured by DNA fragmentation assay in response to a DNA damaging agent.

[0030] In some embodiments, DNA damage response is measured by ATM or H2AX phosphorylation in response to a DNA damaging agent.

[0031] In some embodiments, the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to approximately that of Y-iPSC.

[0032] In some embodiments the supplementation is sufficient to reduce GSS or GPX2 levels in said A-iPSC to approximately those of Y-iPSC.

[0033] In some embodiments the expression of ZSCAN10 and/or GLUT3 and/or an exosome subunit in said cells is increased by transfecting said cells with a vector harboring nucleic acid for said ZSCAN10 and/or GLUT3 and/or an exosome subunit.

[0034] In some embodiments, expression of said vector harbored nucleic acid encoding ZSCAN10 is transient.

[0035] In some embodiments, the reprogramming factors are the Yamanaka factors OCT4, SOX2, KLF4 and MYC.

[0036] In some embodiments, the reprogramming pluripotency factors are selected from the group of those of Yamanaka wherein one or more of OCT4, SOX2, KLF4 and MYC are replaced as follows:

[0037] Factors(LIN28+Nanog,Esrrb,Pax5shRNA,C/EBPa,p53.siRNA,UTF1,DNMTshRNA,Wnt3a,SV40LT(T),hTERT)or chemicals(BIX-01294, BayK8644,RG108,AZA,dexamethasone, VPA,TSA, SAHA,PD025901+CHIR99021(2i), A-83-01).

[0038] In some embodiments the reprogramming pluripotency factors are selected from the group of those of Yamanaka wherein one or more of OCT4, SOX2, KLF4 and MYC are replaced as follows: Nanog and Lin28 replace Klf4 and MYC; esrb replaces Klf4; SV40 LT (T) replaces Klf4, MYC, lin28 and Nanog; BIX-01294 replaces SOX2, and OCT4; VPA replaces Klf4 and MYC.

[0039] In some embodiments, the supplementation is with an exosome subunit, the exosome subunit being one or more of the following EXOSC1, EXOSC2, EXOSC3, EXOSC4, EXOSC5, EXOSC6, EXOSC7, EXOSC8, EXOSC9, EXOSC10 and hDis3.

[0040] In some embodiments, the supplementation is by DNA gene transfer or by RNA delivery or by delivery of proteins into the A-iPSC.

[0041] In another aspect, the present disclosure provides an iPSC derived from a somatic cell of an aged donor where the iPSC has been engineered to express ZSCAN10 at levels comparable to an iPSC derived from a young healthy donor.

[0042] In another aspect, the present invention comprises one or more vectors comprising nucleic acid encoding (i) stem cell reprogramming factors and (ii) ZSCAN10.

[0043] Thus, as a result of the work described herein, ZSCAN10 has emerged as a major co-regulatory factor of reprogramming protocols to make induced pluripotent stem cells from somatic cells, especially but not exclusively from somatic cells of aged donors, which upon reprogramming using the existing protocols would be deficient in ZSCAN10, GLUT3 or an exosome subunit.

[0044] Accordingly, in another aspect, the present disclosure provides an iPSC derived from a somatic cell where the iPSC in the absence of ZSCAN10 supplementation would be deficient in ZSCAN10 expression, expressing either no ZSCAN10 or a level of ZSCAN10 substantially lower than that of a control iPSC derived from a healthy young donor, wherein the iPSC has been engineered to express ZSCAN10 levels comparable to those of an iPSC derived from a healthy young donor.

[0045] In a related aspect, the present disclosure is directed to an iPSC derived from a somatic cell said iPSC originally displaying one or more of (i) reduced ZSCAN10 expression level, (ii) increased oncogenic potential (as measured for example by reduced DNA damage response, reduced apoptosis response, genomic instability and reduced glucose metabolism), (iii) reduced GLUT3 expression level;

(iv) reduced exosome subunit level; and (v) increased GPX2 or increased GSS expression level, compared to a Y-iPSC or ESC control, wherein the iPSC has been supplemented with ZSCAN10 to restore said one or more reduced or increased levels to levels substantially closer to those encountered in said control.

[0046] In another aspect the present disclosure is directed to a vector or set of vectors comprising nucleic acid encoding (i) reprogramming pluripotency factors and (ii) ZSCAN10. In a more specific embodiment, the disclosure relates to a set of vectors according to claim 38 wherein the vector comprising ZSCAN10 nucleic acid is a separate vector from the vector or vectors comprising the reprogramming factors nucleic acid.

[0047] In some embodiments, the present disclosure is directed to a method for assessing the quality of an iPSC comprising measuring or testing the expression level of one or more proteins selected from the group of ZSCAN10, GLUT3, an exosome subunit (such as a core exosome subunit), GPX2 and GSS and comparing it to a control expression level of the same protein in Y-iPSC or ESC; and determining said quality on the basis of whether the measured or tested expression level is substantially similar to the control expression level. In more specific embodiments the quality assessed is one or more of oncogenic potential or glutathione/hydrogen peroxide homeostasis.

BRIEF DESCRIPTION OF THE DRAWINGS

[0048] FIGS. 1A-1G show karyograms of ESC (FIG. 1A), Y-iPSC (FIG. 1B), A-iPSC-ZSCAN10 (FIG. 1C), and A-iPSC (FIGS. 1D and 1E). FIG. 1F is a bar graph showing a higher frequency of polyploidy in multiple independent clones of A-iPSC, and rescue of polyploidy defect with ZSCAN10 expression. DNA content was estimated by Propidium Iodide (PI) staining followed by flow cytometry analysis of multiple independent clones. The number of clones analyzed is indicated in each group. Statistical significance was determined by chi-squared test. FIG. 1G is a dot plot of a number of chromosomal structural abnormalities observed by cytogenetic analysis in each A-iPSC clone, and rescue with ZSCAN10 expression. Error bars indicate standard error of the mean of four independent clones analyzed per group. The total number of metaphases analyzed is indicated in each group. Statistical significance was determined by t-test.

[0049] FIG. 2 is a dot plot showing image-quantification of lower apoptotic response by DNA fragmentation assay after phleomycin treatment (30 µg/ml for 2 hours) in ESC, Y-iPSC, A-iPSC, and recovery with ZSCAN10 expression (A-iPSC-ZSCAN10). Error bars indicate standard error of the mean of technical and biological replicates. The exact number of biological replicates is indicated below each group.

[0050] FIG. 3 is a schematic representation of a method used to identify ZSCAN10. Initially, 59 core pluripotency genes derived from the pluripotency network analysis were filtered against genes that are known to be associated with DNA damage response, such as p53, SIRT1, PLK1, and genes upstream of p53 (ATM, PARP, and DNAPK). The gene list was then filtered based on differential expression in A-iPSC vs. Y-iPSC/ESC, which narrowed down the candidates to a single gene, ZSCAN10.

[0051] FIG. 4 is a bar graph showing poor activation of ZSCAN10 expression in A-iPSC and complete reactivation

with transient expression of ZSCAN10. Endogenous ZSCAN10 mRNA levels were determined by Q-PCR in ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10. Endogenous ZSCAN10 levels were normalized to β -ACTIN. Error bars indicate standard error of the mean. Statistical significance was determined by t-test.

[0052] FIG. 5A is a bar graph showing increased mutagenic frequency in A-iPSC compared to ESC and Y-iPSC. The mutation frequency was estimated by the inactivation of HPRT promoter activity in the presence of 6-thioguanine-mediated negative selection, and confirmed by Q-PCR. Higher mutation frequency observed in A-iPSC was decreased to normal levels following ZSCAN expression. Error bars indicate standard error of the mean of three replicates. Statistical significance was determined by t-test. FIG. 5B-5E show hematoxylin and eosin (H&E) staining of teratomas indicating higher *in vivo* oncogenicity of A-iPSC compared to ESC and Y-iPSC. Teratoma analysis was carried out by injecting 10^6 undifferentiated cells into the subcutaneous tissue above the rear haunch of Rag2/yC immunodeficient mice (Taconic), and teratoma formation was monitored for 3 months post-injection. Collected tumors were fixed in 10% formalin solution and processed for hematoxylin and eosin (H&E) staining. ESC (FIG. 5B) and Y-iPSC (FIG. 5C) form Y-iPSC form benign teratoma containing various tissue types that develop into cystic structures, with no signs of carcinoma. In contrast, 48% (n=28) (FIG. 5D) of individual A-iPSC clones generated a mixture of malignant carcinoma and benign teratoma tissues, and 52% (n=30) (FIG. 5E) of A-iPSC clones contained only teratocarcinoma.

[0053] FIG. 6 are immunoblots showing impaired DNA damage response in A-iPSC compared with Y-iPSC and ESC, and permanent restoration following transient expression of ZSCAN10. Reduced ATM phosphorylation was observed in A-iPSC after phleomycin treatment (2 h, 30 μ g/ml), and recovery of ATM activation upon ZSCAN10 expression (FIG. 6A). FIG. 6B shows impaired p53 DNA damage response in A-iPSC and recovery with transient expression of ZSCAN10 in three independent clones after phleomycin treatment (2 h, 30 μ g/ml). The red line indicates the same ESC sample loaded in both immunoblots as an internal control. FIG. 6C indicates low H2AX phosphorylation in A-iPSC after phleomycin treatment (2 h, 30 μ g/ml) and recovery of H2AX signal with ZSCAN10 expression. FIG. 6D are scanned images of immunoblots showing phosphorylated levels of ATM and H2AX proteins, and levels of p53 in ATM-/-H2AX-/- ESC, A-iPSC, Y-iPSC, and in Y-iPSC transduced with shRNA against ZSCAN10 (Y-iPSC-shZSCAN10). Beta-actin was used as a loading control. FIG. 6E is a bar graph of mRNA ZSCAN10 levels in fibroblasts, ESC, Y-iPSC and Y-iPSC-shZSCAN10. FIG. 6F is a scanned image of an immunoblot indicating phospho-ATM, pH2AX, and p53 levels in ESC, Y-iPSC, A-iPSC and A-iPSC-ZSCAN10 following radiation treatment. FIG. 6G is a scanned image of an immunoblot of pATM and beta-actin in ESC, Y-iPSC, A-iPSC and A-iPSC-ZSCAN10 following the treatment with H₂O₂.

[0054] FIG. 7 is a scatter plot showing higher DNA methylation of ZSCAN promoter in A-iPSC compared to ESC and Y-iPSC. FIG. 7A is a plot of pyrosequencing data of ZSCAN10 promoter, indicating relatively higher DNA methylation in A-iPSC. Transient expression of ZSCAN10 led to lower DNA methylation of ZSCAN promoter

(A-iPSC-ZSCAN10). Error bars indicate standard error of the mean of four independent clones analyzed per group. Statistical significance was determined by t-test. FIG. 7B is a bar graph showing mRNA levels of DNMT3b normalized to beta-actin in fibroblasts, A-iPSC, A-iPSC-ZSCAN10, Y-iPSC, and ESC.

[0055] FIG. 8A is a bar graph showing excessive oxidation capacity of glutathione in A-iPSC, and recovery by ZSCAN10. Quantification of reduced glutathione (GSH) and oxidized glutathione (GSSG) was used to determine the total glutathione level (maximum oxidation capacity) in ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10. Mean \pm standard deviation is plotted for three replicates from each condition. FIG. 8B is a bar graph indicating H₂O₂ scavenging activity of ESC, Y-iPSC, A-iPSC-ZSCAN10, and A-iPSC expressed as reactive oxygen species ROS activity. A cellular reactive oxygen species assay kit (Abcam, ab113851) was used to measure the H₂O₂ scavenging activity after the treatment with TBHP (tert-butyl hydrogen peroxide; stable chemical form of H₂O₂) for 3 hours at 50 μ M. Mean \pm standard deviation is plotted for four replicates from each condition.

[0056] FIG. 9A is a bar graph showing mRNA levels (determined by Q-PCR) of GPX2 in ESC, Y-iPSC, A-iPSC-ZSCAN10, A-iPSC-GLUT3, and A-iPSC. Error bars indicate standard error of the mean. FIG. 9B is a bar graph of oxidation capacity of glutathione in ESC, Y-iPSC, Y-iPSC-GPX2, A-iPSC, A-iPSC-ZSCAN10, and A-iPSC-shRNA-GPX2. Quantification of reduced glutathione (GSH) and oxidized glutathione (GSSG) was measured to determine the total glutathione level (maximum oxidation capacity). Mean \pm standard deviation is plotted for three replicates from each condition. Glutathione analysis was conducted using Glutathione Fluorometric Assay (Biovision, K264-100). FIG. 9C is a bar graph showing H₂O₂ scavenging activity in ESC, Y-iPSC, Y-iPSC-GPX2, A-iPSC, A-iPSC-ZSCAN10, and A-iPSC-shRNA-GPX2 after the treatment with TBHP (tert-butyl hydrogen peroxide; stable chemical form of H₂O₂) for 3 hours at 50 μ M. Mean \pm standard deviation is plotted for four replicates from each condition. FIG. 9D is bar graph showing TUNEL-positive apoptotic cells (TMR-DUTO) in ESC, Y-iPSC, Y-iPSC-GPX2, A-iPSC, A-iPSC-ZSCAN10, and A-iPSC-shRNA 15 hours after the end of phleomycin treatment (2 hours, 30 μ g/ml). FIG. 9E is an immunoblot of pATM/pH2AX/p53 showing recovery of the DNA damage response (p-ATM, pH2AX and p53) after phleomycin treatment in three independent clones of A-iPSC with GPX2 shRNA and in controls (ATM and H2AX knockdown ESC as well as Y-iPSC and A-iPSC with and without phleomycin).

[0057] FIG. 10A is a bar graph showing real time qPCR for mRNA of GLUT3 in somatic cells (fibroblast samples from young and aged donors), ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10. FIG. 10B is a bar graph showing intracellular glucose uptake rate in ESC, Y-iPSC, A-iPSC, A-iPSC-ZSCAN10, and A-iPSC-GLUT3. Glucose uptake rate was measured by a glucose uptake analysis kit (cat#K606-100, Biovision Inc., Milpitas, Calif., USA). FIG. 10C is a bar graph of activation of the oxidative phosphorylation by glutamine A-ntESC (ES cells generated using nuclear transfer method), ESC, Y-iPSC, A-iPSC, A-iPSC-ZSCAN10, and A-iPSC-GLUT3. Oxygen consumption rate was determined after adding glutamine to a final concentration of 4 mM. FIG. 10D is an immunoblot of ATM showing

recovery of the DNA damage response after phleomycin treatment in three independent clones of A-iPSC with increased GLUT3 expression compared to controls (ESC, ATM knockdown in ESC, Y-iPSC and A-iPSC). FIG. 10E a graph showing Chromatin IP analysis of ZSCAN10 binding to the GLUT3 promoter. ESC, Y-iPSC, or A-iPSC were incubated with Igg control or ZSCAN10 antibody, followed by the qPCR using primers specific for GLUT3 promoter. FIG. 10F is a bar graph of ROS levels in ESC, Y-iPSC, A-iPSC, Y-iPSC expressing shRNA against GLUT3 (Y-iPSC-shGLUT3), and A-iPSC expressing shRNA against GLUT3 (A-iPSC-shGLUT3).

[0058] FIG. 11 A is a histogram showing statistical probability to find 14 genes with ARE-sequences by random resampling as disclosed in Kim, K. et al *Nature*. 2010 Sep. 16; 467(7313):285-90. doi: 10.1038/nature09342. Epigenetic memory in induced pluripotent stem cells.

[0059] FIG. 11B is a series of bar graphs showing relative mRNA levels (normalized to β -actin) of exosome subunits EXOSC1, EXOSC2, and EXOSC5 in FESC, Y-iPSC, A-iPSC-ZSCAN10 (A-iPSC supplemented with ZSCAN10, and A-iPSC. The histogram indicates that the likelihood of any given transcript to have the UUAUUUA(A/U)(A/U) ARE sequence is 7, so the odds of finding 14 in a sample based on just random chance are very low ($p=0.01224$).

[0060] FIG. 12A is a bar graph of relative GPX2 mRNA expression (normalized to β -actin) in ESC, ESCshEXOSC2, ESCshEXOSC8, ESCshEXOSC2&8, and A-iPSC. Error bars indicate standard error of the mean. FIG. 12B is a quantification of apoptotic response by DNA fragmentation assay after phleomycin treatment of ESC, ESCshEXOSC2, ESCshEXOSC8, and ESCshEXOSC2&8. Error bars indicate standard error of the mean of technical and biological replicates.

[0061] FIG. 13A is a schematic representation of reprogramming in different individuals. FIG. 13B is a scanned image of an immunoblot showing the levels of pATM and beta-actin proteins. ESC, Y-iPSC and A-iPSC were generated from different individuals (A-iPSC AG8-76 years old, A-iPSC AG4-71 years old, A-iPSCB, and A-iPSCS) and treated with phleomycin. FIG. 13C is karyogram of A-iPSC generated from AG4 individual. FIG. 13D is a scanned image of an immunoblot of p53^{-/-} iPSC (negative control), A-iPSC generated from B6129 mouse genetic background, and A-iPSC generated from B6CBA mouse genetic background and treated with phleomycin. Levels of p53 and β -actin are shown. FIGS. 13E-13H show scanned images of immunoblots showing the levels of pATM and beta-actin proteins in six different clones of human A-iPSC (FIG. 13E), one clone of human A-iPSC-outlier (FIG. 13F), five different clones of Y-iPSC (FIG. 13G), and six clones of A-iPSC overexpressing ZSCAN10. FIG. 13I is a bar graph of relative mRNA levels of ZSCAN10 normalized to beta-actin in human ESC, human A-iPSC that exhibit no DNA damage response, and in A-iPSC that exhibit normal DNA damage response.

[0062] FIG. 14A is a schematic diagram showing ZSCAN10 binding to the glutathione synthetase (GSS) promoter. FIG. 14B is a bar graph of ChIP-quantitative PCR analysis of ZSCAN10 binding to the GSS promoter in Y-iPSC and A-iPSC. Values are given as percent enrichment compared with the input. FIG. 14C is a bar graph showing mRNA levels (determined by Q-PCR) of GSS in ESC, Y-iPSC, A-iPSC-ZSCAN10, and A-iPSC. Error bars indi-

cate standard error of the mean. FIG. 14D is a quantification of apoptotic response by DNA fragmentation assay (obtained by image quantification) after phleomycin treatment of ESC, Y-iPSC, Y-iPSCGSS, A-iPSC, A-iPSC-ZSCAN10, and A-iPSCshGSS. Error bars indicate standard error of the mean of technical and biological replicates. FIGS. 14E and 14F are immunoblots of phospho-ATM showing recovery of the DNA damage response (p-ATM) after phleomycin treatment in three independent clones of A-iPSC with GSS shRNA expression (FIG. 14E), or in three independent clones of Y-iPSC after lentiviral expression of GSS (FIG. 14F). β -actin levels are used as a loading control. FIG. 14G is a bar graph showing mRNA levels of GSS normalized to beta-actin in human ESC, A-iPSC (no DNA damage response) and A-iPSC (with normal DNA damage response).

[0063] FIG. 15A is a plot of data from Principal Component Analysis (PCA) using whole gene expression profiles of fibroblast cells (A-SC, Y-SC), iPS cells (A-iPSC, Y-iPSC, A-iPSC-ZSCAN10) and ES cells (ESC). FIG. 15B is a heat map of unsupervised clustering analysis of whole gene expression profiles. The heat maps shows pairwise gene expression similarities measured by Pearson Correlation Coefficient. FIG. 15C is a microarray heat map of relative expression levels of ES cell specific genes in fibroblast (A-SC, Y-SC), iPS cells (A-iPSC, Y-iPSC, A-iPSC-ZSCAN10) and ES cells (ESC). ES cell specific genes were defined as those with 3 fold or higher expression levels in ES cells than average expression in adult and young fibroblast cells. The heat map shows relative expression fold differences over ES cells.

DETAILED DESCRIPTION

Definitions

[0064] As used herein, the following terms shall have the meanings ascribed to them below unless the context clearly indicates otherwise:

[0065] The term “DNA damage response” refers to any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus, indicating damage to its DNA from environmental insults or errors during metabolism.

[0066] The term “apoptosis response” refers to a process that results in apoptosis of a cell, for example in response to DNA damage. A lower apoptotic rate or a failure of a cell to apoptose at all (collectively referred to a reduced apoptosis response) is associated with uncontrolled cell proliferation and more specifically with malignancy.

[0067] The term “polyploidy” refers to the condition in which a normally diploid cell or organism exhibits more than two sets of chromosomes; the term “aneuploidy” means any ploidy (more or less than the normal two sets of chromosomes).

[0068] The term “chromosomal structural abnormalities” refers to any change in the normal structure of a chromosome. Chromosomal structural abnormalities include, but are not limited to: duplications, deletions, translocations, inversions, and insertions.

[0069] The term “genomic instability” (also “genome instability or “genetic instability”) refers to an increase in structural chromosomal alterations (deletions, amplifica-

tions, and translocations), numerical chromosomal aneuploidy, or mutations on DNA sequence within the genome of a cellular lineage.

[0070] The term “oncogenic potential” means the likelihood that a cell after its transplantation into a host will generate malignant tumors in the host. The term is applied for example to induced pluripotent stem cells, and to their propensity to generate malignant tumors upon differentiation and transplantation to an animal or human. Phenotypic traits such as genomic instability, impaired DNA damage response, reduced apoptosis response and reduced glucose metabolism indicate elevated oncogenic potential whether the iPSC has been derived from an aged donor or not.

[0071] The term “effective amount” of a factor or other active molecule means an amount effective to bring about a particular result. For example, in the case of ZSCAN10 or GLUT3 or exosome subunit supplementation (or GPX2 or GSS inhibition), an effective amount is that which brings about substantial restoration of apoptosis response, and/or DNA damage response and/or glucose metabolism defect or preserves genomic stability.

[0072] The term “reprogramming factors” refers to transcription factors i.e., proteins that alone, or in combination with other reprogramming factors, have the ability to reprogram differentiated somatic cells to cells to a pluripotent state.

[0073] The term “transcriptional pluripotency network” refers to a network of transcription factors involved in the transcriptional control of pluripotency in embryonic stem cells (ESC). The present inventors have shown that ZSCAN10 is part of the “transcriptional pluripotency network” and should be supplemented in stem cells deficient in ZSCAN10 by comparison to Y-iPSC or ESC.

[0074] The term “mutagenic potential” refers to the potential or capacity of a substance to induce a change in the regulatory, protein-coding or other portions of a DNA sequence, increasing the frequency of mutations above a normal (background) level.

[0075] The term “young” used in connection with iPSC means iPSC derived from young donors, in case of mice up to 5 days old, in case of humans up to 16 years old and more generally to iPSC derived from donors that exhibit a “young” signature, e.g., slowing active growth stage to initiate the entry into fully grown adult stage.

[0076] The term “old” used in connection with iPSC means iPSC derived from aged donors, in case of mice older than 1.4 years old, in case of humans later than 50 years old, which begin to show age related degenerative diseases or states.

[0077] The term “substantial” used in the context of restoration, preservation recovery or rescue of glucose metabolism or DNA damage response, or apoptosis response, or genomic stability of A-iPSC denotes achievement of a state approximately or exactly the same as that of Y-iPSC and ESC. See for example FIGS. 1F-G, where A-iPSC with ZSCAN10 supplement have about the same ploidy and structural chromosomal abnormalities as Y-iPSC. See also FIGS. 2, 5a and 6. Additionally, levels of ZSCAN10 and/or GLUT3 and/or exosome subunit in A-iPSC of about 50% or more of the respective levels of embryonic stem cells are considered substantially restored. Finally, if the oxidation capacity of glutathione in A-iPSC is reduced (for example by supplementation of ZSCAN10 or by inhibition of GSS or GPX2) to be within the range from about

80% to about 120% of that of ESC or Y-iPSC, it is considered substantially restored.

[0078] The term “exosome” refers to the multi-protein exosome complex (or PM/Scf complex, often just called the exosome) capable of degrading various types of RNA (ribonucleic acid) molecules. Substrates of the exosome include messenger RNA, ribosomal RNA, and many species of small RNAs. Exosome comprises nine core subunits and two exonuclease co-factors listed in Table 3.

[0079] The term “exosome subunit” refers to eleven components (listed in Table 3) of the exosome, comprising nine core subunits and two co-factors: EXOS1, EXOS2, EXOS3, EXOS4, EXOS5, EXOS6, EXOS7, EXOS8, EXOS9, EXOS10, and DIS3.

[0080] Unless otherwise required by context, singular terms shall include the plural. For example, “an exosome subunit” shall mean one or more exosome subunits.

General Description of this Disclosure

[0081] The present disclosure is based on the following discoveries:

[0082] 1. Induced pluripotent stem cells derived from aged donors (A-iPSC), which have been previously shown to have a higher oncogenic potential, show increased genomic instability, a defect in apoptosis, and a blunted DNA damage response compared to those derived from young donors (Y-iPSC).

[0083] 2. A-iPSC are also shown to exhibit excessive glutathione-mediated H₂O₂ scavenging activity (glutathione/H₂O₂), which in turn inhibits DNA damage response and apoptosis.

[0084] 3. Inhibition of this pathway substantially rescues these defects and consequently reduces the oncogenic potential of A-iPSC.

[0085] 4. A-iPSC are shown to be deficient in a pluripotency factor ZSCAN10 which is poorly activated in A-iPSC. ZSCAN10 acts to inhibit GPX2, a glutathione-mediated H₂O₂ scavenger protein. ZSCAN10 expression shows a strong relationship with induction of the glucose transporter GLUT3 such that GLUT3 endogenous expression is increased when ZSCAN10 expression is increased. ZSCAN10 regulates GLUT3 directly by binding to its promoter.

[0086] 5. It was further found that supplementation of ZSCAN10, e.g., by expression (even transient expression) in A-iPSC as an adjunct to reprogramming, leads to substantial or even complete recovery of genomic stability, DNA damage response, apoptosis response and glucose metabolism in A-iPSC, to render them similar to those of Y-iPSC. This is shown to be accomplished through normalizing homeostasis of glutathione/H₂O₂. Significantly, adequate or even complete recovery of these Y-iPSC attributes has been shown not to require supplementation of ZSCAN10 to exactly the levels present in ESC or even in Y-iPSC. Moreover, because ZSCAN10 is not expressed in A-iPSC, it is anticipated that this finding transcends induction protocols. In other words, ZSCAN10 supplementation can be added to any stem cell induction protocol to be used in the event of deficiency in this factor. This a vector comprising nucleic acid encoding ZSCAN10 can be added to a set of vectors comprising nucleic acid for other reprogramming factors. Alternatively, a single vector comprising nucleic acid for reprogramming factors and ZSCAN10 can be utilized for example in the event of reprogramming of cells that would otherwise yield iPSC deficient in ZSCAN10.

[0087] 6. GLUT3 (a pluripotent stem cell-specific glucose transporter) is also poorly activated in A-iPSC. Poor activation of GLUT3 in A-iPSC inhibits the pluripotent stem cell specific transition from oxidative phosphorylation to glycolysis in glucose metabolism due to lack of sufficient intracellular glucose. Thus, A-iPSC use energy efficient oxidative phosphorylation (FIG. 10) to generate enough energy source with less glucose. However, oxidative phosphorylation generates higher H_2O_2 , and consequently increases GPX2/glutathione mediated H_2O_2 scavenging activity (FIG. 8). Excessive GPX2/glutathione mediated H_2O_2 scavenging activity blocks H_2O_2 - and ATM-mediated DNA damage response (FIG. 6). Direct or indirect supplementation of GLUT3, e.g., through increased expression in A-iPSC or addition to culture media or ZSCAN10-mediated increase in GLUT3, has similar effects in that it also normalizes DNA damage response and apoptosis in A-iPSC (FIG. 10D) as well as glucose metabolism.

[0088] 7. These results indicate that inhibition of glutathione/ H_2O_2 notably through delivery of ZSCAN 10 and/or GLUT3, will be clinically useful, resulting in A-iPSC of reduced oncogenic potential. Thus, the present results indicate that supplementation (including without limitation any upregulation) of ZSCAN10 and by extension modulation of any factor, such as GSS or GPX2 that contributes to inhibition of excessive glutathione/ H_2O_2 activity (or its effects) in A-iPSC, will be clinically useful in substantially restoring DNA damage response, apoptosis response, glucose metabolism and genomic stability (integrity) in A-iPSC and consequently reduce their oncogenic potential. Assessment of one or more such factors would be useful in ascertaining the quality of iPSC.

[0089] 8. Intervention in reducing excessive glutathione/ H_2O_2 activity is preferably practiced simultaneously with reprogramming somatic cells from aged donors into iPSC. Thus ZSCAN10 can be introduced into somatic cells at the same time or shortly following reprogramming whether through use of the Yamanaka factors OCT4, SOX2, KLF4, and c-MYC or through any other induction protocol, such as those discussed and/or cited in the Background section. ZSCAN10 supplementation can take place during or shortly following reprogramming and in any event prior to inducing differentiation. Increased GLUT3 expression can be introduced at the same times as ZSCAN10. Alternatively, GSS and/or GPX2 can be inhibited either by curbing their expression or by introducing effective amounts of inhibitors of the corresponding proteins.

[0090] The present inventors discovered genes associated with A-iPSC by comparing expression of genes in Y-iPSC, A-iPSC and ESC. Very few genes were differentially expressed and even fewer affected the oncogenicity potential as assessed by DNA damage response, apoptosis response and genomic stability. To arrive at the significant genes, the inventors first generated Y-iPSC (using mouse skin fibroblasts from E15.5 embryos to 5-day-old neonates) and A-iPSC (using mouse skin fibroblast from donors 1.4 years old) using standard Yamanaka iPSC reprogramming methods as described in Kim, K. et al, 2010 supra (as discussed elsewhere herein, alternative iPSC induction protocols could have been used instead). A large number of clones were selected based on morphology and groups of at least 12 clones of each type. Each Y-iPSC and A-iPSC clone was put through a series of pluripotency tests and compared to ESC as the gold standard, e.g., multi-lineage contribution to three

germ layers in teratoma analysis and pluripotent gene expression analysis (AP/OCT4/SSEA1/NANOG)(data not shown). Silencing of the four reprogramming factors (OCT4, SOX2, KLF4, MYC) in each clone was confirmed by quantitative PCR (Q-PCR) (data not shown). DNA ploidy was tested in multiple iPSC clones, and Y-iPSC and A-iPSC clones with normal ploidy (data not shown) were identified. However, a higher frequency of polyploidy was observed in A-iPSC compared to Y-iPSC (FIG. 1F). A-iPSC also displayed more chromosomal structural abnormalities than Y-iPSC (FIG. 1G).

[0091] The inventors hypothesized that the poor genomic stability of A-iPSC was due to poor induction of apoptosis response as in iPSC it is direct apoptosis that eliminates severely damaged cells from the population. They found that both Y-iPSC and ESC controls showed a significant level of apoptosis after treatment with phleomycin (a drug inducing DNA breakage which would normally mobilize DNA damage response such as apoptosis). In contrast, A-iPSC showed a poorer apoptotic response to phleomycin. They then set about to develop methods to correct the apoptotic response and therefore improve genomic stability in A-iPSC. They reasoned that additional pluripotency factors would be necessary to yield iPSC with the genomic stability of ESC or Y-iPSC. Screening of a number of previously identified pluripotency network genes yielded ZSCAN10 a transcription factor specifically expressed in ESC (and not expressed in somatic cells) and forming part of the transcriptional pluripotency regulatory network including SOX2, OCT4, and NANOG. ZSCAN10 also binds to the promoters of DNA damage response genes, such as ATM, PLK1 and JNK2.

[0092] The inventors further found that the ZSCAN10 promoter is hypomethylated/activated in Y-iPSC and ESC, and hypermethylated/inactive in A-iPSC. When added to the pluripotency induction protocol, ZSCAN 10, when transiently expressed during reprogramming of A-iPSC, led to hypomethylation/activation of the endogenous ZSCAN10 promoter to levels closer to that seen in Y-iPSC. A-iPSC with the foregoing ZSCAN10 supplementation exhibited reduced abnormalities in chromosomal ploidy and structure to levels comparable to Y-iPSC and ESC. ZSCAN10 also reduce the mutagenicity of A-iPSC to levels comparable to Y-iPSC and ESC. ZSCAN10 also recovered responsiveness of A-iPSC to DNA damaging agents (ATM phosphorylation, H2AX phosphorylation and p53 expression) confirming that ZSCAN10 recovers the DNA damage response of A-iPSC bringing it closer to that of Y-iPSC.

[0093] They inventors also investigated the mechanism by which the oxidative capacity of glutathione is elevated in A-iPSC and found that in mice it is driven by glutathione peroxidase 2 (GPX2) elevated expression in A-iPSC but not in Y-iPSC or ESC. Reduction of GPX2 expression in A-iPSC recovered glutathione/ H_2O_2 homeostasis to levels comparable to Y-iPSC and ESC. Conversely overexpression of GPX2 in Y-iPSC induced an imbalance in glutathione/ H_2O_2 homeostasis. In humans however, the elevation of the oxidative capacity of glutathione in A-iPSC is driven by elevated levels of glutathione synthetase (GSS). Downregulation of GSS results in recovery of glutathione/ H_2O_2 homeostasis.

[0094] Oncogenic Potential

[0095] It is known that aging and oncogenicity are known to be strongly correlated. See, e.g., Stoll E A, Horner P J,

Rostomily R C. The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment. *Aging Cell*. 2013; 12(5):733-41. PMID: 23711239. Furthermore, it is also known that oncogenicity in general is increased by events such as DNA hypermethylation, defective apoptosis mechanisms (whereby apoptosis occurs less frequently) and blunting of DNA damage response. Liu, J. C. et al. High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. *Cell stem cell* 13, 483-491, doi:10.1016/j.stem.2013.07.018 (2013). In addition, excessive glutathione and/or excessive glutathione activity is associated with certain cancers such as pancreatic cancer and colorectal cancer. Furthermore, the inventors found that excessive glutathione activity is triggered by excessive expression of GPX2 in A-iPSC in mice and excessive expression of GSS in humans. Accordingly, one or more of such phenotypic defects have been used in the present disclosure to assess oncogenic potential and can be used for this purpose as well as more generally to assess the quality of iPSC in methods of the present disclosure. Furthermore, amelioration in these phenotypic defects is considered to reduce oncogenic potential. Donnerstag, B. et al *Cancer Lett*. 1996 Dec. 20; 110(1-2):63-70.

[0096] Both DNA damage response and apoptosis play a critical role in tumorigenesis. Certain DNA damage response proteins such as ATM, H2AX, and p53 link DNA damage pathway to apoptosis. Thus, apoptosis is a secondary response to DNA damage. However, induction of DNA damage response can occur without the trigger of programmed cell death. For example, activation of the tumor suppressor p53 by DNA damage induces either cell cycle arrest or apoptosis, and the outcome of this is highly contextual. Thus, a defect in the activation of any of the proteins that mediate DNA damage response, and/or apoptosis, such as H2AX, ATM, and p53, may indicate a defect in A-iPSC and can be used to assess quality of such stem cells.

[0097] ZSCAN10 is an embryonic stem (ES) cell-specific transcription factor required to maintain ES cell pluripotency. See <http://www.genecards.org/cgi-bin/carddisp.pl?gene=ZSCAN10> (last visited Feb. 24, 2015). It and nucleic acid encoding it (see, e.g., NCBI Genbank Reference Sequence: NC 000016.10) are publicly available. Human, mouse and rat ZSCAN10 cDNA is available from GE Dharmacon Life Sciences (<http://dharmacon.gelifesciences.com/mammalian-cdna/mgc-cdnas/?term=ZSCAN10&sourceId=EG/84891&productId=416CB003-5022-4263-B1C6-293625B70CE1>) (last visited Feb. 24, 2015). Human cDNA is also available as plasmid pENTR223.1 e.g., from DNASU plasmid Repository at Tempe Ariz. (<http://dnasu.org/DNASU/GetCloneDetail.do?cloneid=295134>; last visited Feb. 24, 2015) The human cDNA insert for ZSCAN10 has SEQ ID NO:1.

[0098] The methods of this disclosure relate to the exposure of iPSC to ZSCAN10 to accomplish improved reprogramming of iPSC. In some embodiments, the present disclosure relates to iPSC cells generated from aged donors (A-iPSC). In some embodiments, the iPSC cells are characterized by genomic instability, reflected by polyploidy or increased chromosomal structural abnormalities. In some embodiments, iPSC cells exhibit poor DNA damage response. In some embodiments, iPSC cells exhibit a defect in induction of apoptosis. In some embodiments, iPSC cells

exhibit a defect in glucose metabolism. iPSC exhibiting one or more of these defects (genomic instability, poor DNA damage response, decreased apoptotic response and lower glucose metabolism) can be improved to levels comparable to those of Y-iPSC or ESC by increasing the levels of ZSCAN10. (As disclosed elsewhere herein, the levels of ZSCAN 10 may but need not reach levels of Y-iPSC as long as the phenotypic defect is adequately restored.) This process can be achieved by introduction of an mRNA encoding ZSCAN10 into the iPSC-derived somatic cell and subsequent translation into a functional ZSCAN protein. Additional methods for increasing the levels of ZSCAN10 include, but are not limited to transfection with numerous vectors, such as adeno-associated virus, lentivirus, retrovirus, Sendai virus, DNA plasmids such that ZSCAN10 expression is effected at the DNA, RNA, and/or protein level in either a transient or long-term manner. Additionally, ZSCAN10 protein levels can be increased by contacting the cell with an agent that leads to increased ZSCAN10 protein levels (expressed in a transient or long-term manner), or by contacting the cell directly with recombinant ZSCAN10 protein. As disclosed herein, the present method provides increasing the levels of ZSCAN10 in iPSC at a dosage sufficient to substantially: (a) restore genomic instability, (b) improve poor DNA damage response, or (c) restore apoptotic response in human or animal (e.g., mouse) iPSC.

[0099] When used as an adjunct to reprogramming, ZSCAN10 supplementation can be added to one or more vectors harboring nucleic acid encoding reprogramming factors or can be included in a separate vector (such that it will be used only if needed) in a set of such vectors. Vectors useful for reprogramming are commercially available. Any of these can be modified to include nucleic acid encoding ZSCAN10 (and optionally any other elements useful for its expression as one of ordinary skill in this field would appreciate).

[0100] ZSCAN10 supplementation in amounts effective to substantially restore one or more of DNA damage response, apoptosis response, glucose metabolism and genomic stability should be in an amount related to the deficiency in ZSCAN10 exhibited by the particular A-iPSC (reprogrammed in the absence of such intervention) compared to ZSCAN10 levels of Y-iPSC. In this regard, FIG. 4 is informative because it shows that increased expression of ZSCAN10 in A-iPSC to a level about 5 times that of the untreated cells to a level of about 50% of the ESC level (and about 60% of the Y-iPSC level) was effective to restore the assessed phenotypic responses. In general, the more meaningful comparison of appropriate ZSCAN10 is to be closer or even identical to the level of ESC and Y-iPSC (although identical level is not required for restoration of defects). Supplementation of ZSCAN10 to reach a level from about 40% up to about 90 or 95% of ESC ZSCAN10 level or from about 50% to 100% of Y-iPSC ZSCAN10 level is an effective range. In some embodiments, supplementation sufficient to substantially restore the assessed phenotypic parameters (DNA damage response, apoptosis response, genomic stability or glucose metabolism) is sufficient even though higher levels are possible and indeed encountered in Y-iPSC and ESC.

[0101] In the event sufficient endogenous amounts ZSCAN10 are expressed but ZSCAN10 is not effective, the amount of supplementation should be adjusted upwards as

appropriate and in such instances can reach amounts higher than 100% of the amount of Y-iPSC.

[0102] Methods of supplementation of ZSCAN10 or any other factor proposed to be supplemented herein include addition to the culture medium or transfection with a delivery vector or any other system that facilitates expression of these factors or in any event exposure of a cell to these factors. For methods of vector-free delivery, see, e.g., Zhou H, et al. (2009), Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell* 4: 381-384. Any type of DNA gene transfer (retroviral, lentiviral, adenoviral, Talen, CrispR etc.) can be used to effect supplementation. Alternatively, RNA delivery or delivery into the cells in form of proteins can also be used. These techniques are well-known in the art. The time of delivery can be before, during or after adding the reprogramming factors and before differentiation and transplantation. Accordingly combinations of reagents (vector or vector-free) for reprogramming cells including reagents for supplementation of ZSCAN10 are envisioned for producing induced pluripotent stem cells of higher quality and phenotypic traits resembling those of Y-iPSC and ESC. These are commercially available or can be readily constructed given that both nucleic acid and amino acid sequences for ZSCAN10 are known. For example, vectors and viral particles that can be used to introduce Yamanaka reprogramming pluripotency factors into the cells can be obtained from such sources as Applied Biological Materials, Richmond BC, Canada; Clontech Laboratories, Mountain View, Calif.; and Addgene, Cambridge, Mass.

[0103] While the present examples provide for transient expression of ZSCAN10, the methods of the present invention are not limited by whether ZSCAN10 expression is inducible or not. Nor are they limited to supplementation of ZSCAN10 in A-iPSC induced by a particular protocol. Indeed, there are many known protocols for iPSC induction and any one of them can be used with the present methods. See, Singh, V K et al, *Front. In Dev. Biol.* 3(2):1-18, February 2015; Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., et al., (2007). Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318, 1917-1920. doi:10.126/science.1151526. Dimos, J. T., Rodolfa, K. T., Niakan, K. K., Weisenthal, L. M., Mitumoto, H., Chung, W., et al. (2008). Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 321, 1218-1221. doi:10.1126/science.1158799. Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C., Wernig, M., et al. (2008) Direct reprogramming of terminally differentiated mature B Lymphocytes to pluripotency. *Cell* 133, 250-264. doi: 10.1016/j.cell.2008.03.028. Huangfu, D., Macht, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A. E., et al. (2008a). Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat. Biotechnol.* 26, 795-1797. doi:10.1038/nbt1418. Mali, P., Ye, Z., Hommond, H. H., Yu, X., Lin, J., Chen, G., et al. (2008) Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. *Stem Cells* 26, 1998-2005. doi:10.11634/stemcells.2008-0346; Marson, A., Foreman, R., Chevalier, B., Bilodeau, S., Kahn, M., Young, R. A., et al. (2008). Wnt signaling promotes reprogramming of somatic cells to pluripotency. *Cell Stem Cell* 3, 132-135. doi:10.1016/j.stem.2008.06.019; Mikkelsen, T. S., Hanna, J.,

Zhang, X., Ku, M., Wernig, M., Schorderet, P., et al. (2008). Dissecting direct reprogramming through integrative genomic analysis. *Nature* 454, 49-55. doi:10.1038/nature07056; Park, I. H. Zhao, R., West, J. A., Yabuchi, A., Huo, H., Ince, T. A., et al. (2008a). Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 451, 141-146. doi:10.1038/nature06534; Shi, Y., Desponts, C., Do, J. T. Hahm, H. S., Scholer, H. R., and Ding, S. (2008a). Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. *Cell Stem Cell* 3, 568-574. doi:10.1016/j.stem.2008.10.004; Shi, Y., Do, J. T. Desponts, C., Hahm, H. S., Scholer, H. R., and Ding, S. (2008b). A combined chemical and genetic approach for the generation of induced pluripotent stem cells. *Cell Stem Cell* 2, 525-528. doi:10.1016/j.stem.2008.05.011.

[0104] Vectors for Increasing ZSCAN10 Expression

[0105] Suitable vectors include without limitation viral gene delivery vectors (lentivirus-based vectors such as those derived from HIV1, HIV2, FIC and EIAY, which may be pseudotyped, AAV-based vectors etc.), plasmids, etc. In the experiments described herein delivery of ZSCAN10 and GLUT3 was made by using a commercially available lentiviral vector harboring OCT4 gene (Plasmid 19778: FU-tet-o-hOct4 from Addgene), excising the same and replacing it by ZSCAN10 or GLUT3. See <http://www.addgene.org/19778/> (last visited Feb. 25, 2015).

[0106] Examples of additional vectors that can be used include excisable vectors such as STEMCCA available from EMD Millipore. However, ZSCAN10 supplementation is not limited to any particular expression vector and any method suitable for induction of pluripotent stem cell (whether using a vector or not) can be readily adapted for supplementing ZSCAN10. The same holds true for GLUT3, GPX2 and any other nucleotide inserted into stem cells in accordance with the present disclosure.

[0107] Vector free methods can also be used following and adapting known protocols as exemplified herein.

[0108] Provenance of iPSC

[0109] In principle, any somatic cell can be reprogrammed into iPSC. The basic Yamanaka protocol (Takahasji, K. et al, *Cell*. 2006 Aug. 25; 126(4):663-76; Takahashi, K. et al *Cell*. 2007 Nov. 30; 131(5):861-72) can be used with such modifications as described for example in the references cited in the Background section for alternative protocols of iPSC induction. Additionally, there are other protocols for reprogramming known in the art. See for example WO2013177228 Generation of Integration/Transgene-Free Stem Cells.

[0110] The cells most often used for reprogramming include fibroblasts, such as embryonic, neonatal, young and adult fibroblasts as needed.

[0111] It should be noted that according to Kim, K. et al, *Nature*, 2010, supra, and Kim, K. et al, *Nature Biotechnology* 2011, supra, there is some tissue specificity in the properties of iPSC depending on the tissue from which the somatic cells were chosen from prior to reprogramming. The present disclosure is directed to A-iPSC (and more broadly to any iPSC) exhibiting defects in genomic stability and/or apoptosis response and/or DNA damage response and to an increase in oncogenic potential associated with dysregulation of the glutathione/H₂O₂ pathway and in more specific embodiments with deficiency in ZSCAN10 and/or in glucose metabolism, for example those associated with insulf-

ficient endogenous expression of GLUT3. Accordingly, when it is not known whether iPSC exhibit such defects, testing should be performed following for example the procedure of Example 1. If determination of ZSCAN10 deficiency is needed, the procedure of assessing ZSCAN10 levels in Example 2 can for example be followed. If GLUT3 levels need to be assessed, the procedure of Example 8 for assessing GLUT3 levels of expression can for example be used.

[0112] GLUT3

[0113] Cellular uptake of glucose occurs through facilitated diffusion mediated by a family of glucose transporter proteins, where GLUT3 (also known as SLC2A3) is one of the major isoforms. With the exception of neurons and a few hematopoietic cell types, GLUT3 is generally not expressed in adult tissues. However, GLUT3 expression has been detected in various cancer types. While the expression of GLUT3 in different cancer types has been observed, its functional role remains unknown.

[0114] Within the context of brain tumor initiating cells (also often referred to as brain cancer stem cells), GLUT3 expression has been found to correlate with the induced pluripotency and to predict poor survival in multiple tumor types (Flavahan, W A, *Nature Neuroscience* 16: 1373-1382 (2013)).

[0115] The inventors discovered that GLUT3 levels are significantly lower in iPSC cells that exhibit defect in chromosome number and/or structure, induction of DNA damage response, or in apoptosis compared to cells characterized by normal chromosome number and/or structure, induction of DNA damage response, or apoptosis. In one instance, cells expressing lower or non-detectable levels of GLUT3 are A-iPSC cells. As illustrated in Example 8, increased expression of GLUT3 in A-iPSC led to substantial restoration of DNA damage response, similarly to the effects of ZSCAN10 expression in A-iPSC (FIG. 10D). Moreover, data presented in this disclosure show that ZSCAN10 leads to the induction of GLUT3, implying that ZSCAN10 and GLUT3 are interlinked in iPSC. ChIP-seq and immunoprecipitation analysis revealed that ZSCAN10 binds to the GLUT3 promoter, indicating direct regulation of GLUT3 by ZSCAN10. The following materials are commercially available and can be procured online using websites such as those exemplified below (all last visited on Feb. 25, 2015).

[0116] cDNA sequence encoding human, murine, and rat GLUT3 can be found here (SEQ ID NO:2): <http://www.ncbi.nlm.nih.gov/gene/6515>. (Kayano T. *J. Biol. Chem.*, 263 (30): 15245-15248 (1988))

[0117] <http://www.ncbi.nlm.nih.gov/gene/20527> (Nagamatsu S. *J Biol Chem.*, 267 (1): 467-72 (1992)).

[0118] <http://www.ncbi.nlm.nih.gov/gene/25551> (Krishnan S N. *Life Sci.* 56 (14): 1193-7 (1995)).

[0119] Plasmids carrying human GLUT3 are commercially available from Genecopoeia, and can be found here: <http://www.genecopoeia.com/product/search/detail.php?prt=1&cid=&key=C0200> (visited on Oct. 6, 2014, at 12:30 pm).

[0120] Additionally, recombinant GLUT3 protein is commercially available from mybiosource.com and can be found here: http://www.mybiosource.com/datasheet.php?products_id=1214582 (last visited Feb. 25, 2015).

[0121] GLUT3 supplementation in the amounts effective to substantially restore one or more of glucose metabolism, genomic stability, DNA damage, and/or apoptotic defects in

iPSC, or more specifically, in A-iPSC, should be in an amount related to GLUT3 levels in iPSC cells that do not exhibit the above-mentioned defects. Alternatively, GLUT3 supplementation in A-iPSC can be related to the amount of GLUT3 detected in Y-iPSC and ESC. It is expected that the supplementation amounts effective in restoring the defects observed in iPSC due to reduced levels of GLUT3, will be in the range qualitatively similar to the range determined for ZSCAN10. Methods of supplementation of GLUT3 are diverse and the protocols described for the supplementation of ZSCAN10 apply to the supplementation of GLUT3.

[0122] The supplementation of GLUT3 can be achieved by introduction of an mRNA encoding GLUT3 into the iPSC-derived somatic cell and subsequent translation into a functional GLUT3 protein. Additional methods for increasing the levels of GLUT3 include, but are not limited to transfection with numerous vectors, such as adeno-associated virus, lentivirus, retrovirus, Sendai virus, DNA plasmids such that GLUT3 expression is effected at the DNA, RNA, and/or protein level in either a transient or long-term manner.

[0123] Alternatively, protein levels of GLUT3 can be increased by contacting the cell with an agent that leads to increased GLUT3 protein levels (in a transient or long-term manner). As shown in Example 8, ZSCAN10 expression leads to increased levels of GLUT3. Thus, it is expected that increasing the cellular levels of ZSCAN10 will result in the upregulation of GLUT3. Additionally, GLUT3 levels can be increased by contacting the cell with recombinant GLUT3 protein. As disclosed herein, the present method provides increasing the levels of ZSCAN10 in iPSC at a dosage sufficient to substantially or completely: (a) restore genomic stability, (b) improve poor DNA damage response, or (c) restore apoptotic response in human or animal (e.g., mouse) iPSC, or (d) restore glucose metabolism to levels similar to ESC or Y-iPSC.

[0124] GPX2

[0125] Glutathione peroxidases catalyze the reduction of H₂O₂ using reduced glutathione. GPX2 is a member of the glutathione peroxidase family encoding one of two isoenzymes responsible for the majority of the glutathione-dependent hydrogen peroxide-reducing activity in the epithelium of the gastrointestinal tract. Published literature suggests that stem cells reside in redox niches with low ROS levels, where the balance of redox homeostasis governs stem cell self-renewal by an intricate network. In the work described herein, it was found that A-iPSC show perturbed glutathione-H₂O₂ homeostasis, with the oxidation capacity of glutathione elevated compared to ESC and Y-iPSC (FIG. 8A).

[0126] Prior analysis of GPX2 expression in the intestine suggested a role for GPX2 in the stem cell compartment of the gut, however, a role for GPX2 in ESC or iPSC has not been described so far. As shown in Example 7, in mouse A-iPSC, excessive glutathione activity scavenges hydrogen peroxide generated by genotoxic insult (abnormal glutathione-hydrogen peroxide homeostasis), thus blocking the normal apoptosis and DNA damage response. As a result, cells that are damaged are not eliminated. The enhanced glutathione activity is due to excessive elevation of GPX2. As indicated in FIGS. 9B and 9C, knockdown of GPX2 in A-iPSC resulted in the normalization of glutathione-H₂O₂ homeostasis. Moreover, downregulation of GPX2 restored the defects in DNA damage and apoptosis in mouse A-iPSC

(FIGS. 9E and 9D). Mechanistically, the inventors discovered that GPX2 expression in the mouse is regulated by ZSCAN10 in A-iPSC, as overexpression of ZSCAN10 in A-iPSC led to a decrease of GPX2 mRNA.

[0127] As further proof that high levels of GPX2 are indeed responsible for the abnormal reprogramming of A-iPSC, the inventors overexpressed GPX2 in mouse Y-iPSC. High levels of GPX2 in Y-iPSC shifted the behavior of Y-iPSC towards that of A-iPSC. Overexpression of GPX2 in Y-iPSC decreased apoptosis, reduced the DNA damage response, decreased glucose metabolism and induced an imbalance in glutathione-H₂O₂ homeostasis (increased oxidative metabolism).

[0128] Thus, in one aspect of the present disclosure, reduction of GPX2 levels in cells exhibiting abnormal chromosome number and/or structure, induction of DNA damage, or apoptosis can lead to substantial restoration of the mentioned defects to substantially those of ESC and Y-iPSC. In one aspect, the iPSC cell can be A-iPSC. Reduction of GPX2 levels in A-iPSC can cause the molecular and phenotypic changes within the iPSC in a way that will make it closely resemble ESC or Y-iPSC. Levels of GPX2 in A-iPSC or more generally in iPSC and their proximity or difference to those of Y-iPSC from healthy young donors or ESC can also be used as a surrogate marker for assessing quality of iPSC.

[0129] Reduction in levels of GPX2 can be achieved through numerous methods. For example, a small molecule inhibitor known to directly or indirectly reduce protein levels of GPX2 can be used. Additionally, various RNA interference (such as siRNA, shRNA) technologies can be used to inhibit GPX2 at the RNA level. Thus, any agent that leads to reduction of protein, RNA, or DNA levels of GPX2 can be used to restore the chromosomal stability, DNA damage, and/or apoptotic defects observed in A-iPSC, or any iPSC that are characterized by one or more of those defects. Human GPX2 ORF cDNA is available commercially for example from GeneCopoeia, Rockville Md. (<http://www.genecopoeia.com>); mouse GPX2 ORF cDNA is also available commercially for example from Origene, Rockville Md. <http://www.origene.com/cdna>.

[0130] DNA Methylation

[0131] Although somatic cells within an organism share the same genomic sequence, they can differ significantly in gene expression patterns due to chromatin modifications as well as DNA methylation. The conversion of somatic cells into pluripotent stem cells via overexpression of reprogramming factors involves epigenetic remodelling. However, recent studies have revealed that the process of reversal is not fully completed at all times. For example, although mice have been successfully generated from iPSC, not all pluripotent stem cell-derived mice are epigenetically stable, and instability has been linked to overweight and sudden-death syndrome in mice. Furthermore, iPSC contain a residual epigenetic signature depending on the tissue type of the donor tissue used (Kim et al. *Nat Biotechnol* 29(12): 1117-1119, 2011). Finally, iPSC from aged donors (A-iPSC) have been shown to preserve an aging-specific epigenetic memory (Kim et al. *Nature* 467(7313):285-290, 2010).

[0132] In normal cells, DNA methylation assures accurate regulation of gene expression and stable gene silencing. DNA methylation is linked to histone modifications and the interplay between these modifications is critical for the functioning of the genome by changing chromatin architec-

ture. The covalent addition of a methyl group occurs generally in cytosine within CpG dinucleotides which are concentrated in large clusters known as CpG islands. The aberrant DNA methylation landscape is a characteristic feature of cancer. It has been established that inactivation of specific tumor-suppressor genes arises as a consequence of hypermethylation (inactivation) within the promoter regions and numerous studies have shown a broad range of genes silenced by DNA methylation in various types of cancer. Furthermore, hypomethylation (activation), which can induce genomic instability, also contributes to cell transformation.

[0133] In the present disclosure, the ZSCAN10 promoter is activated in Y-iPSC and ESC, and inactive in A-iPSC. This modification resulted in poor levels of ZSCAN10, but was restored with the transient expression of ZSCAN10 in A-iPSC which led to hypomethylation (activation) of the endogenous ZSCAN10 promoter to levels similar to those detected in Y-iPSC (FIG. 7). Furthermore, DNA methylation analysis of mouse Y-iPSC and A-iPSC compared with mouse ESC showed that A-iPSC contain a higher number of differentially methylated regions (DMRs) than Y-iPSC. In addition, the number of hypermethylated DMRs is higher in mouse A-iPSC than in Y-iPSC. Moreover, depending on the genetic background of the donor, human A-iPSC show greater DNA methylation, similar to that observed in mouse A-iPSC. Moreover, recent studies have revealed that poor DNA demethylation in human cells is associated with inefficient reprogramming (Bagci, H. et al, *Cell Stem Cell* 3:265-269 (2013)), further establishing comparable patterns of DNA methylation between mouse and human cells. Thus, in one aspect, the present disclosure provides a method where distinct epigenetic differences such as the number of hypermethylated DMRs or the methylation status of ZSCAN10 in iPSC can serve as a marker or indicator of the specific iPSC properties. In another aspect, the present disclosure provides a method for substantially or completely restoring DNA methylation patterns in A-iPSC to be similar to those observed in Y-iPSC.

[0134] Genes affecting oncogenic potential of A-iPSC were identified by performing microarray analysis on ESC/Y-iPSC/A-iPSC/ZSCAN10/A-iPSC to detect differential expression of genes in A-iPSC. Both GPX2 and GLUT3 were identified thus.

ZSCAN10 Regulates Exosome, which in Turn Regulates GPX2

[0135] In the present disclosure, ChIP-Seq analysis revealed that ZSCAN10 binds to and upregulates subunits of the exosome complex. A-iPSC displayed lower mRNA levels of exosome subunits compared to FESC and Y-iPSC (FIG. 11A). Furthermore, overexpression of ZSCAN10 led to restoration of exosome subunit mRNA, demonstrating a direct interaction between ZSCAN10 and exosome.

[0136] The multisubunit exosome complex is a major ribonuclease of eukaryotic cells that participates in the processing, quality control and degradation of nearly all classes of RNA (Schmid et al. *Trends Biochem Sci.* (10): 501-10, (2008)). Previous studies have demonstrated that the interaction between the exosome and AU-rich elements (ARE) plays a key role in regulating the efficiency of ARE-containing mRNA turnover. The GPX2 gene contains highly conserved ARE sequences (Singh et al. *Am J Respir Cell Mol Biol.* 35(6):639-50 (2006)), making the ZSCAN10→EXOSOME→GPX2 axis a potential mecha-

nism of GPX2 regulation. To test this hypothesis, different exosome subunits were knocked-down in ESC and the levels of GPX2 mRNA determined (FIG. 12A). Knock-down of EXOSC2 or EXOSC8 led to dramatic increase in GPX2 expression in ESC, which was accompanied by lower apoptotic response (FIG. 12B). Thus, these findings indicate that ZSCAN10 regulates GPX2 via mechanism that involves exosome complex including various subunits. Consequently, supplementing A-iPSC in the mouse with an exosome subunit would lead to amelioration of phenotypic defects and oncogenic potential associated with aging iPSC.

[0137] iPSC Cells Derived from Aged Human Donors Exhibit Different Reprogramming Efficiencies and Phenotypic Defects

[0138] A-iPSC cells generated from aged human donors confirm the findings observed in A-iPSC generated from aged animals regarding low reprogramming efficiency (FIG. 13A). Interestingly, a significant difference in reprogramming efficiency is observed between two different donors of similar age, which was also reflected in their DNA damage response (FIG. 13B). A-iPSC generated from the donor that exhibited significant defect in DNA damage response also displayed structural chromosome abnormality (FIG. 13C). These results suggest that genetic background of an individual plays a significant role in reprogramming efficiency and DNA damage response of A-iPSC. It is anticipated that this defect can be rescued by supplementation as described herein.

[0139] Multiple laboratory mouse strains of various genetic backgrounds are available. To test the hypothesis that genetic background is crucial for A-iPSC, A-iPSC were generated from distinct mouse strains, B6129 and B6CBA. As shown in FIG. 13D, A-iPSC derived from the B6129 background mice exhibit normal DNA damage response (indicated by activation of p53), while A-iPSC from the B6CBA background mice showed blunted DNA damage response. Collectively, these findings indicate that reprogramming efficiency, chromosomal stability, as well as a DNA damage response associated with A-iPSC are all highly dependent on genetic background of the individual or animal from which they are derived as well as on epigenetic factors and aging.

[0140] GSS

[0141] De novo synthesis of glutathione (GSH) is catalyzed by two enzymes, γ -glutamylcysteine synthetase (γ -GCS) and glutathione synthetase (GSS). The rate-limiting step of GSH synthesis is the formation of the amide linkage between the gamma-carboxyl moiety of glutamic acid and the amino moiety of cysteine. The rate at which GSH is synthesized is based on both the activity of the enzyme (GCS) and the availability of cysteine. GSS completes the GSH synthesis by catalyzing the conversion of the γ -GluCys dipeptide to GSH via the addition of glycine (Johnson et al. *Nutrients*. 4(10): 1399-440 (2012)).

[0142] The enzymes involved in GSH synthesis are controlled by multiple mechanisms both pre and post transcriptionally. Previous studies focused on genome-wide mapping of ZSCAN10-binding sites in ESC identified ~3500 target genes, including GSS (Yu et al. *J Biol Chem*. 284(45): 31327-31335 (2009)). In the present disclosure, the inventors have shown that in humans ZSCAN10 binds directly to the GSS promoter (Example 12, FIG. 14B). Additionally, they have shown that the levels of GSS mRNA are significantly upregulated in A-iPSC compared with Y-iPSC and

ESC and that this upregulation is diminished upon ZSCAN10 overexpression in A-iPSC (Example 12, FIG. 14C).

[0143] Additional experiments disclosed herein provide further proof that GSS is indeed involved in regulating oncogenic potential of A-iPSC in humans. As described in Example 13 and FIGS. 14D-F, GSS plays a role in both apoptosis, as well as in the regulation of the DNA damage response. Down-regulation of GSS in A-iPSC using shRNA led to increased apoptotic response (Example 13, FIG. 14D) as well as in the rescue of the DNA damage response (Example 13, FIGS. 14E-14F). On the contrary, overexpression of GSS in Y-iPSC caused lower apoptotic response compared to control Y-iPSC cells (FIG. 14D) and loss of DNA damage response (FIGS. 14E and 14F).

[0144] Thus, in one aspect of the present disclosure, reduction of GSS levels in cells exhibiting abnormal chromosome number and/or structure, induction of DNA damage, or apoptosis can lead to substantial restoration of the aforementioned defects in these phenotypic traits and their restoration to substantially those of ESC and Y-iPSC. In one aspect, the iPSC cell can be A-iPSC. Reduction of GSS levels in A-iPSC can cause the molecular and phenotypic changes within the iPSC in a way that will make it closely resemble ESC or Y-iPSC.

[0145] Reduction in levels of GSS can be achieved through numerous methods. For example, various RNA interference (such as siRNA, shRNA) technologies can be used to inhibit GSS at the RNA level. Thus, any agent that leads to reduction of protein, RNA, or DNA levels of GSS can be used to restore the chromosomal stability, DNA damage, and/or apoptotic defects observed in A-iPSC, or any iPSC that are characterized by one or more of those defects. Both human and mouse GSS ORF cDNA is available commercially for example from OriGene Technologies, Rockville, Md. (<http://www.origene.com/cdna>). To target GSS at the DNA level, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas genome editing tool can be used (Sander and Joung, *Nature Biotechnology* 32, 347-355 (2014)). Additionally, GSS levels or activity can be reduced using inhibitors known to directly or indirectly reduce protein levels and/or activity of GSS. For example, buthionine sulfoximine (Drew and Miners, *Biochem Pharmacol.* 33(19):2989-94 (1984)), 6-Diazo-5-oxo-L-norleucine (Vanoni M A and Curti B, *IUBMB Life*. 60(5):287-300 (2008)), and azaserine (Hensley et al. *J Clin Invest*. 123(9): 3678-84 (2013)) have been shown to inhibit GSS. Thus, in one embodiment of the present disclosure, GSS levels are reduced or activity inhibited using buthionine sulfoximine, 6-Diazo-5-oxo-L-norleucine (Vanoni M A and Curti B, *IUBMB* and/or azaserine, or any inhibitor shown to reduce the activity and/or levels of GSS. In addition to using each inhibitor individually, the reduction of GSS activity and/or levels can be achieved by combination of two or more known inhibitors. In inhibiting GSS it is important that the inhibition not be complete. Some amount of glutathione is important to the cell.

[0146] Alternatively, ZSCAN10 can be upregulated as described herein to suppress upregulation of GSS since the present inventors have shown that GSS is directly regulated by ZSCAN10 through binding to the promoter of GSS. Through the work described herein ZSCAN 10 has emerged as an important coregulatory of somatic cell reprogramming to produce iPSC especially iPSC from aged donors.

[0147] GSS can also be used as a surrogate marker for assessing oncogenic potential and glutathione/H₂O₂ homeostasis and more generally quality of iPSC especially A-iPSC by measuring levels of GSS in A-iPSC and more generally iPSC and comparing them to those of Y-iPSC or ESC from healthy donors. If the levels of GSS are low, i.e., comparable to those of Y-iPSC and ESC then the stem cells have low oncogenic potential, have robust glutathione homeostasis and are generally of good quality.

[0148] Experimental Procedures

[0149] Cell Culture

[0150] ESC and iPSC were cultured in ESC media containing 10% FBS and 1,000 U/ml of LIF (ESGRO® Leukemia Inhibitory Factor [LIF], 1 million units/1 mL). For generation of ESC, established methods previously reported were used (Kim et al. *Nature* 467: 285-290, 2010). For iPSC reprogramming of somatic cells, retrovirus expressing OCT4, SOX2, KLF4, and MYC were introduced. For the somatic cells containing inducible reprogramming factors, the media was supplemented with 2 µg/ml doxycycline (MP Biomedicals, doxycycline hyclate). For DNA and RNA isolation, ESC or iPSC were trypsinized and re-plated onto new tissue culture dishes for 30 min to remove feeder cells, and nucleic acids were extracted from the non-adherent cell suspension.

[0151] Generation of Mouse Y-iPSC, A-iPSC, A-iPSC-ZSCAN10, A-iPSC-shGPX2, A-iPSC-shGSS, A-iPSC-GLUT, ESC-shEXOSC2, ESC-shEXOSC8, ESC shEXOSC2&8, Human Y-iPSC, and Human A-iPSC

[0152] 10⁶ skin fibroblast cells were collected from B6CBAF1 mouse E15.5 embryonic skin, 5-day-old tail tip skin, and 1.4-year-old tail tip skin; infected with retrovirus generated from pMX-mOCT4, pMX-mSOX2, pMX-mKLF4,2 and pEYK-mMYC3 in 6-well dishes with 0.5 ml of each viral supernatant (total 2 ml per well); and spun at 2500 rpm at RT for 90 min (BenchTop Centrifuge, BeckmanCoulter, Allegra-6R). For the generation of A-iPSC-ZSCAN10, the procedure was identical but in addition to the four reprogramming factors, a doxycycline inducible system was added to overexpress ZSCAN10. This system consisted of two lentiviruses generated from a plentiRZ-ZSCAN10 and a plenti-RTTA vector (Kim et al. *Nat Biotechnol* 29: 1117-1119, 2011). The vector was generated by replacing the insert of a commercially available vector with ZSCAN10 (or GLUT3 or other insert described herein). All cells infected with the reprogramming factors and those with additional ZSCAN10, shGPX2, shGSS and GLUT3 were plated on irradiated CF-1 mouse embryonic feeder cells in a 10-cm tissue culture dish in ESC media containing 20% FBS and 1,000 U/ml of LIF. Media were changed on day 2 and doxycycline addition started on day 3 for ZSCAN10 over-expression. Floating cells were collected by media centrifugation and returned to culture during media changes. On day 4, cultured cells were trypsinized and replated onto four 10-cm dishes pre-coated with gelatin (0.1%) and irradiated mouse embryonic fibroblasts in ESC maintenance media. Media were changed daily until ESC-like colonies were observed. The reprogrammed colonies were tested for pluripotency by teratoma assay formation, alkaline phosphatase staining, SSEA-1 and NANOG staining, and OCT4 expression levels.

[0153] For the generation of A-iPSC-shGPX2, A-iPSC were infected post-reprogramming with a set of shRNA viral vectors for GPX2 (6 GIPZ Lentiviral shRNA vectors from

Thermo Scientific: RMM4532-EG14776). Clones were selected with puromycin, and the levels of down-regulation were measured by Q-PCR. For the generation of A-iPSC-shGSS, A-iPSC were infected post-reprogramming with a set of shRNA viral vectors for GSS (GE DHARMACON, RMM4532-EG14854).

[0154] For the generation of A-iPSC-shZSCAN10, mouse A-iPSC were infected post-reprogramming with a set of shRNA lentiviral vectors designed to target NM_001033425.3. A set of ZSCAN10 set shRNAs is commercially available from Abmgood.com (last visited on Oct. 6, 2015).

[0155] For the generation of Y-iPSC-GPX2, mouse Y-iPSC were infected with a lentivirus carrying the GPX2 cDNA post-reprogramming (Harvard Plasmid Core (<http://plasmid.med.harvard.edu/PLASMID/Home.jsp>). The infected clones were assessed for GPX2 expression levels by Q-PCR. For the generation of Y-iPSC-GSS, mouse Y-iPSC were infected with a lentivirus carrying the GSS cDNA (Harvard Plasmid Core (<http://plasmid.med.harvard.edu/PLASMID/>) post-reprogramming. The infected clones were sorted for a red fluorescent marker and the GSS expression levels were assessed by Q-PCR.

[0156] For the generation of human A-iPSC, 10⁵ skin fibroblasts from 84 years old, 76 years old, and 81 years old subjects were infected with retrovirus generated from the tetracistronic SFG-SV2A vector encoding for hOCT4, hSOX2, hKLF4 and hMYC in 6-well dishes with 0.5 ml of each viral supernatant (total 2 ml per well); and spun at 2500 rpm at RT for 90 min (BenchTop Centrifuge, Beckman-Coulter, Allegra-6R).

[0157] For the generation of ESC-shEXOSC2, ESC-shEXOSC8 and ESC shEXOSC2&8, ESC were infected with a set of shRNA viruses for EXOSC2 and/or EXOSC8 (2 GIPZ Lentiviral shRNA vectors for EXOSC2 from GE DHARMACON: RMM4431-200370629, RMM4431-200332733 and 3 GIPZ Lentiviral shRNA vectors for EXOSC8 from GE DHARMACON: RMM4532-EG69639). Clones were selected with puromycin treatment.

[0158] Retrovirus Generation

[0159] 293T cells were seeded overnight at 5×10⁶ cells per 150-mm dish with DMEM supplemented with 10% FBS and penicillin/streptomycin. Retrovirus was generated using pMX-mOCT4, pMX-mSOX2, pMX-mKLF4, and pEYK-mMYC constructs as described previously (Koh et al. *Nucleic Acids Res.* 30: e142, 200; Takahashi et al. *Cell* 126: 663-676, 2006). The cells were transfected with standard calcium phosphate method as previously described. Media were replaced with fresh DMEM two times, 18 hours after transfection. Approximately 48 hours after transfection, medium containing the lentivirus was collected and the cellular debris was removed with centrifugation. The supernatant was filtered through a 0.45-µm filter, and the retrovirus was pelleted with ultracentrifugation at 33,000 rpm in 45 Ti rotors (Beckman) for 90 min at 4° C. The retroviral particles were resuspended in the ESC medium and stored at -80° C.

[0160] Lentivirus Production

[0161] 293T cells were seeded overnight at 5×10⁶ cells per 150-mm dish with DMEM supplemented with 10% FBS and penicillin/streptomycin. The cells were transfected with plentiRZ-ZSCAN10 and plenti-RTTA using calcium phosphate cell transfection, as previously described (Kim et al. *Nat Biotechnol* 29: 1117-1119, 2011). The ZSCAN10 cDNA

was clone MmCD00295052 in the pENTR223.1 backbone. The cDNA for mZSCAN10 was subcloned into a plentiRZ vector and the cDNA for GPX2 into a plenti-puro vector using the Gateway® system. See <https://tools.lifetechnologies.com/content/sfs/manuals/gatewayman.pdf>. At 48 hours after transfection, the medium containing the lentivirus was collected and the cellular debris was removed with centrifugation. The supernatant was filtered through a 0.45- μ m filter, and the lentivirus was pelleted with ultracentrifugation at 33,000 rpm in 45Ti rotors (Beckman) for 90 min at 4° C. The lentivirus particles were resuspended in DMEM medium and stored at -80° C.

[0162] Teratoma analysis was carried out for ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10 cells. The results revealed decreased incidence of malignant tumors for A-iPSC-ZSCAN10 cells compared to A-iPSC without insert. Teratoma analysis for A-iPSC-GLUT3 will be performed in analogous manner and it is anticipated that the results will be qualitatively the same.

[0163] Quantitative Real Time-PCR (Q-PCR) Analysis

[0164] The expression levels of genes (ZSCAN10, OCT4, GPX2, GLUT3, and β -ACTIN) were quantified by Q-PCR with Power SYBR Green PCR mastermix (Applied Biosystems). Total RNAs (1 μ g) were reverse-transcribed in a volume of 20 μ l using the M-MuLV Reverse Transcriptase system (New England Biolabs), and the resulting cDNA was diluted into a total volume of 200 μ l. 10 μ l of this synthesized cDNA solution was used for analysis. For pluripotent genes, each reaction was performed in a 25- μ l volume using the Power SYBR Green PCR mastermix (Applied Biosystems). The conditions were programmed as follows: initial denaturation at 95° C. for 10 min followed by 40 cycles of 30 sec at 95° C., 1 min at 55° C., and 1 min at 72° C.; then 1 min at 95° C., 30 s at 55° C., and 30 sec at 95° C. All of the samples were duplicated, and the PCR reaction was performed using an Mx3005P reader (Stratagene), which can detect the amount of synthesized signals during each PCR cycle. The relative amounts of the mRNAs were determined using the MxPro program (Stratagene). The amount of PCR product was normalized to a percentage of the expression level of β -ACTIN. The PCR products of OCT4, ZSCAN10, GPX2 and β -ACTIN were also evaluated on 1.2% agarose gels after staining with ethidium bromide. The primers used to amplify the cDNA were the following: OCT4-For 5'-GGCTCTCCCATGCAITCAA-3' and OCT4-Rev 5'-TTTAACCCCAAAGCTCCAGG-3', ZSCAN10-For 5'-GGCTCAGAGGAATGCGTTAG-3' and ZSCAN10-Rev 5'-CATCTACAGGCCACCAGTT-3', GPX2-For 5'-GTGCTGATGAGAAATGTGGC-3' and GPX2-Rev 5'-AGGATGCTCGTTCTGCCCA-3', β -ACTIN-For 5'-TCGTGGGTGACATCAAAGAGA-3' and β -ACTIN-Rev 5'-GAACCGCTCGTTGCCAATAGT-3', and HPRT-For 5'-CTCCTCAGACCGCTTTTTCG-3' and HPRT-Rev 5'-TCGAGAGCTTCAGACTCGT-3', EXOSC2-For CCCAAGGAGCATCTGACAA and EXOSC2-Rev CCCAACCCATTACCTCCC, EXOSC1-For ATGGGTGCGTATGGGCATAG and EXOSC1-Rev CCCATGCTGTCCTATTGGGT, EXOSC5-For CCGATTCTACCGGGAATCACT and EXOSC5-Rev CTACATGGGCACAGACAGAGG. Transgene silencing (OCT4, SOX2, KLF4, and MYC) was confirmed using the following primers, which span the 5' region of the viral vector and the 5' end of the structural genes. Uninfected fibroblasts were used as a negative control and day 3

fibroblasts transfected with Yamanaka factors were used as a positive control. The primer sequences to detect the transgene flanked the pMX vector and the transgene: pMX-51811-For 5'-GACGGCATCGCAGCTTGGATACAC-3', and OCT4-Rev 5'-CAGTCCAACCTGAGGTCCAC-3', KLF4 Rev 5'-GACAACGGTGGGGGACAC-3', SOX2 Rev 5'-CTGGAGTGGGAGGAAGAGT-3', and MYC Rev 5'-CCAGATATCCTCACTGGGCG-3'. the primers for GLUT3 were mGlut3-xba-F attctagaATGGGACAACGAAGGTGACC and mGlut3-xba-R atggtatccTCAGGCGTGGCCAGGGGTC.

[0165] Drug Treatments and Irradiation

[0166] Phleomycin (Sigma) was added at 30 μ g/ml for 2 hours. Cells were processed for analysis 30 min after phleomycin treatment unless indicated otherwise. After the 30-min recovery in ESC media, the cells were collected and processed for following experiments. For the detection of the DNA damage response in the extended period, the cells were given 6 hours to recover after phleomycin treatment and were processed for H2AX immunostaining. In the DNA fragmentation assay, the cells were given 15 hours to recover. To check the mutagenesis potential, the cells were treated with phleomycin 30 μ g/ml for 2 hours and cultured for one passage after each treatment. This process was repeated three times and then the cells were processed for 6TG selection. Cells were irradiated at 10 Gy, allowed to recover for 2 hours, and then lysates were collected for immunoblot analysis.

[0167] Teratoma Analysis

[0168] iPSC were collected by trypsin collagenase treatment, resuspended in Matrigel mix (DMEM:Matrigel:collagen at 2:1:1 ratio), and 10⁶ undifferentiated cells were injected into the subcutaneous tissue above the rear haunch of Rag2 γ C immunodeficient mice (Taconic). Teratoma formation was monitored for 3 months post-injection. Collected tumors were fixed in 10% formalin solution and processed for hematoxylin and eosin (H/E) staining by the Molecular Cytology facility of Memorial Sloan Kettering Cancer Center and by Histowiz, Inc. Protocols for H/E staining are provided at <http://protocolsonline.com/histology/dyes-and-stains/haematoxylin-eosin-he-staining/> and http://www.nsh.org/sites/default/files/Guidelines_For_Hematoxylin_and_Eosin_Staining.pdf.

[0169] Immunoblot Analysis

[0170] Treated and untreated cells (1 \times 10⁵ cells) were collected 30 min after the 2-hour phleomycin treatment (30 μ g/ml). To harvest protein, 100-200 μ l RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP40, 0.25% Na-deoxycholate, 1 mM PMSF, protease inhibitor cocktail, and phosphatase inhibitor cocktail) was added to floating cell pellets and the remaining adherent cells. The samples were incubated on ice (10 min) and centrifuged (14,000 g, 10 min, 4° C.). Protein concentrations were determined using a BCA protein assay kit (Pierce). Samples were adjusted to the same concentration with RIPA buffer (3000 μ g/ml) and were combined with Laemmli Sample Buffer (Biorad) and β -Mercaptoethanol (Sigma) then heated at 95° C. for 5 min and loaded onto a 4-15% Mini Protean TGX SDS-PAGE gel (BioRad). Samples on the SDS-PAGE gel were transferred to a 0.2-mm PVDF membrane at 100 V for 1 h, using a wet electro-transfer method (0.2 M glycine, 25 mM Tris, and 20% methanol). The membrane was blocked with 5% BSA in PBS-T (1 h at 4° C.), followed by incubation with primary antibodies anti-H2AX (Millipore, 05-636) (1:1000), anti-

p53 (Leica Biosystems, P53-CM5P) (1:1000), anti phospho-ATM (Pierce, MA1-2020), or anti-beta actin (Cell Signaling, #4967) (1:5000) in blocking solution (5% BSA in phosphate-buffered saline containing Tween-20 [1:1000] PBS-T, overnight at 4° C.). After primary antibody incubation, membranes were washed three times in PBS-T prior to addition of secondary antibody labelled with peroxidase. Secondary antibodies were from Cell Signaling (1:10,000).

[0171] Bisulfite Pyrosequencing Analysis

[0172] 500 ng of genomic DNA was bisulfite-treated using the EZ DNA Methylation-Gold Kit (Zymo Research) according to the manufacturer's specifications. Bisulfite-treated genomic DNA was PCR-amplified using ZSCAN10 specific primers. The position of interest of ZSCAN10 promoter was based on Ensembl Genome assembly: GRCm38 (GCA000001635.4) on Chr17:2359958-23600647. The assay (PCR and Pyrosequencing) covered three CpG sites immediately upstream of the transcription start site on 23600600 (CpG 3), 23600645 (CpG 2), and 23600647 (CpG 1). The pyrosequencing was designed and performed by Epigenix (Hopkinton, Mass., USA).

[0173] Cytogenetic Analysis

[0174] Cytogenetic analysis was performed by metaphase chromosome preparation, G-band karyotyping, and flow cytometry analysis with PI staining. Metaphase chromosome preparation and the G-band karyotyping were performed by the Molecular Cytogenetics Core Facility of Memorial Sloan Kettering Cancer Center. For PI staining, the cells were harvested and washed in PBS and then fixed in cold 70% ethanol (added drop-wise to the pellet while vortexing to minimize clumping) for 30 min at 4° C. The cells were washed in PBS twice, treated with ribonuclease, and stained with PI (Propidium Iodide Staining Solution: 3.8 mM sodium citrate, 40 µg/ml PI [Sigma, P 4170] in PBS).

[0175] Immunohistochemistry Staining

[0176] Cells were fixed in 3.7% formaldehyde for 20 min at room temperature and washed with PBS. Samples were then permeabilized with 0.1 Triton X-100 in PBS for 20 min and blocked for 1 h with 3% BSA in PBS-T, and primary antibodies were incubated for 2 h at room temperature or overnight at 4° C. Anti-H2AX was purchased from Millipore (05-636), anti-SSEA-1 phycoerythrin conjugated was purchased from R&D systems (FAB2155P), and anti-NANOG from BETHYL Laboratories (A300-397A). Primary antibodies were used at 1:500 dilution. Alexa 568-conjugated goat anti-mouse IgM (A-21124) and Alexa 633-conjugated goat anti rabbit IgG (A-21072) were from Molecular Probes. Secondary antibodies were used at 1:1000 dilution. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Sigma). Alkaline phosphatase (AP) staining was performed using the Alkaline Phosphatase Detection Kit (Millipore) according to the manufacturer's instructions. Fluorescence images were obtained using an AxioImager Z1 microscopy system (Zeiss).

[0177] DNA Fragmentation Analysis

[0178] DNA fragmentation was measured using an in situ cell death assay kit (Roche) for visualization of DNA strand breaks by labelling the free 3'-OH termini with modified nucleotides (e.g., biotin-dUTP, DIG-dUTP, fluorescein-dUTP) in an enzymatic reaction. iPSC cells (1×10⁵ cells) were treated with phleomycin (30 µg/ml) for 2 hours. Samples were collected as control or treated for analysis 15 hours after phleomycin treatment. Additionally, cells were treated with DNAase I recombinant (Roche) (10 min, 3 U/ml, at 15° C. to 25° C.) to induce DNA strand breaks, as a positive control for apoptosis. Medium containing floating

cells and attached cells was centrifuged (1000 g, 5 min) and collected. Cells were processed for flow cytometry analysis.

[0179] H₂O₂ Reactive Oxygen Species (ROS) Assay

[0180] H₂O₂ scavenging activity was measured using a cellular reactive oxygen species assay kit (Abcam, ab113851). ESC/iPSC were labelled with 20 µM DCFDA (2',7'-dichlorofluorescein diacetate; a fluorogenic dye that measures hydroxyl, peroxy, and other ROS activity within the cell), and cultured for 3 h with 50 µM TBHP (tert-butyl hydrogen peroxide; stable chemical form of H₂O₂). Cells were then analyzed on a fluorescent plate reader. Mean±standard deviation is plotted for four replicates from each condition.

[0181] TBHP Treatment

[0182] Cells were treated with 350 µM TBHP solution (Luperox® TBH70X, tert-Butyl hydroperoxide solution 70 wt. % in H₂O, 458139) for 30 min in PBS. Lysates were collected for immunoblot analysis. The control untreated cell lines were cultured in either ESC media or PBS, and DNA damage response was not induced in both media without TBHP treatment (data not shown).

[0183] HPRT Assay

[0184] HPRT assay was performed according to the previously published protocol (Tsuda et al., *AATEX* 11 (2), 118-128, 2005). After ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10 were cultured with three rounds of phleomycin treatment, 10⁶ ESC and iPSC were plated onto 10-cm tissue culture dishes containing feeder cells (CF-1 MEF) and added 5 µg/ml of 6-TG (2-amino-6-mercaptopurine; Sigma) for negative selection. The mutation frequency was estimated by the inactivation of HPRT promoter activity. Individual colonies were counted/picked at day 12, and the number of colonies was normalized to the percentage of colonies that did not express HPRT in each group by Q-PCR analysis.

[0185] Glutathione Detection Assay

[0186] Feeder-free cells were cultured on Matrigel-coated tissue culture plates in MEF-conditioned ESC-media. On day 3, the cells were washed in PBS and scraped and pelleted by centrifugation. Subsequent steps were performed using a Glutathione Fluorometric Assay Kit (cat# K264-100, Biovision Inc., Milpitas, Calif., USA) according to the manufacturer's manual. Briefly, cell pellets were homogenized in ice cold glutathione assay buffer, preserved in perchloric acid, and centrifuged. Supernatants were neutralized with potassium hydroxide. After centrifugation, the supernatant was either used to detect reduced glutathione (GSH), or total glutathione was measured by reducing oxidized glutathione (GSSG) to GSH before measurement. For measuring GSSG concentrations specifically, existing GSH was quenched before reducing agent was applied. OPA (o-phthalaldehyde) probe, which reacts with GSH and emits fluorescence, was added to samples, and signal was acquired at Ex/Em=340 nm/420 nm on a Varioscan Flash by Thermo Scientific. Oxidation capacity of glutathione was determined by the quantity of total glutathione (GSH+GSSG).

EXAMPLES

Example 1

[0187] iPS Cells Derived from Aged Mice Exhibit Higher Genomic Instability and Lower Apoptotic Activity

[0188] Yamanaka and others (Takahashi et al., *Cell*, 126, 663-676, 2006) identified the four epigenetic reprogramming factors for generating iPSC using young donor tissue,

but never tested whether or not the same four factors were sufficient for iPSC reprogramming of aged donor tissue.

[0189] Here, iPSC cells were generated using mouse skin fibroblasts from E15.5 embryos to 5-day-old neonates (Y-iPSC) or using mouse skin fibroblast from donors 1.4 years of age (A-iPSC) according to the standard Yamanaka iPSC reprogramming protocol.

[0190] 12 clones of each cell type were randomly picked based on the morphology, and analyzed for pluripotency compared to ESCs as the gold standard. Multi-lineage contribution to three germ layers in teratoma analysis and pluripotent gene expression analysis (AP/OCT4/SSEA1/NANOG) showed successful reprogramming of mouse skin fibroblasts isolated from both young and aged donors. Silencing of the four reprogramming factors (OCT4, SOX2, KLF4, MYC) in each clone was confirmed by quantitative PCR (Q-PCR). Initially, when DNA ploidy was tested in multiple iPSC clones, both Y-iPSC and A-iPSC clones with normal ploidy were observed (FIGS. 1A, 1B, and 1D); however, a higher frequency of polyploidy was observed in A-iPSC compared to Y-iPSC (FIGS. 1B, 1E, and 1F). Additionally, A-iPSC displayed more chromosomal structural abnormalities than Y-iPSC (FIG. 1G).

[0191] Pluripotent stem cells are known to have a unique DNA damage response that is different from the canonical DNA damage response of somatic cells and cancer cells. The maintenance of genomic stability in pluripotent stem cells is achieved by directly inducing apoptosis to eliminate severely damaged cells from the population (Liu, J, Trends in Cell Biology, 24, 268-274, 2014; Liu, J, Cell Stem Cell, 13, 483-491, 2013). Thus, it was postulated that the poor genetic stability observed in A-iPSC was due to defects in apoptosis. In order to test this hypothesis, activation of apoptosis in response to DNA damage was evaluated in all independent clones.

[0192] In situ cell death assays of ESC, Y-iPSC, and A-iPSC were performed 15 hours after the end of treatment with a DNA damage inducing agent, phleomycin (2 hours, 30 $\mu\text{g}/\text{ml}$). A-iPSC show fewer cells staining for cell death compared to ESC and Y-iPSC. Y-iPSC group treated with dye in the absence of enzymatic reaction was used as a negative control. Nuclei were stained with DAPI. As shown in FIG. 2, lower apoptotic response was observed by DNA fragmentation assay after phleomycin treatment of A-iPSC, while ESC and Y-iPSC displayed comparable DNA fragmentation under same conditions. Collectively, the data presented here suggest that A-iPSC are characterized by higher genomic instability and lower apoptotic activity compared to ESC and Y-iPSC.

Example 2

[0193] ZSCAN10 is a Pluripotency Factor Poorly Activated in A-iPSC Compared to ESC and Y-iPSC

[0194] In order to identify ESC-specific pluripotency factors that are poorly activated in A-iPSC compared to ESC and Y-iPSC, and are most likely responsible for the defects observed in A-iPSC, a strategy was developed starting from a known network of 59 pluripotency genes. Kim et al. (Kim, J., *Cell* 132, 1049-1061) previously reported 59 core pluripotency genes derived from the pluripotency network analysis (FIG. 3). Initially, these 59 core genes were filtered against the genes known to be associated with DNA damage response, such as p53, SIRT1, PLK1, and genes upstream of p53 (ATM, PARP, and DNAPK). From there, the gene list

was further filtered based on differential expression in A-iPSC vs. Y-iPSC and A-iPSC vs. ESC, which narrowed down the candidates to a single gene, ZSCAN10. ZSCAN10 is a known zinc finger transcription factor specifically expressed in ESC, and is an integrated part of the transcriptional regulatory network with SOX2, OCT4, NANOG, and ZSCAN4.

[0195] To further evaluate the role of ZSCAN in reprogramming, the levels of ZSCAN were determined in ESC, Y-iPSC, and A-iPSC by quantitative real-time-PCR (Q-PCR). As expected, ZSCAN10 mRNA levels were significantly lower in A-iPSC compared to ESC and Y-iPSC (FIG. 4). Thus, it was concluded that ZSCAN10 expression is low in somatic cells, higher in Y-iPSC and ESC, but restricted in A-iPSC.

[0196] The data presented here suggests that ZSCAN10 is a potential factor responsible for the genomic instability observed in A-iPSC cells.

Example 3

[0197] ZSCAN10 Expression Restores Genetic Stability and Apoptosis in A-iPSC

[0198] To explore the function of ZSCAN10 in reprogramming, iPSC were generated from aged donor fibroblasts using the four Yamanaka factors (OCT4, SOX2, KLF4, and MYC) plus ZSCAN10 within a doxycycline (Dox)-inducible lentiviral expression vector. A-iPSC-ZSCAN10 cells were grown in media supplemented with 2 $\mu\text{g}/\text{ml}$ of doxycycline for two days. Following doxycycline withdrawal, reprogrammed colonies were tested for pluripotency by teratoma assay formation, alkaline phosphatase staining, SSEA-1 and NANOG staining, and OCT4 expression levels, which confirmed that A-iPSC-ZSCAN10 have undergone successful reprogramming. Next, A-iPSC-ZSCAN10 were tested for their ability to rescue genomic stability and apoptotic defects observed in A-iPSC containing low levels of ZSCAN10.

[0199] Using a doxycycline system, transient expression of ZSCAN10 in A-iPSC permanently increased endogenous ZSCAN10 expression to levels similar to those in Y-iPSC and ESC (FIG. 4). Moreover, transient expression of ZSCAN10 during reprogramming in A-iPSC reduced the abnormal chromosomal ploidy and structural abnormalities to levels comparable to Y-iPSC and ESC (FIGS. 1C, 1F, and 1G). In order to test the effect of ZSCAN10 on apoptosis in A-iPSC, A-iPSC-ZSCAN10 were treated with DNA damage inducing agent, phleomycin (2 hours, 30 $\mu\text{g}/\text{ml}$), and the apoptotic response was evaluated by DNA fragmentation assay. ZSCAN10 expression in A-iPSC restored the defect in induction of apoptosis following DNA damage induction (FIG. 2).

[0200] These results indicate that ZSCAN expression in A-iPSC rescues the genomic stability and apoptosis defects detected in iPSC cells generated from aged donors.

Example 4

[0201] A-iPSC Display Higher Mutagenic Potential Compared to ESC and Y-iPSC, which is Restored by ZSCAN10 Expression

[0202] As discussed in Example 3, transient expression of ZSCAN10 in A-iPSC during reprogramming restored genomic stability and apoptosis to levels comparable to ESC and Y-iPSC. To define the mechanism by which ZSCAN10

expression restores genomic stability and apoptosis in A-iPSC, a comprehensive molecular analysis of a minimum of three independent clones (each of ESC, Y-iPSC, A-iPSC-ZSCAN10, and A-iPSC) was performed. Since A-iPSC showed a defect in induction of apoptosis, it was hypothesized that A-iPSC failed to eliminate damaged cells and would accumulate more genomic mutations than Y-iPSC or ESC.

[0203] The mutagenic potential in ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10 was determined using the mutagenic destruction of HPRT promoter activity (Tsuda et al., AATX 11 (2), 118-128, 2005). The hypoxanthine phosphoribosyl transferase (HPRT), gene located on the X chromosome of mammalian cells, is widely used as a model gene to investigate gene mutations in mammalian cell lines. The HPRT methodology detects mutations that destroy the functionality of the HPRT gene and or/protein, where the detection of mutations is achieved by selection using a toxic analogue 6-thioguanine (6-TG). Various types of mutations in the HPRT gene lead to cells resistant against lethal 6-TG incorporated into their DNA. Thus, only cells with HPRT mutations can grow in 6-TG containing media. This method detects a broad range of mutagens, since any mutation resulting in the ablation of proper gene function produces an HPRT mutant.

[0204] Following three rounds of phleomycin treatment (2 hours each, at 30 µg/ml), ESC, Y-iPSC, and A-iPSC were cultured in media containing 6-TG (5 µg/ml). The mutation frequency was estimated by the inactivation of HPRT promoter activity. Individual colonies were counted/picked at day 12, and the number of colonies was normalized to the percentage of colonies that did not express HPRT in each group by Q-PCR analysis.

[0205] A-iPSC displayed significantly higher mutation rate compared to ESC and Y-iPSC (FIG. 5A). Consistent with the findings that ZSCAN10 can restore genomic stability and apoptosis defects in A-iPSC, transient expression of ZSCAN10 reduced the mutagenic potential in these cells (FIG. 5A).

[0206] Mutagenic potential of ESC, Y-iPSC, and A-iPSC was further tested *in vivo*. Teratoma formation is an established assay that determines the capacity of differentiation *in vivo* and is considered to be the essential method for evaluating human ES and iPSC cell lines. Teratoma analysis revealed that while ESC and Y-iPSC form benign teratoma, significant percentage of A-iPSC clones (48%) form a mixture of malignant carcinoma and benign teratoma (FIGS. 5B-5E).

[0207] Taken together, these results show that A-iPSC exhibit higher mutagenic potential, both *in vitro* and *in vivo*, than ESC and Y-iPSC.

Example 5

[0208] ZSCAN10 Corrects the Blunted DNA Damage Response in A-iPSC Via ATM, p53, and H2AX

[0209] The aging process gradually alters DNA repair mechanisms through a chronic activation of the DNA damage response. To evaluate the DNA damage response in more detail in A-iPSC and the role of ZSCAN10 in this process, activation of known DNA damage effector proteins was assessed.

[0210] The cellular response to DNA damage involves a series of events that lead to apoptosis. One of the early events is the phosphorylation of Ataxia telangiectasia

mutated (ATM), a serine/threonine kinase that plays a central role in the repair of DNA double-strand breaks. ATM further phosphorylates several key proteins that initiate activation of the DNA damage checkpoint, leading to cell cycle arrest and apoptosis. ATM activation leads to phosphorylation of tumor suppressors p53 and histone 2AX (H2AX). With the goal of gaining a better understanding of the events affected by ZSCAN10, phosphorylation of ATM, H2AX, and p53 was examined in A-iPSC following the induction of DNA damage.

[0211] ESC, Y-iPSC, and A-iPSC were treated with 30 µg/ml of DNA damage inducing agent phleomycin for 2 hours. Protein levels of ATM, H2AX, and p53 were determined by immunoblot analysis. As shown in FIGS. 6A, 6B, and 6C, A-iPSC exhibit either low, or undetectable levels of phosphorylated ATM, p53, and H2AX following the treatment with phleomycin compared to ESC and Y-iPSC. These defects are, in part, mediated by ZSCAN10 since expression of ZSCAN10 in A-iPSC restores the phosphorylation of DNA damage pathway proteins to levels comparable to those detected in ESC and Y-iPSC (FIGS. 6A, 6B, and 6C). In order to confirm that the defect in DNA damage response was universal and not dependent on phleomycin, experiments were conducted using the same experimental design, but changing the DNA damage inducing agent. Similarly to data observed with phleomycin, ESC and Y-iPSC, but not A-iPSC, show an increase in ATM/H2AX/p53 levels after irradiation and hydrogen peroxide H₂O₂ treatment. For radiation experiments, cells were irradiated with 10 Gy, allowed to recover for 2 hours, and the lysates were collected for immunoblot analysis. Both radiation and H₂O₂ are known inducers of DNA damage response. Importantly, the ATM/H2AX/p53 response to irradiation and H₂O₂ in A-iPSC was recovered by transient expression of ZSCAN10 (FIGS. 6F and 6G).

[0212] In addition to overexpression experiments, the inventors reduced ZSCAN10 levels using shRNA targeting ZSCAN10 in Y-iPSC (FIGS. 6D and 6E). Further providing support for the role of ZSCAN10 in the regulation of DNA damage response, Y-iPSC with reduced ZSCAN10 expression exhibited lower apoptotic response compared to those that had normal ZSCAN10 levels (FIG. 6D).

[0213] Collectively, these results indicate that impaired DNA damage response in A-iPSC is recovered with the transient expression of ZSCAN10.

Example 6

[0214] Endogenous ZSCAN10 is Hypermethylated in A-iPSC and Hypomethylated in ESC and Y-iPSC

[0215] Induction of pluripotency in somatic cells is considered an epigenetic process that among other things entails changes in DNA methylation patterns. With the aim of further elucidating the changes that occur in A-iPSC compared to ESC and Y-iPSC, and the role of ZSCAN10, DNA methylation analysis was performed. Bisulfite pyrosequencing analysis of the ZSCAN10 promoter regions showed that the ZSCAN10 promoter is hypomethylated/activated in Y-iPSC and ESC, and hypermethylated/inactive in A-iPSC (FIG. 7). To test whether transient ZSCAN10 expression can restore the methylation pattern of A-iPSC, A-iPSC-ZSCAN10 cells generated using a Dox-inducible expression system were analyzed. Similar to the ability of ZSCAN10 to restore other defects in A-iPSC, transient expression of

ZSCAN10 in A-iPSC led to hypomethylation/activation of the endogenous ZSCAN10 promoter to levels closer in Y-iPSC.

[0216] Microarray analysis of mouse ESC versus aged and young mouse fibroblasts (Y-SC and A-SC—wherein “SC” here stands for “somatic cells”) as well as Y-iPSC, A-iPSC, revealed differential regulation of DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3b) gene (a gene reviewed in (Kim et al. *Cell Mol Life Sci.* 66(4): 596-612 (2009)). Contrary to DNMT3b, the levels of DNMT3a were similar among various cell types. This finding was further corroborated by q-PCR (FIG. 7B), where DNMT3b mRNA levels were lowest in fibroblasts, and highest in ESC. Given the role of DNMT3b in DNA methylation, the inventors postulate that poor activation of DNMT3b may be responsible for differential methylation of ZSCAN promoter in A-iPSC. In addition DNMT3b can be overexpressed in A-iPSC cells and achieve the same result as ZSCAN10 overexpression. Thus, the exogenous introduction of DNMT3b into the A-iPSC cells may result in diminished oncogenic potential of these cells or any stem/iPSC cells associated with reduced ZSCAN10 expression.

Example 7

[0217] Imbalance of H₂O₂/Glutathione Homeostasis in A-iPSC, and Recovery by ZSCAN10 Via Reduction of Excessively Activated GPX2 in A-iPSC

[0218] As described in Example 5, the defective DNA damage response of A-iPSC and its restoration by ZSCAN10 were also confirmed in response to various DNA damaging agents such as radiation and H₂O₂. DNA damaging agents can induce H₂O₂ and result in genomic damage. A normal cellular response against H₂O₂ involves two distinct mechanisms: (1) H₂O₂ can be scavenged by glutathione to maintain genomic stability, and (2) H₂O₂ itself acts as a signal transducer to activate DNA damage response pathways, such as ATM. An imbalance in glutathione-H₂O₂ homeostasis, with lower glutathione and higher H₂O₂ activity, induces genomic damage to trigger the DNA damage response. Conversely, higher glutathione activity that favors H₂O₂ scavenging and lowers H₂O₂ activity blunts the DNA damage response and damaged cells fail to be eliminated, leading to genomic instability. Therefore, homeostasis of glutathione-H₂O₂ regulation plays a critical role in maintaining overall genomic stability.

[0219] To determine the status of glutathione-H₂O₂, oxidation capacity of glutathione as well as H₂O₂ scavenging activity (maximum oxidation capacity) were evaluated in various iPSC lines. The ratio of intracellular reduced and oxidized forms of glutathione

[0220] (GSH/GSSG) is often used as an indicator of cellular redox state, the degree of oxidative stress and the antioxidant capacity of cells. Glutathione analysis was conducted using Glutathione Fluorometric Assay (Biovision, K264-100). As shown in FIG. 8A, A-iPSC exhibit excessive oxidation capacity, which was normalized to the level of ESC and Y-iPSC by transient expression of ZSCAN10. H₂O₂ scavenging activity was measured using reactive oxygen species (ROS) assay kit (Abcam, ab113851). A-iPSC show strong H₂O₂ scavenging activity (FIG. 8B), with a reduced response against the treatment of TBHP (tert-butyl hydrogen peroxide; stable chemical form of H₂O₂, 3 h).

Upon ZSCAN10 expression, the elevated glutathione activity was reduced to levels equivalent to those seen in Y-iPSC/ESC (FIGS. 8A and 8B).

[0221] The mechanism by which the oxidation capacity of glutathione to scavenge H₂O₂ is elevated in A-iPSC compared to Y-iPSC and ESC was further evaluated. A comparative gene expression analysis among the different cell lines led to the identification of candidate genes that were up- or down-regulated in A-iPSC compared to A-iPSC-ZSCAN10, and that were expressed at similar levels in A-iPSC-ZSCAN10, ESC, and Y-iPSC. Glutathione peroxidase 2 (GPX2) gene was excessively expressed in A-iPSC and its expression was normalized by ZSCAN10 expression (FIG. 9A).

[0222] GPX2 is a H₂O₂ scavenger protein that regulates glutathione-mediated scavenging activity. In order to test whether excess levels of GPX2 are responsible for imbalance in glutathione-H₂O₂ homeostasis in A-iPSC, GPX2 was inhibited in A-iPSC using shRNA. Knockdown of GPX2 in A-iPSC normalized glutathione-H₂O₂ homeostasis (FIGS. 9B and 9C), increased apoptosis (FIG. 9D), and recovered the DNA damage response (FIG. 9E).

Example 8

[0223] GLUT3 Gene Expression is Significantly Increased in Y-iPSC, but not in A-iPSC

[0224] In order to gain a deeper understanding of biological processes that occur during cellular reprogramming, an innovative approach was taken to reveal additional factors important for the reprogramming of aged somatic cells. Comparative genomic analysis of ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10 in the presence or absence of pleomycin treatment (30 µg/ml for 2 hours) led to identification of GLUT3, a pluripotent stem cell-specific glucose transporter. FIG. 10A shows poorly activated GLUT3 in A-iPSC compared to ESC and Y-iPSC.

[0225] Glucose metabolism is essential to maintain cell homeostasis within the microenvironment of various tissues. Most somatic cells generate 36 ATP from each glucose molecule through oxidative phosphorylation in the presence of oxygen; by contrast, ESC use glycolysis to generate 2 ATP from each glucose in the absence of oxygen. During iPSC reprogramming, glucose metabolism shifts from somatic cell-specific oxidative phosphorylation to ESC-specific glycolysis. Although ESC-specific glycolysis consumes 18-fold more glucose than oxidative phosphorylation to generate the same amount of ATP, the benefit of glycolysis is that it generates ATP while producing fewer H₂O₂ which can cause genomic mutation.

[0226] To investigate a role of GLUT3 in glucose metabolism within the context of mouse A-iPSC, intracellular glucose uptake was monitored in mouse ES and iPSC cell lines. A-iPSC take up 18-fold less glucose than Y-iPSC and ESC (FIG. 10B) and have a higher oxygen consumption rate as measured by oxidative phosphorylation (FIG. 10C). These results suggest that A-iPSC continue to generate ATP via somatic cell-specific oxidative phosphorylation, rather than switching to ESC-specific glycolysis.

[0227] During the transition from somatic cells to iPSC, GLUT3 gene expression is significantly increased in Y-iPSC, but not in A-iPSC (FIG. 10A). Interestingly, GLUT3 expression is induced by ZSCAN10 (FIG. 10A), suggesting that the loss of ZSCAN10 and GLUT3 activity are mechanistically connected in A-iPSC. Indeed, increased

expression of GLUT3 also shows the recovery of DNA damage response (FIG. 10D) as increased expression of ZSCAN10 had, confirming the hypothesis of mechanistic connection. To test the ability of ZSCAN10 to target GLUT3, the inventors tested the ability of ZSCAN10 to bind to the promoter of GLUT3 using Chromatin IP analysis. As demonstrated in FIG. 10E, ZSCAN10 binds to the GLUT3 promoter in ESC, Y-iPSC, and A-iPSC.

[0228] Given that GLUT3 expression is induced by ZSCAN10, and that oxidative phosphorylation induces production of H_2O_2 , which is known to trigger the DNA damage response, it is likely that the loss of this response in A-iPSC contributes to increased oncogenicity. Indeed, overexpression of GLUT3 in A-iPSC recovered the normal ROS levels, wherein the downregulation of GLUT3 in Y-iPSC decreased the ROS levels (FIG. 10F). Furthermore, glutathione levels were reduced to normal (similar to those observed for ESC and Y-iPSC) in A-iPSC upon overexpression of GLUT3 (FIG. 10G).

[0229] Collectively, the data presented here suggest a model where poor GLUT3 activation in A-iPSC, as a consequence of low ZSCAN10 expression (or even independently), leads to hyperactivation of oxidative phosphorylation and an increase in H_2O_2 production, which induces glutathione.

Prophetic Example 1

[0230] As a part of preliminary analysis, the inventors sought to determine what are the major differences between the various types of iPSC (Y-iPSC, A-iPSC, A-iPSC-ZSCAN10) and ESC. Microarray analysis of ESC versus Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10 revealed sets of the differentially expressed genes. Table 1. indicates the number of differentially regulated genes among the specific groups. Using the mean Z-score analysis, it was determined the genes were grouped based on the fold change of differential expression. A higher score in the table means a more pronounced difference in expression from ESC.

[0231] The data summarized in Table 1. show that a smaller number of genes are differentially expressed in A-iPSC-ZSCAN10 compared to ESC, than the number of genes differentially expressed between Y-iPSC and ESC. These results suggest that at least on the level of overall gene expression, A-iPSC-ZSCAN10 share more similarities with ESC not only compared to A-iPSC, but also compared to Y-iPSC. In order to confirm that this observation is also reflected in the analysis of the core pluripotency network genes, expression of core pluripotency network genes among different iPSC lines and ESC was performed. As shown in Table 2. Similarly to what was observed in Table 1, number of genes differentially expressed between A-iPSC-ZSCAN10 and ESC was fewer than the number of genes differentially expressed between the Y-iPSC and ESC. Collectively, this data suggests unique features

[0232] Future experiments will include further investigation into why ZSCAN10-supplemented A-iPSC are closer to ESC than to Y-iPSC when it comes to gene expression. This will be part of a deeper level analysis of epigenetic alterations that affect aged somatic cells and also A-iPSC in a negative manner (e.g., block differentiation of A-iPSC, favor oncogenicity upon transplantation of cells derived from A-iPSC). For example, the ability of ZSCAN10 to recover poor tissue differentiation potential of A-iPSC will be assessed. It is anticipated that after ZSCAN10 supplementa-

tation, A-iPSC will display substantially improved tissue differentiation compared to untreated A-iPSC. Thus, tissue differentiation potential will be another aspect of the quality of A-iPSC that will be improved by ZSCAN10 supplementation (and can be assessed by measuring ZSCAN10 levels or measuring levels of another surrogate marker described herein and comparing the level to that of a Y-iPSC or ESC control).

TABLE 1

	Differentially expressed gene between ESC vs.		
	Y-iPSC	A-iPSC-ZSCAN10	A-iPSC
1.2 fold change	3304	2115	4212
1.5 fold change	2036	11195	3361
2.0 fold change	775	507	2010
3.0 fold change	141	127	386

TABLE 2

2.0 Fold Change Number of	Differentially expressed gene between ESC vs.				
		Genes	Y-iPSC	A-iPSC-ZSCAN10	A-iPSC
common target					
7 Core factor		47	6	6	12
6 Core factor		100	24	18	35
5 Core factor		124	36	30	57
4 Core factor		227	53	47	94
3 Core factor		427	76	68	148
2 Core factor		901	129	106	251
1 Core factor		2350	252	186	543
0 Core factor		9686	292	168	770
Total Target Genes		13862	868	629	1910

[0233] Furthermore, DNA methylation status of the genes most prominently differentially expressed between ESC and Y-iPSC, A-iPSC, or A-iPSC-ZSCAN10 will be assessed. One of the aims of this analysis is to test whether already observed difference in DNA methylation (comparing ESC to A-iPSC and Y-iPSC in the absence of ZSCAN10 supplementation) follows the same pattern as the gene expression pattern outlined in Table 1 and Table 2. It is anticipated that the methylation pattern of ZSCAN10-supplemented A-iPSC, similarly to gene expression pattern, will be closer to that of ESC than that of Y-iPSC.

[0234] The same experiment may be repeated with GLUT3 supplementation instead of ZSCAN10 supplementation in A-iPSC. The results are anticipated to be qualitatively the same.

TABLE 3

Exosome components and co-factors				
	Domains	Human ^c	Loc ^d	
Exosome core	RNasePH	hRrp41 (hSki6; EXOS4)	n + c	
		hRrp42 (EXOS7)	n + c	
		hRrp46 (EXOS5)	n + c	
		hRrp43 (OIP2; EXOS8)	n + c	
		hMtr3 (EXOS6)	n + c	
		hRrp45 (Pm/Sc1-75; EXOS9)	n + c	
		Si and KH domains	hRrp4 (EXOS2)	n + c
			hRrp40 (EXOS3)	n + c
			hCs14 (EXOS1)	n + c

TABLE 3-continued

Exosome components and co-factors			
	Domains	Human ^c	Loc ^d
Exonuclease	RNase II	hRrp44 (hDis3)	n + c
	RNase D	hRrp6 (PM/Sci-100; EXOS10)	n + c

Example 9

[0235] ZSCAN10 Binds and Up-Regulates Exosomes

[0236] In further study, the inventors sought to gain a better understanding of the mechanism by which ZSCAN10 inhibits the expression of GPX2 in A-iPSC. Analysis of GPX2 sequence revealed that GPX2 gene contains highly conserved ARE sequences (Singh et al. *Am J Respir Cell Mol Biol.* 35(6):639-50 (2006)). Interestingly, it is known that exosome, which mediates the degradation of mRNA, targets ARE sequences to induce mRNA decay. (Mukherjee et al. *EMBO J.* 21(1-2):165-174 (2002); Schmid et al. *Trends Biochem Sci.* 2008 October; 33(10):501-10.).

[0237] mRNA turnover is a highly regulated process that plays a role in regulating the levels of transcripts that encode an array of proteins (Schoenberg et al. *Nat Rev Genet.* 13 (4): 246-259 (2012)). Given the presence of ARE sequences in GPX2, the inventors performed enrichment analysis of ARE sequences in 60 upregulated genes in A-iPSC (upregulated compared to Y-iPSC/ESC and A-iPSC-zscan10). Gene enrichment analysis (FIG. 11A histogram) showed that the likelihood of any given transcript to have the UUAUUUA (A/U)(A/U) ARE sequence is 7, so the odds of finding 14 genes containing ARE sequences in a sample of 60 genes based on just random chance is very low ($p=0.01224$). The control group was 18,299 non-duplicated longest ensemble transcripts based on the microarray ILLUMINA platform Mouseref-8 v2.0. Thus, the enrichment analysis of A-iPSC demonstrates a significant up-regulation of genes with ARE sequences, which is highly likely a result of non-functional exosomes.

[0238] In order to gain a deeper understating of the type of interactions that relate to ZSCAN10, Chromatin Immunoprecipitation sequencing (ChIP-Seq), which combines chromatin IP with DNA sequencing, was performed. ChIP-Seq detects DNA-protein interactions and as such could provide knowledge regarding the network of proteins regulated by ZSCAN10. The exosome constitutes a complex of 11 exonucleases. In order to test the hypothesis that ZSCAN10 regulates GPX2 via exosomes in A-iPSC, ChIP-Seq was performed, and the results showed that indeed, ZSCAN binds to exosome subunits. ESC and Y-iPSC were used as the comparison in the study. Furthermore, as shown in FIG. 11B, ZSCAN10 up-regulates exosomes. A-iPSC contained lower mRNA levels of exosome core subunits EXOSC1, EXOSC2, and EXOSC5 than ESC and Y-iPSC. Importantly, overexpression of ZSCAN10 in A-iPSCs resulted in the restoration of EXOSC1, EXOSC2, and EXOSC5 levels comparable to those observed in ESC and Y-iPSC, confirming that ZSCAN10 regulates the expression of various exosome subunits. Endogenous mRNA levels were normalized to β -ACTIN. Error bars indicate standard error of the mean.

Example 10

Regulation of GPX2 by ZSCAN10 Via ARE Sequences is Mediated by Exosomes

[0239] To expand on functional relevance of findings described in Example 9, ESC containing high level of exosomes (FIG. 11B) were depleted of EXOSC2, EXOSC8, or both. Following knockdown of exosomes using shRNA, GPX2 mRNA was determined by Q-PCR. While ESC contain low expression levels of GPX2, depletion of exosomes resulted in dramatic increase of GPX2 mRNA (FIG. 12A). This increase was similar to the levels observed in A-iPSCs. DNA fragmentation assay demonstrated that cells deficient in exosomes contained lower apoptotic response after phleomycin treatment (2 h, 30 μ g/ml) of A-iPSC (FIG. 12B), further confirming the functional significance of exosomes in the maintenance of DNA damage response, apoptosis response, glucose metabolism and genomic stability to levels approximating those of Y-iPSC or ESC (FIG. 12B).

Example 11

[0240] Depending on the Donor, iPSC Cells Derived from Aged Human Donors Exhibit Different Reprogramming Efficiencies, DNA Damage Response, and Structural Chromosomal Abnormality

[0241] Findings disclosed in Example 1 showed that iPSC cells derived from aged mice exhibit higher genomic instability and lower apoptotic activity than iPSC generated from young mice. To determine whether results observed in animal cells are comparable to human cells, i-PSC derived from young and aged individuals were generated and their reprogramming efficiency evaluated. As shown in FIG. 13A, aging phenotype observed in mice was also present in human A-iPSC. However, there was a significant difference in programming efficiency among individuals of similar age. In order to analyze DNA damage response in human iPSC and test whether it parallels the findings regarding reprogramming efficiency, cells were treated with double-strand break inducing drug phleomycin for 4 h (30 μ g/ml).

[0242] Immunoblot analysis revealed blunted DNA damage response in A-iPSC from certain donors (See FIG. 13B, donors AG4, AG8, "B" and "S"). Furthermore, karyotype examination of A-iPSC from the donor AG4 showed structural chromosome abnormality (FIG. 13C). In respect to A-iPSC derived from donor AG8, the results are not final and are subject to further confirmation regarding whether or not A-iPSC derived from this patient display normal or defected DNA damage response. Finally, similar results were obtained for A-iPSC generated from different mouse strains. To determine whether genetic background affects DNA damage response, A-iPSC were generated from two distinct mouse strains and treated with phleomycin for 4 h (30 μ g/ml). p53 protein levels were used as an indicator of DNA damage response. As demonstrated in FIG. 13D, A-iPSC derived from the mice of B6129 background exhibit normal DNA damage response (indicated by activation of p53) in higher frequency, while A-iPSC from the mice of B6CBA background contained blunted DNA damage response. These findings indicate that reprogramming efficiency, chromosomal stability, as well as a DNA damage response associated with A-iPSC are in substantial part dependent on genetic background of the individual or animal from which they are derived. Nevertheless, use of the

materials and reagents of the present disclosure would ameliorate the quality of A-iPSC regardless of whether they work on genetic or epigenetic traits or both.

[0243] Analysis of 6 additional human A-iPSC clones revealed poor DNA damage response (FIG. 13E), whereas one A-iPSC clone referred to as “A-iPSC-outlier” displayed proper activation of DNA damage response as indicated by the phosphorylation of ATM. Overexpression of ZSCAN10 in human A-iPSC that exhibited poor DNA damage response rescued that defect (FIG. 13H). Comparison of FIGS. 13G and 13H illustrates that overexpression of ZSCAN10 in human A-iPSC leads to the restoration of the DNA damage response similar to the one observed in human Y-iPSC (FIG. 13G).

[0244] It was postulated that the “A-iPSC outlier” maintains a proper DNA damage response due to the normal expression levels of ZSCAN10. Indeed the inventors observed that ZSCAN10 mRNA expression in the “A-iPSC outlier” is similar to the levels observed in the ESC, while the ZSCAN10 expression in a clone that exhibited poor DNA damage response was low (FIG. 13 I). Since ZSCAN10 mRNA levels correlate with the ability of A-iPSC to elicit a proper DNA damage response, ZSCAN10 can serve as a suitable biomarker of genomic integrity, where higher ZSCAN10 levels correlate with improved genomic integrity.

Example 12

[0245] ZSCAN10 Binds to GSS and Downregulates its Expression

[0246] As discussed in Example 8, glucose metabolism is essential for both tissue homeostasis as well as in reprogramming. Glutathione synthetase (GSS) is an enzyme that catalyzes the second and final step in the synthesis of GSH from gamma-glutamylcysteine (c-GC) and glycine. Genome-wide mapping of ZSCAN10-binding sites in ESC identified more than 3500 target genes, including GSS (Yu et al. *J Biol Chem.* 284(45): 31327-31335 (2009)). Thus, given the importance of glutathione activity in apoptosis and DNA damage response, it was postulated that ZSCAN10 might exert its function, at least in part, through GSS especially in humans.

[0247] To test this hypothesis, the ability of ZSCAN10 to bind directly to the GSS promoter was initially tested in mouse cells. Chromatin IP (ChIP) qPCR was performed using general steps of the ChIP, which include: (1) cross-linking the protein to the DNA; (2) isolating the chromatin; (3) chromatin fragmentation; (4) immunoprecipitation with antibodies against the protein of interest; (5) DNA recovery; and (6) PCR identification of factor associated DNA sequences. In the present example, IgG isotype was used as a negative control, while ZSCAN10-specific antibody was used to pull down the ZSCAN10-DNA complexes. Following the recovery of DNA, GSS specific primers were used for the detection of GSS promoter sequences. The experiment was performed both in Y-iPSC and A-iPSC. As shown in FIG. 14B, ZSCAN10 binding to the GSS promoter was detected in both mouse Y-iPS and A-iPS cells, while IgG control did not result in the detection of GSS promoter by qPCR.

[0248] To further confirm the role for ZSCAN10 in the regulation of GSS expression, mRNA levels of GSS were evaluated in ESC, Y-iPSC, A-iPSC, and A-iPSC-ZSCAN10 cells. As illustrated in FIG. 14C, human A-iPSC express

significantly higher levels of GSS compared to Y-iPSC and ESC. Importantly, overexpression of ZSCAN10 in A-iPSC lead to downregulation of GSS to the levels comparable to or below those observed in ESC and Y-iPSC.

[0249] Taken together, the results described in FIGS. 14B-14D demonstrate that ZSCAN10 regulates GSS expression via direct binding to the GSS promoter (FIG. 14A). These findings imply that inhibition of GSS in A-iPSC would lead to the reduction in oncogenic potential of iPSC cells with decreased ZSCAN10 expression, such as A-iPSC. This was confirmed in the experiment described below.

Example 13

Recovery of Apoptotic and DNA Damage Defects in A-iPSC by ZSCAN10 Via Reduction of Excessively Activated GSS

[0250] Considering the findings described in Example 12, the inventors further postulated that GSS may play a role in processes associated with oncogenic potential of human cells, including, but not limited to apoptosis and DNA damage response. To evaluate the role of GSS in apoptosis, a DNA fragmentation assay was performed. Briefly, a DNA fragmentation assay was carried out in mouse ESC, Y-iPSC, Y-iPSC-GSS, A-iPSC, A-iPSC-ZSCAN10, and A-iPSC with GSS shRNA expression (FIG. 14D). Briefly, cells were treated with phleomycin for 2 hours at 30 µg/ml, and samples were collected for analysis 15 hours after phleomycin treatment. Fluorescence was determined by image quantification analysis. Similar to the observation seen in Example 1 (FIG. 2), lower apoptotic response was detected in A-iPSC, which was recovered by ZSCAN10 overexpression (A-iPSC-ZSCAN10) (FIG. 14D). Additionally, knock-down of GSS in A-iPSC using shRNA (A-iPSC-shGSS) rescued the apoptotic defect in these cells (FIG. 14D). Further demonstrating a role for GSS in mediating oncogenic potential, such as apoptotic response, overexpression of GSS in Y-iPSC resulted in lower apoptotic response compared with Y-iPSC (FIG. 14D). Together, these observations indicate that GSS inhibition restores the lower apoptotic response associated with A-iPSC.

[0251] Example 5 demonstrated that impaired DNA damage response in A-iPSC is recovered with the transient expression of ZSCAN10. In order to further delineate the role for GSS in A-iPSC, phleomycin treatment (2 hours, 30 µg/ml) was performed in Y-iPSC, A-iPSC, A-iPSC-shGSS (FIG. 14E), and Y-iPSC-GSS (FIG. 14F). Cells were collected and Western blot performed using p-ATM antibody. β-actin was used as a loading control. As shown in FIG. 14E, inhibition of GSS in A-iPSC using shRNA restored the ATM phosphorylation. Furthermore, overexpression of GSS in Y-iPSC resulted in no ATM phosphorylation (FIG. 14F). Thus, GSS expression leads to a defect in DNA damage response, whereas GSS inhibition rescues the defect.

[0252] The inventors next sought to evaluate GSS levels in human cells. In accordance with mouse data, GSS levels were significantly higher in A-iPSC that exhibited poor DNA damage response compared with the levels observed in human ESC (FIG. 14G). Furthermore, A-iPSC cells that exhibited normal DNA damage response displayed low levels of GSS (FIG. 14G), supporting the notion that similar to ZSCAN10, GSS can also serve as a good biomarker of genomic integrity.

[0253] Collectively, these results indicate that excessively activated GSS mediates both impaired apoptosis and impaired DNA damage response observed in A-iPSC, while the inhibition of GSS leads to the restoration of those deficiencies.

Example 14

Reprogramming and Pluripotency Improvement of A-iPSC by Addition of ZSCAN10

[0254] Next, the inventors sought to determine the significant differences between distinct types of mouse cells: fibroblast cells (A-SC, Y-SC), iPSC (A-iPSC, Y-iPSC, A-iPSC-ZSCAN10) and ES cells (ESC). FIG. 15A shows Principal Component Analysis (PCA) using whole gene expression profiles of each cell type. FIG. 15B illustrates unsupervised clustering analysis of whole gene expression profiles. The heat map in FIG. 15B shows pairwise gene expression similarities measured by Pearson Correlation Coefficient. Finally, FIG. 15C presents a heat map of relative expression levels of ES cell specific genes in fibroblast and various iPS cells. ES cell specific genes were defined as those with 3 fold or higher expression levels in ES cells than average expression in adult and young fibroblast cells. The heat map shows fold differences in relative expression over ES cells. The results are summarized in Table 4, where reprogramming and pluripotency network genes are defined by core factor co-occupancy. Correlation between seven core factor co-occupancy (Kim et al. Cell 132(6) 1049-61 (2008)) and number of ESC specific genes (2 fold or higher in ESC over indicated sample) were tested to define the functional link between pluripotency networks and reprogramming. Core factors tested in this analysis are Nanog, Sox2, Oct4, Klf4, Dax1, Nac1, and Zfp281. The number of ESC enriched genes and their core factor co-occupancies (by 7 TFs to 0 TF) are shown.

TABLE 4

Genes	Number of common targets	2 fold or more higher in ES cells			
		ESC over ESC	ESC over AIPSC-ZSCAN10	ESC over Y-iPSC	ESC over A-iPSC
40	7	0	5	5	10
89	6	0	12	13	16
103	5	0	13	9	16
198	4	0	18	13	29
376	3	0	21	17	33
767	2	0	39	41	68
2045	1	0	79	87	178
8252	0	0	179	207	470

[0255] The results shown in Table 4 indicate that a greater number of genes is differentially expressed in A-iPSC compared to ESC, than the number of genes differentially expressed between Y-iPSC and ESC. However, overexpression of ZSCAN10 in A-iPSC cells resulted in a decreased number of differentially expressed genes. Furthermore, ZSCAN10 overexpression lead to differences in gene expression (between A-iPSC-ZSCAN10 and ESC) similar to those observed between Y-iPSC and ESC. Therefore, ZSCAN10 expression in A-iPSC influences the the global gene expression of reprogramming and pluripotency net-

work, by making A-iPSC resemble Y-iPSC in reprogramming and pluripotency properties.

[0256] From the work described in this disclosure, ZSCAN10 emerges as an important co-regulatory factor in induced pluripotent stem cells.

[0257] The breadth of the present disclosure is not limited to specific embodiments described herein.

[0258] All references cited herein, whether patents, patent applications or nonpatent literature are incorporated by reference in their entirety.

EMBODIMENTS

[0259] A. Use for improving for improving at least one of DNA damage response, apoptosis response, genomic stability and glucose metabolism of A-iPSC, the use comprising supplementing A-iPSC with at least one of (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter GLUT3; and (iii) an exosome subunit, each as an adjunct to reprogramming of the A-iPSC to substantially restore said at least one of DNA damage response, apoptosis response, glucose metabolism and genomic stability to levels approximating those of Y-iPSC.

B. The use of Embodiment A, wherein excessive expression of GPX2 or GSS is inhibited by at least one of the following:

[0260] supplementing A-iPSC with pluripotency factor ZSCAN10; and/or

[0261] supplementing A-iPSC with pluripotent stem cell-specific glucose transporter 3 GLUT3; and

[0262] supplementing A-iPSC with an exosome subunit wherein the supplementation is an adjunct to reprogramming pluripotency factors and is in an amount effective to accomplish substantial rescue in one or more of DNA damage response, apoptosis and genomic stability in said A-iPSC.

C. The use of Embodiment A or B wherein the supplementation is carried out by adding ZSCAN 10 and/or GLUT3 and/or an exosome subunit to a culture medium in which said A-iPSC are maintained.

D. The use of one of Embodiments A through C wherein the supplementation is carried out by increasing the expression of ZSCAN10 and/or GLUT3 and/or an exosome subunit in said cells.

E. The use of one of Embodiments A through D wherein the supplementation is sufficient to restore ZSCAN 10 and/or GLUT3 and/or an exosome subunit levels in said A-iPSC to about 50% or more of the respective levels of embryonic stem cells (ESC).

F. The use of one of Embodiments A through E wherein the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to within the range from about 80% to about 120% of that of ESC.

G. The use of one of Embodiments A through F wherein the supplementation is sufficient to restore genomic stability of said A-iPSC to approximately that of Y-iPSC.

H. The use of one of Embodiments A through G wherein genomic stability is measured by incidence of hypertriploid clones.

I. The use of one of Embodiments A through H wherein the supplementation is sufficient to restore apoptosis rate of said A-iPSC to approximately that of Y-iPSC.

J. The use of Embodiment I wherein said apoptosis rate is measured by DNA fragmentation assay in response to a DNA damaging agent.

K. The use of one of Embodiments A through J wherein the supplementation is sufficient to restore DNA damage response of said A-iPSC to approximately that of Y-iPSC.

L. The use of Embodiment K wherein DNA damage response is measured by ATM or H2AX phosphorylation in response to a DNA damaging agent.

M. The use of one of Embodiments A through K wherein the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to approximately that of Y-iPSC.

N. The use of Embodiment N wherein the supplementation is sufficient to reduce GPX2 levels in said A-iPSC to approximately those of Y-iPSC.

O. The use of one of Embodiments A through N wherein the expression of ZSCAN10 and/or GLUT3 and/or an exosome subunit in said cells is increased by transfecting said cells with a vector harboring nucleic acid for said ZSCAN10 and/or GLUT3.

P. The use of Embodiments O wherein expression of said vector harbored nucleic acid encoding ZSCAN10 is transient.

Q. Use for reducing the oncogenic potential of induced pluripotent stem cells derived from aged donors (A-iPSC) said A-iPSC exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to induced pluripotent stem cells derived from young donors (Y-iPSC), the method comprising:

[0263] inhibiting glutathione-mediated H₂O₂ scavenging activity in said A-iPSC to substantially restore glutathione/H₂O₂ homeostasis in said A-iPSC by directly and/or indirectly inhibiting excessive expression of glutathione peroxidase 2 (GPX2) in said A-iPSC.

R. A method for improving at least one of DNA damage response, apoptosis response and genomic stability of A-iPSC the method comprising supplementing A-iPSC with at least one of (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter GLUT3 and/or (iii) an exosome subunit, each as an adjunct to reprogramming to partially or completely restore said at least one of DNA damage response and genomic stability to levels approximating those of 4-iPSC.

AA. The use of Embodiment Q or R wherein the supplementation is carried out by adding ZSCAN 10 and/or GLUT3 and/or an exosome subunit to a culture medium in which said A-iPSC are maintained.

BB. The use of one of Embodiment Q or R wherein the supplementation is carried out by increasing the expression of ZSCAN10 and/or GLUT3 and/or an exosome subunit in said cells.

CC. The use of one of Embodiment Q or R wherein the supplementation is sufficient to restore ZSCAN 10 and/or GLUT3 levels in said A-iPSC to about 50% or more of the respective levels of embryonic stem cells (ESC).

DD. The use of one of preceding Embodiments O wherein the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to within the range from about 80% to about 120% of that of ESC.

EE. The use of one of preceding Embodiments wherein the supplementation is sufficient to restore genomic stability of said A-iPSC to approximately that of Y-iPSC.

FF. The use of one of preceding Embodiments wherein genomic stability is measured by as measured by incidence of hypertriploid clones.

GG. The use of one of preceding Embodiments wherein the supplementation is sufficient to restore apoptosis rate of said A-iPSC to approximately that of Y-iPSC.

HH. The use of Embodiment GG wherein said apoptosis rate is measured by DNA fragmentation assay in response to a DNA damaging agent.

II. The use of one of preceding Embodiments wherein the supplementation is sufficient to restore DNA damage response of said A-iPSC to approximately that of Y-iPSC.

JJ. The use of Embodiment II wherein DNA damage response is measured by ATM or H2AX phosphorylation in response to a DNA damaging agent.

KK. The use of one of preceding Embodiments wherein the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to approximately that of Y-iPSC.

LL. The use of preceding Embodiment KK wherein the supplementation is sufficient to reduce GPX2 levels in said A-iPSC to approximately those of Y-iPSC.

MM. The use of one of preceding Embodiments wherein the expression of ZSCAN10 and/or GLUT3 in said cells is increased by transfecting said cells with a vector harboring nucleic acid for said ZSCAN10 and/or GLUT3 and/or an exosome subunit.

NN. The use of Embodiments MM wherein expression of said vector harbored nucleic acid encoding ZSCAN10 or an exosome subunit is transient.

OO. A use for reducing the oncogenic potential of induced pluripotent stem cells (iPSC) said cells having one or more of genomic instability, a defect in apoptosis, a defect in DNA damage response and a defect in glucose metabolism and exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to embryonic stem cells or induced pluripotent stem cells from young donors (Y-iPSC), the method comprising:

[0264] inhibiting glutathione-mediated H₂O₂ scavenging activity in said to partially or totally restore homeostasis in said iPSC by directly and/or indirectly inhibiting excessive expression of glutathione peroxidase 2 (GPX2) in said iPSC.

PP. A use for reducing the oncogenic potential of induced pluripotent stem cells derived from aged donors (A-iPSC) said A-iPSC exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to induced pluripotent stem cells derived from young donors (Y-iPSC), the method comprising:

[0265] inhibiting glutathione-mediated H₂O₂ scavenging activity in said A-iPSC to partially or completely restore glutathione/H₂O₂ homeostasis in said A-iPSC by directly and/or indirectly inhibiting excessive expression of glutathione peroxidase 2 (GPX2) in said A-iPSC

QQ. A use for reducing the oncogenic potential of induced pluripotent stem cells (iPSC) said cells having one or more of genomic instability, a defect in apoptosis, a defect in DNA damage response and a defect in glucose metabolism, and exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to embryonic stem cells or induced pluripotent stem cells from young donors (Y-iPSC), the method comprising supplementing A-iPSC with at least one of (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter GLUT3; and (iii) an exosome subunit, each as an adjunct to reprogramming to substantially restore said at least one of DNA damage response,

apoptosis response, glucose metabolism and genomic stability to levels substantially the same as those of Y-iPSC or ESC.

RR. The use of Embodiment PP or QQ wherein the supplementation is carried out by adding ZSCAN 10 and/or GLUT3 and/or an exosome subunit to a culture medium in which said A-iPSC are maintained.

SS. The use of Embodiment PP or QQ wherein the supplementation is carried out by increasing the expression of ZSCAN10 and/or GLUT3 and/or in said cells.

TT. The use of Embodiment SS wherein the supplementation is sufficient to restore ZSCAN 10 and/or GLUT3 and/or exosome subunit levels in said A-iPSC to about 50% or more of the respective levels of embryonic stem cells (ESC).

UU. The use of Embodiment PP or QQ wherein the supplementation is sufficient to reduce oxidation capacity of glutathione in said A-iPSC to within the range from about 80% to about 120% of that of ESC.

VV. The use of Embodiment PP or QQ wherein the supplementation is sufficient to restore genomic stability of said A-iPSC to approximately that of Y-iPSC.

WW. The use of embodiment VV wherein genomic stability is measured by incidence of aneuploid clones.

XX. The use of claim PP or QQ wherein the supplementation is sufficient to restore apoptosis rate of said A-iPSC to approximately that of Y-iPSC.

YY. The use of claim 26 wherein said apoptosis rate is measured by DNA fragmentation assay in response to a DNA damaging agent.

ZZ. The use of Embodiment PP or QQ wherein the supplementation is sufficient to restore DNA damage response of said A-iPSC to approximately that of Y-iPSC.

AAA. The use of Embodiment B wherein the reprogramming factors are the Yamanaka factors OCT4, SOX2, KLF4 and MYC.

BBB. The method of Embodiment B wherein the reprogramming pluripotency factors are selected from the group of those of Yamanaka wherein one or more of OCT4, SOX2, KLF4 and MYC are replaced as follows:

[0266] Factors(LIN28+Nanog,Esrrb,Pax5 shRNA,C/EBPa,p53.siRNA,UTF1,DNMTshRNA,Wnt3a,SV40LT(T),hTERT)or chemicals(BIX-01294, BayK8644,RG108,AZA,dexamethasone, VPA, TSA, SAHA,PD025901+CHIR99021(2i), A-83-01)

CCC. The use of embodiment B wherein the reprogramming pluripotency factors are selected from the group of those of Yamanaka wherein one or more of OCT4, SOX2, KLF4 and MYC are replaced as follows: Nanog and Lin28 replace Klf4 and MYC; esrb replaces Klf4; SV40 LT (T) replaces

Klf4, MYC lin28 and Nanog; BIX-01294 replaces SOX2, OCT4; VPA replaces Klf4 and MYC

DDD. The Use of Embodiment A wherein the supplementation is with an exosome subunit, the exosome subunit being one or more of the following EXOSC1, EXOSC2, EXOSC3, EXOSC4, EXOSC5, EXOSC6, EXOSC7, EXOSC8, EXOSC9, EXOSC10 and hDis3.

EEE. The use of Embodiment B wherein the supplementation is by DNA gene transfer or by RNA delivery or by delivery of proteins into the A-iPSC.

Key to the Sequence Listing (SEQ ID NO's):

SEQ ID NO 1: Human ZSCAN10 Protein Sequence

SEQ ID NO 2: Human ZSCAN10 DNA Sequence

[0267] SEQ ID NO 3: Human ZSCAN10 transcript variant 1, DNA Sequence

SEQ ID NO 4: Human Zscan10 transcript variant 1 Protein Sequence

SEQ ID NO 5: Mouse ZSCAN10 Protein Sequence

SEQ ID NO 6: Mouse ZSCAN10 DNA Sequence

[0268] SEQ ID NO 7: Mouse ZSCAN10 transcript variant 1 DNA Sequence

SEQ ID NO 8: Mouse ZSCAN10 transcript variant 1 Protein Sequence

SEQ ID NO 9: Human GPX2 DNA Sequence

SEQ ID NO 10: Mouse GPX DNA Sequence

SEQ ID NO 11: Human GLUT3 DNA Sequence

SEQ ID NO 12: Mouse GLUT DNA Sequence

SEQ ID NO 13: Human GSS Protein Sequence

SEQ ID NO 14: Human GSS Genomic DNA Sequence

SEQ ID NO 15: Mouse GSS DNA Sequence

SEQ ID NO 16: Mouse GSS Protein Sequence

Human Zscan10

[0269]

```

FEATURES             Location/Qualifiers
source                1 . . . 2239
                     /organism = "synthetic construct"
                     /mol_type = "other DNA"
                     /db_xref = "taxon: 32630"
                     /clone = "MGC: 195844 IMAGE: 100068227"
                     /clone_lib = "NIH_MGC_435"
                     /lab_host = "DH10B"
                     /focus
                     /note = "Vector: pENTR223.1 with stop codon"
source                35 . . . 2212
                     /organism = "Homo sapiens"
/

```

-continued

ORIGIN

1 gtacaaaaaa gcagaagggc cgtcaaggcc caccatgggg ccacgggctt ccctgagccg
61 gctccgggag ctctgcgccc actggctgcg gccggtctg cacaccaaga aacagatcct
121 ggagctgctg gtgctggagc agttcctgag tgtgctgctt ccgcacctcc tgggcccctt
181 gcagggggag ccgctcaggg atggggagga ggtggtgctg ctgctcgagg gcatccaccg
241 ggagcccagc cagcgggggc cgtggtattt tagttgtaat gctggcaaga gttgtccccg
301 tgcagacgct accttgaggg aaaaggggtg tgcttcccag gtcccagcc acagcccaca
361 gaaggaattg cctgcggaag agccttcagt gctgggccc tggatgagc ctcccagacc
421 ccagccaagg gctgcccagc ctgctgagcc gggacagtgg aggttcccc caagttcaaa
481 gcagccgctg agcccggggc ccagaagac attccaggcc ctgcaagaaa gcagtcccac
541 gggcccctca ccatggccag aggagagttc ccgagatcag gagctggcgg ctgtgctgga
601 gtgctgaacc tttgaggatg tgccagagaa taaggcgtgg cctgcacacc ccctgggatt
661 cggaagcaga accccagaca aggaggaatt taacaagaa gagcccacaag gggctgctctg
721 gcccaactcc atcttagcag agtcccaggc agatagtctt ggggtgcccg gagagcctg
781 ccccagctg ctcggaaggc gcgctgccc tagcggcctt ggcaagatg ggtcccctt
841 tggcagcagt gaaatcttg aggtcaaagt ggtgagggc gtcccagac ccaatccgga
901 gttgagctt atctgcccg actgcccggg gagcttccc cagctgtctc gcctgaaggc
961 gcaccagctg cgtcgcacc cggctggggc ctcttctctg tgctttgct gcgggaagag
1021 ctccggccgc agctccattc tcaagctgca catgcgcact cacacggagc agcggccgca
1081 cgctgcccac ctgtgcccgc accgcttccg ccagagctcg cacctgagca agcacctgct
1141 gaccactccc tccgaaccgc ccttctctgt cgcagagtgc ggcgcccgtt tccagcggc
1201 cgcagcctt gtgcagcacc tgctggcgc cgcacagac cagaagccc cctgctctcc
1261 tgagagtaag gccgaagcgc cgcactgac cgatgtctg tgctcccact gcggccagag
1321 cttccagcgc cgtccagcc tcaagcgcga cctgcccgat cagcccagg acaaggaccg
1381 ccggtctctc gaaggctccg gcagcccgc cgggactccc gaccggaggc ccttcgtgtg
1441 cagcagctgc ggcaaggcct tccggcgcag cagcacctg gtggcccacc ggaggggtga
1501 cagggggcag cggccctctt cctgccaggc ttgcccgcgc agcttcaagc agagctcga
1561 gctggtcagc caccaacggg tgcacacggg cgagaagccc tacgctgtc cgcagtgcgg
1621 gaagcgttt gtgcgcccgg ccagccttgc ccgccactg ctgacccaag gtggccctcg
1681 gccccaccac tgcaccagc gcgggaagag tttcggccag acccaggatc tggcccgcca
1741 ccagcgcagc cacacgggag agaagcctg ccgctgcagc gactgcccgt agggcttctg
1801 ccagagcgc ccctggcgc gccaccagc catccacaca ggggagaagc cccagcctg
1861 cgacacctg gcccaacctt tccgcaatag ctccaacctg gcccccctc gcccgagcca
1921 cagggggcag cggccctaca gctgtcagc gtgcccgtgc agcttcccgc gcaacgcgca
1981 tctgcccggc cacctggcta cccatgcgga gccggggcag gagcaggccg agccccgca
2041 ggagtgcgtg gactgcccga agagcttctg ccgagctgc aatctgctg gacacctgct
2101 ggtgcacacg ggcgccaggc cctactctg cagcagctg ggcgcagct tcagcccga

-continued

2161 ctcccacctg ctgcgccacc tgcgcaccca cgccccgag acgctgtact agggcctcat

2221 gggcccagct ttcttgta

1 atggggccacgggcgtccctgagccggctccgggagctctgcggc
M G P R A S L S R L R E L C G

46 cactggctgcccggctctgcacaccaagaacagatcctggag
H W L R P A L H T K K Q I L E

91 ctgctggctgaggcagttcctgagtgctgcctccgcacctc
L L V L E Q F L S V L P P H L

136 ctgggcccctgcaggggagccgctcaggatggggaggagggtg
L G R L Q G Q P L R D G E E V

181 gtgctgctgctcagggcatccaccgggagcccagccagcgggg
V L L L E G I H R E P S H A G

226 ccgctggatthttagttgtaatgctggcaagagttgtcccggtgca
P L D F S C N A G K S C P R A

271 gacgtcacctggaggaaaaggggtgcttcccagggtcccagc
D V T L E E K G C A S Q V P S

316 cacagcccaagaaggaattgctgcggaagagccttcagtgtg
H S P K K E L P A E E P S V L

361 ggccatcggatgagcctccccagcccagccaagggtgccag
G P S D E P P R P Q P R A A Q

406 cctgctgagccgggacagtgagggttcccccaagttcaaagcag
P A E P G Q W R L P P S S K Q

451 ccgctgagccccggggcccagaagacattccaggccctgcaagaa
P L S P G P Q K T F Q A L Q E

496 agcagtccccagggcccctcaccatggccagaggaggttccgca
S S P Q G P S P W P E E S S R

541 gatcaggagctggcggctgtgctggagtgccctgacctttgaggat
D Q E L A A V L E C L T F E D

586 gtgccagagaataagcgctggcctgcacccccctgggattcggga
V P E N K A W P A H P L G F G

631 agcagaaccccagacaaggaggaatttaacaagaagagcccaaa
S R T P D K E E F K Q E E P K

676 ggggctgctggcccactcccattcttagcagagctccagggcagat
G A A W P T P I L A E S Q A D

721 agtccctgggtgcccggagagccttgcgccagtcgctcggaagg
S P G V P G E P C A Q S L G R

766 ggcgctgaggctagcggccctggcgaagatgggtcccttcttggc
G A A A S G P G E D G S L L G

811 agcagtgaaatttggaggtcaaagtggctgaggcgtccccgag
S S E I L E V K V A E G V P E

856 cccaatccggagttgcagttcatctgcgaggactgcccgggtgagc
P N P E L Q F I C A D C G V S

901 ttcccgcagctgtctgcctgaaggcgcaccagctgcgctgcac
F P Q L S R L K A H Q L R S H

946 ccggctggggcctcctcctgctgcttctgctgcccgaagagcttc
P A G R S F L C L C C G K S F

991 ggccgcagctccattctcaagctgcacatgcgcactcacacggac
G R S S I L K L H M R T H T D

1036 gagcggccgcagcctgccacctgtgcggccaccgcttccggcag
E R P H A C H L C G H R F R Q

-continued

1081 agctcgcaactgagcaagcacctgctgacccactcctccgaaccc
S S H L S K H L L T H S S E P

1126 gccttcctgtgctgagagtgccggccgcttccagcgcgcgcc
A F L C A E C G R G F Q R R A

1171 agccttgtgagcacctgctggcgcacgccaggaccagaagccg
S L V Q H L L A H A Q D Q K P

1216 ccctgcgctcctgagagt aaggccgaagcgcgccactgaccgat
P C A P E S K A E A P P L T D

1261 gtctgtgctcccactgcccagagcttccagcgcgcctccagc
V L C S H C G Q S F Q R R S S

1306 ctcaagcgcacactgccgatccacgccaggacaaggaccgccgg
L K R H L R I H A R D K D R R

1351 tcctccgaagctccggcagcccgccgggactccgaccggagg
S S E G S G S R R R D S D R R

1396 cccttcgtgtgagcagcactgcccgaagccttccggcgcagcag
P F V C S D C G K A F R R S E

1441 cacctggtggcccaccggagggtgcacacggggagcggcccttc
H L V A H R R V H T G E R P F

1486 tcctgccagcttgcggccgagcttccagcagagctcgcagctg
S C Q A C G R S F T Q S S Q L

1531 gtcagccaccaacgggtgcacacggggagagaagccctacgctgt
V S H Q R V H T G E K P Y A C

1576 ccgagtgccggaagccttctgtgcccgggcccagccttgcccgc
P Q C G K R F V R R A S L A R

1621 cacctgctgacccacggtggccctcggccccaccactgacccag
H L L T H G G P R P H H C T Q

1666 tgcgggaagagtctcggccagaccagatctggccccaccag
C G K S F G Q T Q D L A R H Q

1711 cgcagccacacggggagagaagccctgcccgtgcagcagtgccgt
R S H T G E K P C R C S E C G

1756 gagggcttcagccagagcgcaccctggcgcgccaccagcgcac
E G F S Q S A H L A R H Q R I

1801 cacacaggggagaagccccacgcctgacacactgcccaccctg
H T G E K P H A C D T C G H R

1846 ttccgcaatagctccaacctggcccgcctcgcgcagccacag
F R N S S N L A R H R R S H T

1891 ggcgagcggccctacagctgtcagacgtgccgtcgcagcttccgg
G E R P Y S C Q T C G R S F R

1936 cgcaacgcgcctctgcccggcacctggctaccatgcccagccc
R N A H L R R H L A T H A E P

1981 gggcaggagcaggccgagccccgcaggagtgcgtggagtgcggg
G Q E Q A E P P Q E C V E C G

2026 aagagcttcagccgagctgcaatctgctgacacactgctggtg
K S F S R S C N L L R H L L V

2071 cacacggggcggccactactcctgacgcagtggtggccgcagc
H T G A R P Y S C T Q C G R S

2116 ttacggcgaactcccactgctgcccactgcccacccacgcc
F S R N S H L L R H L R T H A

2161 cgcgagcgtgtactag 2178
R E T L Y *

Mouse Zscan10

[0270]

```

FEATURES             Location/Qualifiers
source               1 . . . 2410
                    /organism = "synthetic construct"
                    /mol_type = "other DNA"
                    /db_xref = "taxon: 32630"
                    /clone = "MGC: 195458 IMAGE: 100066321"
                    /clone_lib = "NIH_MGC_436"
                    /lab_host = "DH10B"
                    /focus
                    /note = "Vector: pENTR223.1 with stop codon"
source               35 . . . 2383
                    /organism = "Mus musculus"
                    /mol_type = "other DNA"
                    /db_xref = "taxon: 10090"
ORIGIN
1  gtacaaaaaa gcagaagggc cgtcaaggcc caccatgctg gcggaaccag tccctgatgc
61  cctggaacaa gagcatcccc gagcagtga gttggaggag gatgaagttg gcgaggagga
121 tcccaggctc gcagagtcca ggctaggcc tgaggtggcc caccagcttt tcagatgctt
181 ccagtatcag gaagatatgg ggccacgggc atccctgggc cggtccggg aactctgcaa
241 ccactggctc cgaccggctc tgcacaccaa gaagcagatc ctggagctgc tggtagtgga
301 gcagttcctg agtgtcctgc ccccgcatgt gctgagccgg ctgcacggcc aaccgctccg
361 ggacggagag gaggtggtag agctattgga gggcgtgccc agagacatca gccacatggg
421 gccactggat tttagcttca gtgctggcaa gaatgccctc gcagacatca tctcagagga
481 acaaaaatag ccttcccagg tcccagcca cagccccag acggagtgtc cctcagaaga
541 gattccagcc ctacatccac tgaatgagtt acctccacct cagccagcac ccataaggcc
601 tgctgagcct gaggagtgga gactggcccc cagttcaaat tggccaatga gccccagagc
661 ccaggagata ctccaggacc cacgagaaag caaccttcc cagggccctt catggcttga
721 ggaaaaatcc agagaccaag agctggcggc tgtgttgagg tccctcacct ttgaggatac
781 ctccagagaag agagcttggc ctgcaaacc tcttgattt ggaagcagaa tgcctgacaa
841 tgaggaactt aaagtgaag agcctaaagt gactactgg cctgtcgtca ttggagcaga
901 gtcccagaca gagaaacctg aagtgcagg agagcctctt acgcaaaactg tagggcagga
961 gaccagcagc actggttggg gaggtactcc tgctgacggc agtgaagttg tgaaggttag
1021 aggagcttcc gatgccccag agccccagg ggagatgcag ttcatatgta catattgtgg
1081 ggtaaacttc ccagagatgt ctcatctaca ggccccaccg ttacaatctc accccaactt
1141 gcaacctcac ccaagctctc gatccttccg atgtctgtgg tgtgggaaga cttttggacg
1201 cagctcgatc ctcaagctgc acatgcgcac tcacacagac gagcggccgc acgctgtca
1261 tctctgcaac cgccgcttcc gccagagctc acacctgacg aagcacttgc taacgattc
1321 ctctgagcct gccttccgat gcgcccagtg taaccagggt tttcagcgtc gctccagcct
1381 catgcagcac ctgctggcac atgcccaggg aaagaatctc acgccaatc cagaaggcaa
1441 gacaaaagtg ccagagatgg cagctgtcct ctgttcccac tgcgggcaga ccttcaagcg
1501 gcgctctagc ttaaagcgtc acctgcgtaa ccatgccaa gacaaggacc atctgtcctc
1561 tgaagaccct ggcagccta gctctagcca ggagagtaac ccctatgtgt gtagtgactg
1621 tggcaaggcc tccgacaaa gcgagcaact aatgatccac actaggcgag tccatacccg
1681 tgaacgacc ttctctgccc aggtctgtgg ccgctgttt acccaaaatt cccagctgat
1741 cagccaccag cagattcata cgggtgagaa gcctcacgcc tgtcctcagt gcagcaaacg

```


-continued

1801 ctttgtgaga cgagctggcc ttgctcggca tctgttgacc cacggtagcc tccggcctta
1861 ccactgtgcc caatgtggca aaagctttcg ccaaatcgca gacctaacc gccacgtacg
1921 ctgccacacg ggggagaagc cctgccgatg caacgaatgt ggagaggggt tcaccagaa
1981 tgccccactg gcacgccacc aacgcatcca cacgggggag aagccccacg cctgtgacat
2041 ctgtgggtcac cgctttcgtg acagctccaa ctggccccgc caccgccgca gccacactgg
2101 cgaacggccc tatagctgtc caacctgtgg cgcagtttc cggcgcaatg cgcacctgca
2161 gcgccacctg atcacacaca caggggtcaaa gcaagaaaag gaagttcctc aggagtgcc
2221 tgagtgtggc aagagcttca atcgcagctg caacttgctg cgcacctg cgtttcacac
2281 cggtgcaagg ccttactcct gtgcactgtg tggccgcagc ttcagccgta attcacacct
2341 gctgcgccac ctgcgaacco atgccccgga atcgtgtac tagggcctca tgggcccagc
2401 tttctgtac
1 atgctggcggaaaccagtcctgatgccctggaacaagagcatccc
M L A E P V P D A L E Q E H P
46 ggagcagtgaagttggaggaggatgaagttggcaggaggatccc
G A V K L E E D E V G E E D P
91 aggctcgcagagtcaggcctaggcctgaggtggcccaccagctt
R L A E S R P R P E V A H Q L
136 ttcagatgcttccagatcaggaagataggggccacgggcatcc
F R C F Q Y Q E D M G P R A S
181 ctgggcccggctccgggaactctgcaaccactggctgcgaccggct
L G R L R E L C N H W L R P A
226 ctgcacaccaagaagcagatcctggagctgctggtactggagcag
L H T K K Q I L E L L V L E Q
271 ttctgagtgctcctgccccgcagtgctgagccggctgcacggc
F L S V L P P H V L S R L H G
316 caaccgctccgggacggagaggaggtgtacagctattggagggc
Q P L R D G E E V V Q L L E G
361 gtgcccagagacatcagccacatggggcactggattttagcttc
V P R D I S H M G P L D F S F
406 agtgctggcaagaatgcccctgcagacatcatctcagaggaacaa
S A G K N A P A D I I S E E Q
451 aatagcccttcccaggtcccagccacagccccagacggagttg
N S P S Q V P S H S P Q T E L
496 ccctcagaagagattccagccctacatccactgaatgagttacct
P S E E I P A L H P L N E L P
541 ccacctcagccagcaccataaggcctgctgagcctgaggagtgg
P P Q P A P I R P A E P E E W
586 agactggccccagttcaaattggccaatgagcccagagccccag
R L A P S S N W P M S P E P Q
631 gagatactccaggacccacgagaaagcaacccttcccaggccct
E I L Q D P R E S N P S Q G P
676 tcatggcttgagaaaattccagagaccaagagctggcggctgtg
S W L E E N S R D Q E L A A V
721 ttggagtcctcactttgaggatacctcagagaagagagcttgg
L E S L T F E D T S E K R A W
766 cctgcaaacctcttgatttgaagcagaatgcctgacaatgag
P A N P L G F G S R M P D N E

-continued

811 gaacttaaagttgaagagcctaaagtgactacttggcctgtcgtc
E L K V E E P K V T T W P V V

856 attggagcagagtcaccagacagagaacctgaagttgcaggagag
I G A E S Q T E K P E V A G E

901 cctcttacgcaaactgtaggcaggagaccagcagcactggttgg
P L T Q T V G Q E T S S T G W

946 ggaggtactcctgctgacggcagtgaaagttgtgaagtttagagga
G G T P A D G S E V V K V R G

991 gcttccgatgccccagagccccagggggagatgcagttcatatgt
A S D A P E P Q G E M Q F I C

1036 acatattgtgggtaaaacttccagagatgtctcatctacaggcc
T Y C G V N F P E M S H L Q A

1081 caccagttacaatctcaccaccaacttgcaacctcaccgaagctct
H Q L Q S H P N L Q P H P S S

1126 cgatccttccgatgtctgtgggtggtggaagacttttgacgcagc
R S F R C L W C G K T F G R S

1171 tcgatcctcaagctgcacatgcgcactcacacagacgagcggcgg
S I L K L H M R T H T D E R P

1216 cagcctgtcatctctgcaaccgcccgttccgcagagctcacac
H A C H L C N R R F R Q S S H

1261 ctgacgaagcacttgetaacgcattcctctgagcctgccttccga
L T K H L L T H S S E P A F R

1306 tgcgccgagtgtaaccagggttttcagcgtcgtccagcctcatg
C A E C N Q G F Q R R S S L M

1351 cagcacctgtggcacatgccagggaagaatctcacgccaat
Q H L L A H A Q G K N L T P N

1396 ccagaaggcaagacaaaagtgccagagatggcagctgtcctctgt
P E G K T K V P E M A A V L C

1441 tcccactgcccagaccttcaagcggcgtctagcttaagcgt
S H C G Q T F K R R S S L K R

1486 cacctgcgtaaccatgccaaggacaaggaccatctgtcctctgaa
H L R N H A K D K D H L S S E

1531 gaccctggcagccttagctctagccaggagagtaacccctatgtg
D P G S L S S S Q E S N P Y V

1576 tgtagtgaactgtggcaaggccttccgacaaagcagcaactaatg
C S D C G K A F R Q S E Q L M

1621 atccacactaggcagtcatacccgtaaacgaccttctcctgc
I H T R R V H T R E R P F S C

1666 caggtctgtggcctgtcttaccocaaatcccagctgatcagc
Q V C G R C F T Q N S Q L I S

1711 caccagcagattcatacgggtgagaagcctcagcctgtcctcag
H Q Q I H T G E K P H A C P Q

1756 tgcagcaaacgctttgtgagacgagctggccttgetcggcatctg
C S K R F V R R A G L A R H L

1801 ttgacccaoggtagcctccggccttaccactgtgccaatgtggc
L T H G S L R P Y H C A Q C G

1846 aaaagcttgcgcaaatgcgagacctaacccgccagctacgctgc
K S F R Q M R D L T R H V R C

1891 cacacgggggagaagccctgcccgatgcaacgaatgtggagagggg
H T G E K P C R C N E C G E G

1936 ttcacccagaatgccacctggcagccaccaacgcacatccacag
F T Q N A H L A R H Q R I H T

-continued

1981 ggggagaagccccagcctgtgacatctgtggtcaccgcttctgt
 G E K P H A C D I C G H R F R

2026 aacagctccaacttggcccgccaccgcccgcagccacactggcgaa
 N S S N L A R H R R S H T G E

2071 cggcctatagctgtccaactgtggccgagtttccggcgcaat
 R P Y S C P T C G R S F R R N

2116 gcgcacctgcagcggccactgacacacacagggtcaaagcaa
 A H L Q R H L I T H T G S K Q

2161 gaaaaggaagttcctcaggagtgccctgagtggtggaagagcttc
 E K E V P Q E C P E C G K S F

2206 aatcgagctgcaacttgctgcgccactgctggttcacaccggt
 N R S C N L L R H L L V H T G

2251 gcaaggccttactcctgtgcaactgtgtggccgagcttcagccgt
 A R P Y S C A L C G R S F S R

2296 aattcacacctgctgcgccactgccaaccatgcccgggaatcg
 N S H L L R H L R T H A R E S

2341 ctgtactag 2349
 L Y *

Human GPX2 Transcript mRNA

FEATURES Location/Qualifiers
 source 1 . . . 1105
 /organism = "*Homo sapiens*"
 /mol_type = "mRNA"
 /db_xref = "taxon: 9606"
 /chromosome = "14"
 /map = "14q24.1"

ORIGIN

1 cttgttcaaa cagcacttac aggtggggac ctgtttttgc taagtcatec tggggatgct
 61 caaagctcca ttgttagatc ctttctgtcc tccttcctgg ctctccttc cteccacc
 121 ctctaataag ctcaaatggt ggctcaggcc tctctgegg gctcactctg cgcttcacca
 181 tggtttcat tgccaagtcc ttctatgacc tcagtccat cagcctggat ggggagaagg
 241 tagatttcaa tacgttccgg ggcagggccg tgctgattga gaatgtggct tcgctctgag
 301 gcacaaccac cgggacttc acccagctca acgagctgca atgccgcttt cccaggcgcc
 361 tgggtggtcct tggcttcctc tgcaaccaat ttggacatca ggagaactgt cagaatgagg
 421 agatcctgaa cagtctcaag tatgtccgtc ctgggggtgg ataccagccc accttcacc
 481 ttgtccaaaa atgtgaggtg aatgggcaga acgagcatcc tgtcttcgcc tacctgaagg
 541 acaagctccc ctacccttat gatgacccat ttccctcat gaccgatccc aagctcatca
 601 tttggagccc tgtgcgccgc tcagatgtgg cctggaactt tgagaagttc ctcatagggc
 661 cggagggaga gcccttccga cgctacagcc gcaccttccc aacctcaac attgagcctg
 721 acatcaagcg cctccttaaa gttgcatat agatgtgaac tgctcaacac acagatctcc
 781 tactccatcc agtctgagg agccttagga tgcagcatgc cttcaggaga cactgctgga
 841 cctcagcatt cccttgatat cagtcccctt cactgcagag ccttgccctt cccctctgcc
 901 tgtttccttt tcctctocca accctctggt tgggtattca acttgggctc caagacttgg
 961 gtaagctctg gcccttcaca gaatgatggc accttcctaa acctcatgg gtggtgtctg
 1021 agaggcgtga agggcctgga gccactctgc tagaagagac caataaaggg caggtgtgga
 1081 aacggccaaa aaaaaaaaaa aaaaa
 //

Mus musculus glutathione peroxidase 2 (Gpx2), mRNA

NCBI Reference Sequence: NM_030677.2

GenBank Graphics

[0271]

```

>gi|145275167|ref|NM_030677.2|Mus musculus
glutathione peroxidase 2 (Gpx2), mRNA
GCTACAGCCTTGTTCAAACAGTTCACAGTGGGTACCTGTTTTTTGCT
AAGTCATCCCAGGAATGCTCAAAGGCCCTTTGTGAAGTCCCTTCGGTC
TTCTCCGGCTCCTCCTTTCTCCACCAGTCTAAAGACTTAAGGAGG
CTCACAGAGCAGGGCAGGGCTCACTGCTCTTCAGCATGGCTTACATTG
CCAAGTCGTTCTACGATCTCAGTGCCTGGCTGGATGGGAGAAGA
TAGACTTCAATACGTTTCAAGAGCAGGGCTGTGCTGATTGAGAATGTGG
CGTCACTCTGAGGAACAACACCCGGACTACAACAGCTCAATGAGC
TGCAATGTCGCTTTCCAGGCGCCTGGTAGTTCTCGCTCCCTTGCA
ACCAGTTCGGACATCAGGAGAACTGTCAGAACGAGGAGATCCTGAACA
GCCTCAAGTATGTCGACCTGGGGGTGGGTACCAGCCACCTTTAGTC
TTACCACAAAGTGTGACGTCATAGGGCAGAACGAGCATCCTGTCTTTG
CCTACCTGAAAGACAAGCTGCCCTACCCTTATGATGCCCGTTCTCCC
TCATGACCGATCCCAAGCTCATCATATGGAGTCCCGTGCGCCGCTCAG
ACGTGTCCTGGAACCTTGAGAAGTTCCTCATAGGGCCAGAAGGGGAGC
CCTCCGTCGCTACAGCCGACGCTCCAGACCATCAACATCGAGCCTG
ACATCAAACGGCTCCTCAAAGTTGCCATCTAGATGAGAGTGTCTCAGC
CCAGGAATCTCCCACTGTTTCCCTGAGCAGTCTTCCTCAGGGCTCAG
TGTACCCCTCGGAGACCCCTGGGAGACCAAGGCATTCCTGAAATATCGT
CCCCTTGCCCTTCCCTACCGCCATTTCCCTTAGCTCCCTCAAGGCTCT
TGGGGAGTTTGCTTGGGGCTCTAAGTCTGGGGTAGGTTCTGGGCCTTC
ACAGAATGATGGCATCTTCTAAACCCCTTCTGGGAGATGCTGAGAAG
TTGTGAAGGGTCCAGAGCCAGTCTGCTTTAGAGTCCAATAAAGTGTAG
GTGTGGCAATGAAA

```

Human and Mouse GLUT3 DNA sequence

Human glut3 CDs

```

ATGGGGACACAGAAGGTCAACCCAGCTCGATATTTGCCATCACAGTT
GCTACAATCGGCTCTTTCCAATTTGGCTACAACACTGGGGTCATCAAT
GCTCCTGAGAAGATCATAAAGGAATTTATCAATAAAACTTTGACGGAC
AAGGAAAATGCCCCACCCTCTGAGGTGTGCTCACGCTCTCTGGTCC
TTGTCTGTGGCCATATTTCCGTCGGGGGTATGATCGGCTCCTTTTCC
GTCGGACTCTTCGTCAACCGCTTTGGCAGGCGCAATCAATGCTGATT
GTCAACCTGTTGGCTGTCACTGGTGGCTGCTTTATGGGACTGTGTA
GTAGCTAAGTCGGTTGAAATGCTGATCCTGGGTCGCTTGGTTATTGGC

```

-continued

```

CTCTTCTGCGGACTCTGCACAGGTTTTGTGCCATGTACATTGGAGAG
ATCTCGCCTACTGCCCTGCGGGTGCCTTTGGCACTCTCAACCAGCTG
GGCATCGTTGTTGGAATCTGGTGGCCAGATCTTTGGTCTGGAATTC
ATCCTTGGGTCTGAAGAGCTATGGCCGCTGCTACTGGGTTTTACCATC
CTTCTGCTATCCTACAAAGTGCAGCCCTTCCATTTTGCCTGAAAGT
CCCAGATTTTTGCTCATTAAACAGAAAAGAGAGAGAATGCTAAGCAG
ATCCTCCAGCGGTGTGGGGCACCCAGGATGTATCCCAAGACATCCAG
GAGATGAAAAGATGAGAGTGAAGGATGTCAAGAAAAGCAAGTCAACC
GTGCTAGAGCTCTTTAGAGTGTCCAGCTACCACAGCCCATCATCATT
TCCATTGTGCTCCAGCTCTCTCAGCAGCTCTCTGGGATCAATGCTGTG
TTCTATTACTCAACAGGAATCTTCAAGGATGCAGGTGTTCAAGAGCCC
ATCTATGCCACCATCGGCGCGGGTGTGGTTAATACTATCTTCACTGTA
GTTTCTCTATTTCTGGTGGAAAGGGCAGGAAGAAGACTCTGCATATG
ATAGGCCTTGGAGGGATGGCTTTTGTTCACGCTCATGACTGTTTCT
TTGTTATTAAGGATAACTATAATGGGATGAGCTTTGTCTGTATTGGG
GCTATCTTGGTCTTTGTAGCCTTCTTTGAAATGGACCAGGCCCCATT
CCCTGGTTTATTGTGGCCGAACCTTTCAGCCAGGGCCCCGCCAGCT
GCGATGGCAGTGGCCGGCTGCTCCAACCTGGACCTCCAACCTCCTAGTC
GGATTGCTCTTCCCCTCGGCTGCTCACTATTTAGGAGCCTACGTTTTTT
ATTATCTTACCGGCTTCTCATTACCTTCTGGCTTTTACCTTCTTC
AAAGTCCCTGAGACCCGTCGGCAGGACTTTTGGAGATATCACACGGGCC
TTTGAAGGGCAGGCACACGGTGCAGATAGATCTGGAAGGACGGGCTC
ATGGAGATGAACAGCATCGAGCCTGCTAAGGAGACCACCACCAATGTC
TAA

```

Mouse Glut3 CDs

[0272]

```

ATGGGGACAACGAAGGTGACCCCATCTCTGGTGTTCGCCGTGACTGTT
GCCACGATCGGCTCTTCCAGTTTGGCTACAACACTGGAGTCAATCAAT
GCACCTGAGACAATCCTAAAGGACTTTCTTAACTACACTTTGGAAGAG
CGGTTAGAAGACCTACCAAGTGAAGGACTGTGACTGCCCTCTGGTCC
TTATGTGTGGCCATCTTCTCTGTTGGTGGCATGATTGGCTCTTTTTTCT
GTTGGACTCTTTGTCAACCGCTTTGGCAGACGCAACTCTATGCTTCTA
GTCAACTGTCTGGCCATCATTGCGGGCTGCCTTATGGGATTCGCCAAG
ATAGCGGAGTCTGTTGAAATGCTGATCCTGGGCCCTTACTCATTTGGC
ATTTTCTGTGGCCTGTGCACGGGCTTTGTGCTTATGTACATTGGAGAG
GTGTCTCCCACTGCCCTTCGGGGTGCATTTGGCACAATAAACCAGCTG
GGCATCGTTGTTGGGATCTGGTAGCTCAGATCTTTGGTTTGGACTTT
ATTTGCGGCTCTGAAGAACTGTGGCCTGGGCTCCTTGGCTTAAACCATC

```

-continued

ATTCAGCTATCCTGCAAAGCGCAGCCCTCCATTTTGCCCTGAGAGT
 CCAAGATTCTTGCTCATTAAACAAAAGGAGGAAGACCAAGCTACAGAG
 ATCCTGCAGCGCTTGTGGGGCACCTCGGACGTGGTCCAGGAGATCCAG
 GAGATGAAGGATGAGAGTGTTCGGATGTCACAGGAGAAGCAGGTGACT
 GTGCTGGAGCTCTTCAGGTACCCAACTACGTCCAGCCGCTTCTCATC
 TCCATTGCTCCAGTGTCTCAGCAGCTCTCTGGGATCAATGCTGTG
 TTCTATTACTCAACAGGAATCTTCAAGGACGCGGGTGTCCAGGAACCG
 ATCTATGCCACGATGGAGCAGGCGTGGTCAATACTATCTTCACTGTA
 GTTCTCTGTTCTGGTGGAGAGGGCAGGGAGGAGAACCCTGCATATG
 ATAGCCCTGGGAGGCATGGCTGTTTCTCCGTTTTTCATGACGATTTCC

-continued

CTGTACTAAAGGATGACTATGAAGCCATGAGCTTTGTCTGTATTGTG
 GCTATCTTGATCTACGTAGCCTTCTTTGAGATTGGACCTGGCCCCATT
 CCCTGGTTTATTGTGGCTGAGCTCTTCAGCCAGGGCCCCCGCCAGCT
 GCCATTGCGGTGGCTGGCTGTTGTAACCTGGACCTCCAACTTTCTGGTC
 GGAATGCTCTTCCCTCAGCTGCAGCCTACTTAGGAGCCTACGTTTTTT
 ATCATCTTCGCTGCCTTCTCATCTTCTTCTAATCTTCACCTTCTTC
 AAAGTCCCGGAGACCAAGGCAGGACTTTCGAGGACATTGCCCGGGCC
 TTCGAGGGGCAGGCGCACTCTGGAAAAGGCCCTGCCGGTGTGGAGTTG
 AACAGCATGCAGCCGGTCAAGGAGACCCTGGCAACGCCTGA

Human GSS genomic DNA

LOCUS NG_008848 34366 bp DNA linear PRI

04-MAY-2014

DEFINITION *Homo sapiens* glutathione synthetase (GSS),
 RefSeqGene on chromosome 20.

ACCESSION NG_008848

VERSION NG_008848.1 GI: 209977061

KEYWORDS RefSeq; RefSeqGene.

SOURCE *Homo sapiens* (human)

ORGANISM *Homo sapiens*

ORIGIN

1 tctcacttt gattccacag gcatttctctg agcagcaatg ctggccccagg cctgtgctag
 61 gggctggaag acagaggaat tccactctga atggccaaag cagtgggccc cagccagggt
 121 gggagatggc ctcataaaca acagtatgag gcagggtgat atcactgcta aaaagagaca
 181 gtgacctgt gcacagatgc agacctgtg tgatgcagac cctggggctg acagagatgt
 241 tccaatcaa aggcacagtc cagtggctgg gtgcgggtgg tcccgcctgt aatcccagca
 301 ctttgggagg ctgaggcggg tggatcacia ggtcaggaga tcgagacat cctggctaac
 361 acgggtaaac cccatctcta ctaaaaatag aaaaaatag gcgggcgtgg tggcaggcgc
 421 ctgtagtccc agctactcgg gaggctgagg taggagaatg gcatgaacac gggaggcgga
 481 gcttgcagtg agccaagatg gcgccactgc actctagcct gggctacaaa gcaagactcc
 541 atctcaaaaa acaaaaaaca aaaaaaacc acagtccaga ctggagaga ggcctcgcga
 601 gggagaaaag caagacacia aattaagga ttggcctcca ttcacagtga agtacatccc
 661 tgcatacctt ttttcacctt attcagacct aatggtccc acaaaccca agaacagagg
 721 atgaaattga ttcaacagt agctttggga agtctgagcc catggcatgt cccaaggtag
 781 atatgtggga acacctggc tgacactgct gctgtgatct ttggcaagtc aggatacctc
 841 ttcaagcctt cttttccccg gctgtaaaat ggaggctata aagatactga tgtgataggg
 901 aggtaaggga aagttagata acgactgtaa agtcattagc caagtacctg acacttagcg
 961 accagatcaa taaagggtag ttattgttag gaaaaaacag atttcacttt gaaagtgagg
 1021 aaagccaggc gcggtggctc acacctgtaa tcccagcact ttgggaggct gaggcaggca
 1081 gatcacgagg tcaggagtcc gagaccagcc tggacagcaa ggtgaaaccc tgtctccact
 1141 aaaaatacaa aaaattagct gggcatggtg gcatgtgect gtaatcccag ctactcggga
 1201 gactgaggca ggagaattgc ctgaacccgg gaggcagagg ttgcagttag ccaagatcgt
 1261 gccactgcac tccagcctgg gtgacagaga gagactccat ctcaaaaaaa aaaaaaagaa

-continued

1321 agaaagaaaa aaaataaaat gaggaaagtg ggattcggag aggtgagatg acttctgcac
1381 agtcaggatt caaactcagg tctgagacac cagaggetca gggcaaatca tctccctctg
1441 ctccggaatc ttcagcagg tccctacagt cactacatg gactccatcc ttgccaggga
1501 gtgaggatcc agcaaaaggcc tggggccaaa aagacctgg gcaagtcc aatcctatg
1561 tgtcttgatc tgatcccc aagtgagcct gagaaggtct gtgaattcct ccacgtagct
1621 gatgcaaaat ttatatactaa tggatctcag acgagtctat agcctcaaaa gtaacaaacc
1681 acagactga cctgacttag catggtttct tattcaccca atggagatag gatttctacc
1741 ttgaaaggct gtgaagggat taaatgaggt aatttgtgag aagtactga aacatcctca
1801 gctttcatta aatgttgggt tccttctctt tctctctccc caaactatct ccatcagtta
1861 gcaaatatta ttgagcatct gccacgtggc aggaccagt caggtcctgg gggtaaagtg
1921 gtgaacaaga cagacatggc ccatttctat ggggctcaca ttctagcaga gggaaacagc
1981 aaacaaataa aagcaacaat ttcagatag aataactgct atgaagaaaa tacaaggcgg
2041 ggcacgggtg ctcacgcctg taatcccagc acttgagag gcagaggcgg acggatcaca
2101 aggtcaggag tttgagacca gcctgatcaa catggtgaaa cctgtctct cctaaaaata
2161 caaaaattag ccgggcatgg tggcacgtgc ctgtaatccc agctactcag gagactgagg
2221 caggagaatt gtttgaacc aggagacaga ggtgacgtg agccaagatc gcaccactgc
2281 actccagcct gggcaacaga gtgagactcc atctcaaaaa aaagaaaagg ataacgtgat
2341 agacttatag ggtggggcag cctccaggga tgaaacatct gaatgaccaa aggagccagt
2401 catgccagga ttttgaggga aagcaccag gcagagagtg cagaaggggc aaacgtcccc
2461 tggaaagatt cttagtcaag agtccttcac tcccagcct acccaaaact gggtcacctt
2521 gaacaagtca cgtaacttct gaggtcagc tgccacatct acaaaatggg aataaagaca
2581 tcttacctgc cacattgtga gaggtttcaa ccaagggtct gtttaaggtct gggatcctcc
2641 ccaaatctca ccatagacac ctgatactca tcacttggca cccgtcttgg aagaggggaa
2701 cctgcacaga gaacctggg tcatgctttt gatttttaat ttcatgtgc actagaaata
2761 gcttcttttg ttcctggtg acccaggagc ctcttctgc cacctggggc ctattctagt
2821 taacagctgc ttatcccctc aggtacaaaa gccaacgagg aaaggacatc aggaaacatt
2881 gttctgggaa taaccagaca cctatctgcc accatctccc cccatccgt gaaccacac
2941 gggagactgg aggactcagc ctgtcctgta gtcagataat gtacatggtt tatttaaaga
3001 gtcaaaaggg gccggggcga gtggctaacg cctgtaatcc tagcactctg ggaggctggg
3061 gcgggtggat cacctgagct caagagtctc agaccaatct ggccaacatg gtgaaaccct
3121 gtctctacca aaaatacaaa aattagccgg gtgtggtggt ggaecctgt aatcccagct
3181 acttgggagg ctgaggcagg agaattgctt gaacctggga agtggagggt gcagtgagct
3241 gagatcgtgc cactgcactc cagcctgggc aacaacaacg aaaactccgt ctcaaaaaaa
3301 aaaaaaaaaa aaaagagtca aaaggatctt ggtccctggg ttgggacct gatttacgat
3361 cactaggagt tctcactcct aaatttctt gatctgttcg cttegetcca tctccacagc
3421 tgctgcactg gctacagcct catgatctca catcttaact ctctctgctt tctctggccc
3481 atctccccac ttocaaacca tttgtcacgc tgtaaccagt gcctaacaca caaaactaac
3541 catgtccttc cctgtctaa agcccttagc tctgttget cagtggaact ggcgtctgag
3601 gctacctctc caagcctaag cgcctaagtc ctgttgcaac cctcaggccc tctctcatta

-continued

3661 tccacaccaa actcctcagt gtctgtaaaa caagccgagc aaccctcaga attatatgcc
3721 ttcgctgctc gtttgttttg tttttaggac agggctctcac gctgtcacc aggcaggagt
3781 gctgcagcgt gatctcagct cacagcagcc tccgtctccg gggctcaaga attctcaegc
3841 cgcagcctcc cgagtagctg ggattacagg cacgggccaa cacaccggc taattcttgt
3901 atttctagta gagacggggg ttcccatgt tgcccagcct ggtctccaac tcctgagctc
3961 aagtaatcca cctgctcgg cctctcaaag tgctgggatt acaggtctga gccactgcac
4021 ccagccagcc ttgtgtgctt ttgttctgc aatttggaa actgtcccca tcccagcctc
4081 tcacctctac cctacctcc ttcaactacct ataccttctt atccatcctt caagaccca
4141 aaaaccatcc ctgattcctt cagaaaggca gtttattgcc tatcttatca gactgaaagc
4201 agtggctgtg tcttatttat ggtaattcc ctagaagctg gactgataca ttccatttaa
4261 ctaaaattcg tatcagggtc ttcggactgc agacaagcct atcacaccc agaaggaaga
4321 aacaggaag gcacctggg gctgccaagc aatgaggtgg ggggtaggaa tcatgaaatcc
4381 gcatattttt aaaaactgcc ccagatcctg atgtaaacgg tacaagagag tctgagaaac
4441 acagggtcc cctcaaacag tcctgacttc agcattcctg gaaaaatgaa aatcctttcc
4501 ttttgctctc aatgctttcc ctgctggat cccaggtaa aaaaaatag ataaatcag
4561 ggggatTTTT ctgggacttg gctggctgg gaaacaagcc tgggttctaa tacaggctca
4621 gccctgacg tactatgggc cctgcccct ccttggggcc tccattacca cggccacccc
4681 cacccttacc aattgtgtgc ccctgaggtg gtgactgtcc cgctctgagc attagtttcc
4741 ccactctcca ctagctgtcg tcagctctga cgctctatga gctatgcata cccgtagctc
4801 cccgcccacc ccgatggctc cctcccctcc tcccagggt ccatccgcca ggggtcagcc
4861 gacgcactcc taatgctaag gccgcctctc catcgaccgc ccttctctgg cctcgactca
4921 gcgcaaaagg tatgggtctc tgcccgcct gctctttaag cctagccggg gcggtcagcg
4981 caagcgcact gggctgcac gagggcccgc cccctgagcc tgggtagcgg cgcgagggcc
5041 gggagaaccg ttcgcgagg aaaggcgaac tagtaggttg gggcgccacc gccgcccggc
5101 atgggtcacc tttcctcggg aggaacgatg tgaggggagg gtctggcaag agattggaat
5161 tccggaggcc gggagaccct gtggctgaaa ccctctgtag gagcggggca actagtgtct
5221 agtgaggggg ttggctggc gcgcaactgat cccagacttt cgggatcttc tgctttaga
5281 tcgggcccgt gtccgggat gtaggcccagt gagactggag ccagttagag ctacaacggg
5341 gagcgattag ggccaaactt tgtccagggt ggaagcgagc gggcccgtga agtggggcca
5401 gctggggcag ccgaccgtgt cgttgctcgt gggcctttcc aggcactggc ctaagtccgt
5461 gcgataaagt gcgaccgat tccttgggg cgttttgagg ctttctgtga tctgaccgt
5521 ctgtcattca ttctcattc attcatgtga tgaatgaata cagtactaag cgcggctaat
5581 tactaggtag agaagtgatc aagacaaaca ctgttctac ggtacagga aaagtgatgg
5641 gctgtagaat gtagaagccc gggcgggaga acagggacag cttccggaac gaaatcgca
5701 gccagatca ggagtggtg cgagagttcc aaagagaaga cagcacgtgc caagtccgg
5761 aagggggaca gaggccaaca taccctggtc actgaagaca cctgactctg aatctgtttc
5821 acgcccaggg aagagatgac agtggccggg gctaggctac aaactctgga aatggagata
5881 aataaaggaa ttcaaagtac tatatactta ggcagcaaaa tccataggat ttggggagag
5941 tgagatgtag gaaacaagta ctcaaggctt gggtacctgg gtggggttca tcagagaaga

-continued

6001 agcagatttg tgggagacaa caacaaatc tattctgggt gtatggagac tcgcaggaaa
6061 aaattggata ttctagtttg aaggtaggaa agtattgctg tgaagatgta gatttgaatg
6121 tcatcagcaa aacataaata aagccaaggg agggttgagg ctgtagaatg agaaaaacaa
6181 agggcccact tagcaccttc atctgatttc tttctttct tctctttttt cttttttttt
6241 ttttttgaca gagctttgct cttgttgccc aggctggagt gcaatggcac gatctcggct
6301 cactacaacc tccacctcct gggttcaagc tattctcctg cctcagcctc ccaagtagct
6361 cggattacag gcatcgccca ccaggcccgg ctaattttgt attttttagta gagatggggg
6421 ttctccatgt tggtaggct ggtctegaac tcccgaacctc ggggatccg cctgcctcgg
6481 cctcacaag tgctgggatt acacgagtga gccaccacac ctggcccctg gtgattatct
6541 ttatgtetta tctcctcca tatccccagt acctagtcaa gggagtggca ttaaatgcaa
6601 atcagtgttt gccaaactaa taaaagccca acagcaaaaca gatgttggaa tttcagagtt
6661 gtggaacgat ggggctcat ggagggttctc attactctaa tgtcaaggta atgggttctt
6721 gtcttgctc tgccactagg cttctgtgtg acctctgaca agtctcctcc tactataaa
6781 gagagtacag ccaaaaaatg gtctcatgta tagagcttca aacactgctg ataaatttca
6841 cactgatttt tctcttttaa tccacacagc aatcttactt gaaaggaag tcggctgggc
6901 ggggtgctc acgctgtaa tcccagcact ttgggagggc gagagtgggg gatcacgaga
6961 tcgagaccat cctggctaac acgggtgaaac cccgtctcta ctaaaaatac aaaaaattag
7021 cgggcatgg tggcaggctc ctgtagtccc agctactcgg gaggctgagg caggagaatg
7081 gcatgaaccc agggggcga gcttgctgct agccgagatc gtgcgctgc actccagcct
7141 gggcgacaga gccagactcc gtcaaaaaa aaaaaaaga aagaagagg gagggagaga
7201 gagagaaaga aagaaaaaga aggaagggaag gaaggaaaga aggggggag ggaaaggga
7261 agggaaaagg aaggaagaa agaagggaag gggagaagtc gtattattat ggactcaaac
7321 ccaggctctg ctgtctgtct gacttgaacc ttgttctta ctatgattgc cctcatgat
7381 gtctcactca acagggatat tatcaggacc ctcttgagat cacatgcgca ttctttcaaa
7441 gcattgtgct gaggctggca gactttcata attggcctgg cactggctct gtcattggga
7501 cagggggaca gagctgaatg tgatggaggt ttcctattat tctctaactc ccttctcggg
7561 gaccactgag ttggccaacc atgttctgtt aaatggcaac agggcagaac aaaattagtg
7621 actgtgttct cagattttta ccagatctt aaactcctga ggcctgctga aaaatgaatg
7681 agtatcaggg tgtgagtttg tacacctctg tatgtctctg ggcaaccaat cagacaactt
7741 ctctattac attgacact tgggtttcag caatttccat cttgctaagtg gattttctca
7801 aaaatatttt ctgtcttttg gtgctttgat gataaatgct catatatgga atgtagtcat
7861 ttctgctac taagattcct tctggtttgt ataaggagg agttcacctt attcgcattt
7921 catggtatc cacaagagc tcctccccc tcccctgta atttatttga gatctgctga
7981 catgagttgt tggagcttga agggaattaa taatgtactg cagtgactcc tatcccagga
8041 aaacttgta aaaaatacaa gcctcggctg ggtgtgatgg ctcacgctg taatcccagt
8101 actttgggag gtcgaggcgt gtggatcaca aggtcagaag atcaagatca tctcggctaa
8161 cacggtgaaa cccctctct actaaaaac aaaaaattag ccaggcgtgg tgggtgtgctc
8221 ctgtaatccc agtactcag ggaggctgag gcgggagaat tacttgaacc caggagcgg
8281 aggttgcagt gagccaagat cgagccactg aactccagcc taggcgactg agtgagactc

-continued

8341 catatcaaaa aaaaaaaaaat acaaagcctc aaccctcct tcccatcagg cctcttgeat
8401 cagagtctct gggatggggc ccaggaatct gtattcttct ccagctcccc agaatgttca
8461 gccaggtttg gaaactgatc tatccgattc ttcttgtttc acagttaggg aatctgtagc
8521 tctgggaagg gaaggaactt gccccagtca catctgatat tagtgcttct ttctccaatg
8581 aagagccttt aggctgggag tccagagaca tgggttcaag tccaggctat accagtcatc
8641 acctcgggca agtcatttca cctctccaag cctctgcttc cttactgtga gaataatgcc
8701 attgtgttgg gaatcaaaa agagagtggc aatggaatg ctttgtcaag ctttctatct
8761 tgtgcacatg gaagtgttta agagctagaa ccagccagtg ttcactcctg tataaccagc
8821 tgttcccttc caacagaggt cagggtcctg ctgtgttggg ggtggccgcc agccagtttc
8881 ggtgggtgct gggcttcagg ccatctgtta ccaactctct tctctccatc ttttgagggt
8941 gttgggatgg ccaccaactg ggggagcctc ttgcaggata aacagcagct agaggagctg
9001 gcacggcagg ccgtggaccg ggcctggct gagggagtat tgctgaggac ctcacaggag
9061 cccacttctc cggaggtaag cccctagctc ctccccacag cattcaccat ggcccactgt
9121 ctggccccgg ccaggctgag ggctactcct ttgcatcagg gaccatatct cttttgcctt
9181 attttttcca gtaactaaaa ttgatctcta gaagtagaaa ataaaaaggc agtgtcctgg
9241 agtaatcaaa tttaaatatg gggtttgaag tgtgacttag gcaattact taaccgctct
9301 cagctgcagt ttcttcagggt gtaaaaatgg gataataata ggacctacct cactggtttg
9361 gtaagagaat tacaggatga ttcatgtgaa gcactttgcc cagttagcta ttactgaaaa
9421 ccccataatc actctacctt ctctgtaact ggtttgtgat atatgcttcc aagcctttct
9481 ctgtgcattt atatacatag ataggtatat atagaaatac gtctttttta aaaaacaat
9541 tgtatcatat atattattct atgatatgtt tttggttttt tatttgtctg tcttagaact
9601 ttctaagtcc ttctattagg gtcacttca ttctgaggca tagtattcca gatgtgggtg
9661 tatcacagtt tagcttccct ctactcatgt ctatttaggt gatttctcat tattttatga
9721 ccataaaatg cattataggg aacatccatg catatgtctg ttggggcacc tatgtgagtg
9781 tttctccagg ttcaatactg aaaaatagaa ctgctgagtc caaacccacac ctttttaaaa
9841 cctcatcctt agggaagaaa aaaaaataaa aaaataaat cttttttaat ttggtgacta
9901 ggtaagacat tttcatgggt caaattcaaa tggtaacaaga gtttacccta atgcagcttg
9961 tgttttgggt tcttgttgat ctttccagat ggcttattca taacaagtaa ctaataacaa
10021 gtaaatatat tctctggggc ctctgctctg tgcccaggct ggagtgtagt ggcacaatct
10081 tggctcactg caacctccgc ctctggggtt caagcaattc tcccacctca gcctccaag
10141 tagctgggac tacaggcatg tgccactacg cctggctaat tttttttttt tttttggtag
10201 ggacagggtt tcaccatggt gtccaggctg gtctcaaac cctgacttca agtgatccac
10261 tggcctctgc cccccaaaa tgctgggatt acagggtgta accaccgtgc ccagcctcct
10321 tttgcccact ttttttctt taacttaaca gtacacctta agaccatatt ggtgactaaa
10381 gagctgcaa catctctctt ttttttagcc agaccattc tttttgtct ctgtgtgecc
10441 agaacctaca caggcctgat ggagtccaca ctcagtaatt gtttgcctaa gcccagtaa
10501 atgacaatgt ctgtcaccta aggcaggctg atggtatgga atagaattgc ttgggctgtg
10561 aacctagatt ttgtgaatta cttgtatgaa tctaaaatga agcattttct ctccacgct
10621 tttgtttctt ctgttaatca ataggtacca tgtgaagatc caacacttgg tctttctggg

-continued

10681 aggttatgga gcctagaaaa ggcgtaatcc acaatgagat ttctaatacca gaaaaaaagt
10741 cagaaagtgt acgtgtgtgt gtatgtgtgt gtgtgtgtgt gtgtgagaga gagagagaga
10801 gaatgatttt actccaaatc ttaccaaat gcctgctcta tgccgggcca ttgtaggcac
10861 tgaggacaga gaggtagtc agccagagcc ctgacctctg gggctcctgg tctagttaga
10921 gaacatacca caaaacaaaa ttaaataaca tcagctctat gaggaaacac aggcagtctg
10981 ctacacaaag ttaactatca tttattgagt atttagtatg tgccaggcat tattctaac
11041 actttggaat cactgactcc tcaccacaac agagataagg aaaccgaagc ccagagaggc
11101 taagtaacct acctgaggtt atttaaatgg taaaataatt ggcagagcca ggatgtgaac
11161 ccaaggaatt tggtcctga gtccatgctc tgaacatcca tgcttttttt cctctcccaa
11221 gatactatat aggacagctg gaagaaagag tagttcatta tgattagatg attgagatgg
11281 ggggtggtat ttgaactaga ccttaaaaga caaatagggg aaaggaacag catagcaagg
11341 acccaaaagt aggaaaaggc aaaaaaaaa aaaaatgttc aagagaatgc agctgaaatg
11401 cagggcgcat aagtggatat agtgggaaag aaggcaggcc agcgtcagac agccgcgggg
11461 ccttagctac tgggtggagg aggagtatga actttatcct gtagatcaga gctgcaaaact
11521 agccatatct aggctgagta tttggctcct gcagtgtttg gggagttaat ttgtttttta
11581 caataagtaa tacgttcaaa tacattttaa cagggcgcaa aattcaaaag ggtattcagt
11641 acagagtaag tccccttctc ccagccactg tttccctgac caggggcaag cattgttaac
11701 agttgttttc accagagtat ttttaaaaag tcagagccaa catttaaaaa aaaaaatcat
11761 gaaatataaa caaaaaatct agcaacccaa cttgtcttga aaaattatat catctggcaa
11821 ctctggccta ctttctgca tggcaacaat tggctagagc agagtcttgg ctgccccctt
11881 tagagaagat gcaagtactt ctttttgcca caattcctat cactccctgt tgettctgg
11941 ctacaaagca gaattttgtc atgcacgtgc tataggtttt tttaaatagt agaaaaatgt
12001 ttcttttttt ttttttgaga cagagtctca ctctgtcgcc aggetggagt gcagtggcac
12061 gatctcagct cactgcaacc tctgctcctc gggttcaagc gattctcctg cctcagcctc
12121 cagagcagct gggactacgg gtgtgtgcca ccaagccagc ctaatttttg tatttttagt
12181 agagatgggg tttcaccatg ttggccagga tggctcagat ctcttgatct tgtgatctgc
12241 cgcctcggc ctccccaaat gctgggatta caggcatgag ccaccgctgc cggccagtaa
12301 tgtoatttta tgttaatgtc tctatcaaaa gtgagaagac tgtgtgtttc agcctttagc
12361 ctgtagatag cagagaacag ctataaacta ttgatectaa attcaggagg gcataatgag
12421 cctggggaca gaggcagagg gatgtcttag cagaaaaact ctgagttttt gaggccaaga
12481 tgagacttgt tgggggcagc agagctctat gtgttcaagc caaggaaatg ctctgtagt
12541 catcacatag ctactcaggg tattaggtca ccccttatgt aatctgcagt cattcccatt
12601 ctaactcata aaggcttcag actgaataaa ccttattctc acaaatagcc ttctcagtt
12661 ttatcttaga tgotgaggcc agggcagtggt tacacacctg cagtctcagc tactggggag
12721 gctgagacag gaggattgct tgagcccagg aatttgaggc tatagtgcac tatgatggca
12781 cctatgaata gccactgtat tccagtctgg gcaacatagt aagacccac tccaaaaaaa
12841 aaaaaaaaaag atgctgagaa gggtaattha gaaattatct accaaaaatt aaaatagatt
12901 tacctgaatt acttgatatt tttactttta gaaatttaga atgtatggac tttctcatat
12961 atgaaaaat ctagaatgta tattctagga taccattga aacattaatg gtaataggaa

-continued

13021 aataaagaaa ccacctatat actagattca ataaattatg gtatatocta agagtagaat
13081 aatatacagc aattaaat aatgaaaatg ctctatttga acatataagg aaatatttaa
13141 aaagcacaat gtagtatagt ttgctatggg ggtgaaaaaa agagaaaata tatgtgtata
13201 catatatatc aatacaaaaga tgactggaag gatgtgtgag acaactagtct gtcatttgcc
13261 tctggggagg agaactgggt ggctggggcc cagctctttc cccaggagac tggaatgaga
13321 gtgagacata cttctcacta tatattctta tgtctctttt gaattttgta tcatgtattt
13381 gtattacotg ttaaaaaat aataatattt tggctgggca tgggtgctca tgectgtaat
13441 cccaacactt tgggaggctg aggcaggcag atcacttgag gccagggtt tgagaccagc
13501 ctggacaaca cagtgaaacc ccatctctac taaaaataca aaaattacct ggggtgtggtg
13561 gcacacacct gtagtctcag ctacttggga ggctgaggca ggagaattgc ttgaaccag
13621 gagatggagg ttgcagtgag ccgagattgt accactgcac tccagcctgg gcaacagagt
13681 gagactctac ctcaaaaaa aaaatagtag tttaaaaata aatatctaaa taccaagttc
13741 taacaccgta aacttatacc accataatga caaactgata ttaactcaa ggtaaaactc
13801 aggaatgctt tataatacaa gtcacaagat tttcttttca tctcttacc aagttctagt
13861 tcagttgttg gcagggatct cagaatgcac tttcccttc tagaatcagt gtccttgatg
13921 gtatttgggt ttctcgtcta tgataaagtc caaagaatgc ggaatgcagc tgaactctag
13981 gctgttaac ctgagtcacc atcactaaca ttggtgaaa aaacactcct ggcttctact
14041 aaggaacca gagttcactt gtctaccca gtaaccaat caaaatcaa aggcaaggaa
14101 actggagtgt gagctcctga tgcatggaag ggctgggct tgaacatcaa ccagcaagga
14161 gcaggcttcc atgtatgat gtgtgtgttg tgttagtaa ccactcctgt tcaaatcca
14221 gcaccccggt actagctgaa tataattttg gatctgttaa ctgttctggt tcaaatcca
14281 gcaccagttc ctagctgaat ataattttgg atctgttaac ctctcttctc caggteccgt
14341 ctctgttaag tgtggataat aatagtatct tcctcacagg gctgaatgat gaatctatg
14401 aaagtattta aaatagtacc ttgcacatag taagtgtca ataacttgtg ggtttctttt
14461 tgttatttgc attttctttt ttgtctctc tctcttcaat acgtagagat aaactatcac
14521 agaactctga agctctctgg gttccactct ccccttcca ctctcccaag gtaaccacta
14581 atctacagtt ggtgtgtcct cagtaaatat aggcagact ttccatgga ttccatttgc
14641 aggaagacaa cccgttcaca ggtgcctac ccctgtcca ttctctcttc ttgatcacag
14701 gtggtagact atgccccatt cagctcttc ccctcactgg tcccagtgcc cctgctggag
14761 caagcctatg ctgtgcagat ggacttcaac ctgctagtgg atgctgtcag ccagaacgct
14821 gccttctgag agcaaaactc ttccaggtag gggacagtga agcattgggg gcccaggagc
14881 tgccagagcc aaggaactgg aagattgcag agccgtgagg tgttactgtg tcagctgact
14941 tgggtgggata gaggaaaggt acctccaaag aacaaaagt cataggagtc aggaaagctg
15001 gcttctaate ctggctcgac cagttattta tatggcctca agccactccc tttctcttc
15061 tgggcctaag gtttctctat ctgaaaaatg aagagactgg cttaaatcca agatcccttt
15121 attgttgaca ttctgtaatc cgtgacacc tactttgaag actgatattt ccatttgaa
15181 ttagggaag tcagcctggt ttggaggaa aacagaggta ggaaggtta ttgggttaa
15241 gtcagatttt ctactctcc taagcagcga cacttctctg tcacctcagg cctctcatct
15301 ttggatggga tgggttacag actgggccc actcagggca tgaggaagca acctctgaaa

-continued

15361 tgggttcagcc catccgcct tctctgtctc tttcccttga tctttttttt tttttcttca
15421 gattctgggg caatttctta aaatttcttt atttatttta gaattaaata tatataggct
15481 gggcgcggtg gctcaggcct gtaatccag cactttggga ggccgaggtg ggtggatcac
15541 ttaaggtcag gagtttgaga ccagcctggc caacatggtg aaacccctc tctactaaaa
15601 atataaaaa attagctggg tgtggtggcg ggtgcctata atcccagcta cttgggaggc
15661 tgaggcagga gaatcgcttg aaccaggag gcagaggctg cagtaagcca agatcacgac
15721 actgtactcc agcctgggag acagagcgag actccatctc aaaaaaaaaa aaataataat
15781 acatataat atgtatatat attcattgta gaattaaata tctagaaata ttatgtattt
15841 acatatacat gctagatgtg tatatactgt acaggttgag catcccta at ccaaaaatcc
15901 aaaagctgaa atgtccaaa attcaaaact tgttgaacac cacatgactc taccagtgga
15961 aaagccacg cctgatgtca tgtgacaggt gcagtcacaaa cacagtcaaa agtttgtttc
16021 atgcacaaaa ttaattaaaa tattgtataa aataatcttc aggctatgag tataaggtgt
16081 atatgaaaca aatgaatttt gtgttagac ttgagtcca tcccaagat gtctcattac
16141 gtatatgcaa atcttccaaa atccgaaaga cttctggtcc caagcatttc ggataaggga
16201 tatccaaact gtaattgcat gtctttgatt aatttttcaa cagaaattag acttttggtg
16261 gagacaaaat cttttaaaaa tgtgtgggtg aatatgagaa ggggtcataa tgtaagaag
16321 cttggaaacc attgactgt agccaaaaac ccaatgagtc atgaatgtat gaatctgccc
16381 accaccttgc cctgagctg tttcttgaa tgggccagc tttgtacctg caatcctgga
16441 ttgtgggaaa catgagcagc ctggctata accctaata tgcaattatg aaggagactt
16501 gcagctcacc tttgcaacc ctgcctctc tgttcctctc tctctcata cacatataaa
16561 ccttagttcc taagggagaa gagcccccta caaacatga aggggagcac ctcttcagaa
16621 aaagaaagt gtgtctcaac ttccttgag gctgaagccc agctgggact ctctcctaa
16681 ccaagggctg gcagtagaga gctcacctt gggagagagc tggtgagga gcagaggaac
16741 ttcagggcag gcctgggcta cttggcttcc cccactggt ctgctgtgac gttctgtaa
16801 caaggtgatt caggttgag caggtgtgca gaatccacc tgaatctcaa agggcagtaa
16861 gtgtgatgtt aatcacctgt ggattcctc ttactgtggc tcttgttgag acttcagaaa
16921 accatactgg atagccccct aacacatgtc acatgtcatg gcagtacact gagctgtgac
16981 gatgagcctg catagacaca gccattacct tcatgaggtt tatagtcaaa caggagagat
17041 gacactaatc atcacacaaa gaaaatgtaa aattgcaact gcagtcagtg ctgtaaagga
17101 gtggttctta gttctatgag aacacatagt aggggatct gactcagata gggaggctt
17161 cctgaggaa atcacatcat atgaggacta gttgaagaag aaacaaaca aaaaaaaaaa
17221 cccaggatat ttactttggg tcagaaaaat cttattggtg cacagggcat aactgctgtc
17281 ttctaactct caagggctgc tgtggaggag gaggagaagg ctcaccctgg gaggtcgag
17341 agggtaggaa aagctatgga gagttatgat taggtcaacc agaagcctt ccaaccatca
17401 gagctattca agtagaatag atacatcatg tcatcttcta gctcttctc ggtgcagat
17461 gttcaattct ttgaatgtaa tatcttattg gctttttacc acaactctat gatataaata
17521 taattatatt ctccatttta aagatcagca aactgagaca cagagaggtg aatgattcc
17581 ctgaggttgc ctactagtga gtggtagagc taggatttga acccaggtct agagttggat
17641 tcttagccac tgttctctac cacattgggg cggacattca agttttggcc agtagactca

-continued

17701 gagaggattc aggagtcaat gactgaggat gggactcctt gaaattttag gtccaattaa
17761 gcttgcaaaa tgttctctgt ttcttctctc agcaccatca aacaggatga ctttaccgct
17821 cgtctctttg acatccacaa gcaagtccta aaagagggca ttgcccagggt aaccattccc
17881 agccctactc cagtctgtaa cctgtccctc ccactctctgt ttgttttctg ttttgcttga
17941 agaatttggg ccaggccctc agctcatggg aatctgcctc tcaactgggtcc tcaactgggtt
18001 tatcccagtg accaattcta ggatgaccag aagaatgatt ccaactgggct tgggagtggt
18061 tgctgggtacc tctaattctc gtgtagagtt catggtacct gtgtgctctg tggttaggtc
18121 ctgagagtca gtccctgggc aggtactgtc agccttcagt ttteccca gactgtgttc
18181 ctgggcctga atcgctcaga ctacatgttc cagcgcagcg cagatggctc cccagccctg
18241 aaacagatcg aatcaaacac catctctgcc agctttgggg gcttggcctc ccggacccca
18301 gctgtgcacc ggtgggtccc ctgggcagcc cccggcatac ctgtgggggtg acatgctgat
18361 ggggtgtacag tcaactggta ggccagggaa ctccagctat gattgtgctt tccctggccc
18421 cgggtcacat gttgcccctg gccaccccga cagcagtttc cacttgtaat gagatccttg
18481 gtatgtcagg gaaaaaagg acctcatagc tcatctagtc ctgtccctcc attgtacagg
18541 cagaggggaa aatattctga gagcccaga gagaggaatg cagggacttc tgtctggggg
18601 ctgggccttg tagcatccat ttctagccag cagtgatgct ccaggttgca atgattttag
18661 atggtctgca gcaggattcc agacagcacc tggaggccca gagtaagggg ctccagctca
18721 ctgggacact agggtagggt ggggtgggga cagaggctct caggctcctc ccagcatat
18781 acaccagggg ccaagggttag ggcagcccag catattccaa cctgaagtgg atcttacagg
18841 aatgtgatgg gaggatgctt tttagtctc agctgattct cagagtcagt ttgctgtata
18901 tatgaggtca tgggagcagg ggtcttccag gtccatccaa ttactgaaca gccatctctc
18961 ttccaacaga catgttctca gtgtcctgag taagacaaa gaagctggca agatcctctc
19021 taataatccc agcaagggac tggccctggg aattgccaaa gcttgggagc tctacggctc
19081 acccaagtaa ggggtgtgaaa aggtagcagg aggatcctgc tttagtttca gcattcatgg
19141 gtttagcaac ttcttttctt gccagccatc attagagaat aaggggattt ttctaggaat
19201 agaaaacttat acctttacat gccaaaatta ttttaagggt tcttcttaa ataacagatg
19261 ctgactatga ttttaacttt tcttattgag tggaggctcat cattatgact gtcaacaatt
19321 gcagcttgct gtaatacagt agtgctacct agggttagag aggcacgcaa ggctgtttgc
19381 ctgcgctaat agctctgact gctaggcttt aagtcttag tcaattcctt tttttttttt
19441 ttttgagaca gagtctcact ctctcacca ggtggagtg cagtgttaca atcttgctt
19501 acttcaacct ccacctccg ggttcaagca attcttctgc ctgagcctcc tgagtagctg
19561 ggatttcagg cgcattgctc cacacctggc taatttttgt atttttagta gagacggggt
19621 ttcacatgt tggatgctt ggtctegaac tctgacctc gtgatccgcc caccttgccc
19681 tcccaagtg ctgggattac aggcattgag cactgcacct ggctctctat tcaattttt
19741 catagttttc ttgtctgttt cccaattctc agctcttact tttgactgct gttggtatgc
19801 ttgaatttgg aatctccac ccccatgcc catgcctccc tttctgattg ctgtggttg
19861 ggaaaacaaa tgatccagat tgttatgatt gggctgaag agtgtgaggg cctcttgat
19921 gagtaaatgc ataagctttg actacgaaat tttatggtat cctttttaac tgcttagagg
19981 cattttttgc tttcttctca tttctcaagt gaagatgta ggtaagtgat tttcagatca

-continued

20041 tcgaggggccc gctatactaa cagttattgc aatgtaata tagcattaat agtcottaat
20101 gtacacttac tagtgctaca ccttggtgcta agctctgtac atacaggatc tcattgaatt
20161 ctcataataa gctctctgag gtcaatactg ttcaactccc tcattttaca gatgaggaaa
20221 ctgaggttct gagaacgaa gtgaattggt aaggctaagt gatgagttgg tggcagatcc
20281 caaagtctac ctccctctaa aacctccact cttaatcatg ctcttacctc caagggagcc
20341 tctctgtcct tgctaagcct cactaagccc aaagaaacct cagactgtaa gcatttagaa
20401 gtcacagac aaatattctt tcaagtatat tggctagggt gtattttaag agagtgaagc
20461 caggggatgg gtcagctggg gaactgctga cagacaaatg ctgcagaggg ttttgctgc
20521 cagcctgtca gtaacgtgga cagaaaatac ttgtgtgtcc aaaattagcc actggtaggt
20581 aggagttatg tggcacctga gccagaactg gcttccccca ttgtgagagt gagataggtt
20641 cttctgctga catagcacat gaccttgcca agttagttct tctctgagct tcagtttctt
20701 catttgtaaa ataggagtaa taataatacc taaaggggtg ttagtgagaa ttaaatgaga
20761 tcatggatct gaaaaatggt tttaaaaatc tgtgtggatc attatgtggt actttcaata
20821 ataataatag gccgggtgca gtggctcaca cctctaatcc cagcactttg ggagaccgag
20881 gccgggtgat catcagaggt caggagtcca aggccagcct ggccaacatg gtgaaacctt
20941 gtctctacta aaaaatacaa aaattagcca ggcatggtgg caggcacctg tagtcccagc
21001 tacttgggat gctgaggcag gagaatcact tgaacccggg aggtggaagt tgcagtggcc
21061 aagatcacco cactgcactc cagcctgggc gacagagcga gactccatct caaaaaaaaa
21121 aaaaaaaaaa aacaaaccca aataataata ataataagcta tcatttgaca agtattagtt
21181 ttaattcata caacagcaaa ctgaggctaa gagagtttga ataacttgcc caaagttaca
21241 caaccggtaa gtagagaatt catctgcctc taaagcctat gttctctcta cttccctatt
21301 ctgcctttaa gagatattgt tccacagtat tgactgaaaa actgcattgg tagagcagat
21361 taattttogt caattatctc atgattttta aaatttctta aaaaaggag cctgcaaaat
21421 gacttacaat ttcaatttag acaaactctc aaagcatagg gcctgtggtt agaatgagta
21481 gaataagaaa aggggactac tgggtataaa agtttgggaa ctgtgatctt tttaacacca
21541 attttttct tttttttga gacagagttt cgtttttggt gccaggctg gagtgcaatg
21601 gcacgatctc ggctcactac atctctcacc ttccaggttc aagggatttt cctgccttag
21661 cctcccaagt aactgggatt acaggtgccc accaccacgc ctggctaatt ttgtattttt
21721 agtagaaaac ggggtttctc atgttggtca ggctggtctc aactcccga cctcaggcaa
21781 tccgcccgcc tcggcctctt aaagtgtcgg gactataggc gtgagctacc atgccagcc
21841 ataactctct tattttatag atgggaaaac cagggeccaa ggaacgaaat tgccttacc
21901 aagtcaatta ccaagacaca ctacaagtca ctggcagagc ctggactacc tacgactcag
21961 gggctctcac cccagcccg catgctcctc tagctgacaa ctttctact aggaaacaga
22021 ctgctgagaa ctgctcagaa ctgaaggcag gagaggtcaa atatgttttc tgagcccagc
22081 tctgattggt tagcagttgg caggctgact taattagctg gggcgtgcag ttctcttta
22141 acctccagct gccagcctc ctctccgccc tctttttgga ggtgggcccag cctgggccc
22201 ctgcctccct cccacacaca ccctcacca tgagcgggac agtttaggct gcaaaagtga
22261 gagcaagcc attgcccctt aggactctct cagggaaga tgacttgtga gagcaccact
22321 tttagtttgt ctctcaggca cccaactcaa agccaagact cagcttaaca tcacatctga

-continued

22381 cctcatgaga tttcaggcaa accaggagag gggacttact aagacctata ttttggctaa
22441 gcagaaaagga gtcaggcaaa cagagtttag actaagaggt tcagccaagg tcaggagaag
22501 cagagataga caagagagggc taagcagagg aggtcagggg atacacactt agaactctaa
22561 gccaaaagcct agggttccat gggctcagg aagaagccac agacacaaaag cagtacagtc
22621 acagcaaaaa tggagtgttg aggctgagcg cagtggctca cacctgtaat gctaacactt
22681 tgggaggccg aggcgggag atcacctgag gtcaggagtt cgagcccagc ctggccaaca
22741 tgggtgaaacc ccatctctac tcaactaca aaaattagcc ggcgggggtg gtgcacacct
22801 gaaatcccag ctaccggga ggctgaagca ggagaatcgc tggaaaccag ggggtggagg
22861 ttgcagtgag cctagattgt gccactgac tccagcctgg gcaacagggg gagactccgt
22921 ctcaaaaaaa taataaaaaa aaaatgtaaa agaaaaaaa tgcagtttgg tactgctgag
22981 cattagccct aggaatctct taggggactg gacctatctt tgacaacgga aatatgttag
23041 ctggcagcca aacagatagt tccctggcat aagcttttcc ctgagccctc aagccctgc
23101 ctctttaaga aatacatgaa taatcagaga ggaagaagcc acataagccc tagtgatctc
23161 attaatacta tgagatcaaa tgtggccctg tgtacattat aggaatcttg ggaggccca
23221 ggagataatg tctgtgttg tagttggccc tgtgggttc tgtagggttc catcttgtt
23281 aagaaccaca ttcctttatt gtatccttta caatctagta atagagccat tagccccgga
23341 cccctgcat tgttcttta caaatgttc ctcaactc ccaactgttt attctccag
23401 aaagatttta gaattatgtt aagttctaag aaaaagtcct cttgggtttt tgagatggtt
23461 ttaaatctaa attttaattt gcacagaaat tcatcaacce atgacatcat tacaatatt
23521 catctgcca ctggagaagg gtcagaggca tctcatttt tgaagtttc tatttccag
23581 aaatcatatg tgatagcgc aggtgtctat gcctgaggta atctcaaggt tcttgagaga
23641 ggaacatct gttctttcag ggaagcgggt ttcttattct tattccagga ggtggggcgg
23701 tatgggggtt gagggggaga acaaaagaag aacaagttct atagtgcct cgggccacct
23761 gtgctcttc cccagtgtc tgggtgctact gattgctcaa gagaaggaaa gaaacatatt
23821 tgaccagcgt gccatagaga atgagctact ggccaggtaa gtaaagggaag ggggactct
23881 aggtgtggct ccaggattag ggggtgggca ctcagaacat agcatccatt ccctctggct
23941 cttgccatt tttccagga acatccatgt gatecgacga acatttgaag atatctctga
24001 aaaggggtct ctggaccaag accgaaggct gtttgtgtaa gcattccaa gaatccagt
24061 gaaggctggt ttatgaaact catcctgcca ccctctccc caaatgatt ctttctctg
24121 ggagatgta tggctgtct cttctctca taattctga aatatctcat cctcccagga
24181 aattttggag aaagccagcc acgctgtgct tctatcagag ctgttgacat tctggatcag
24241 ggtctctta gagatcatct tagtttcat atgccctaag ttcccaaaag tttcttgcc
24301 tctctagta aggtgagtc aggcctgaga agctgagctg ggcagtcagg gaggaagagg
24361 agcagctggc tcatgtgtg attggtctgg atgccactgt ctgagctcga gcctggattt
24421 gtgttccaag ccaagcctta tcttttctc taggggccac caccagtag atttggct
24481 acatatttgg gtagcattgc agcacatata tttagacct gaccttctg attgttaaaa
24541 ttaaaactgt ccatggaatt tcacaatacc actcactgtt tttcaaatg tgctttatc
24601 ataactaac aaagtgtta atttactttt cagataaaact agacaatate aaataggtca
24661 aagaaaagga aaagacattt aaaaagcctg tgtcttaac agactcatca tttcatatg

-continued

24721 ttgcggttttc accttcaccc ctgccattaa aaattttttc attctggttt cagctgcttt
24781 aagcagtgga aatataaagt gtgttttact acacatggca gtatgattct gctgctcggt
24841 aatttcgagc caacatttgt atgcatttac caaatttgat tctagtgacc ttcttgttcc
24901 ttctggcctt cttagaatga ctctaactct ggcatattct aaagtattct gtatggcaca
24961 cctccctggt ttcagtggaa gcctcggtag tgtggatata tactttcact ggttccagtg
25021 aaccctgac caggctccca ctgtgggctg aattttgaaa aagccaaatt catcttgatg
25081 caccctgaaa tagattgaac cactgaacaa atcagttata atttaacaca gcagccttct
25141 ccctcctggt ttccagggat ggccaggaaa ttgctgtggt ttaactccgg gatggctaca
25201 tgctcgtca gtacagtcta caggttggtt ttttctgtga gaccattctt tgctcctgg
25261 gaccacaag agctccacag agaccaatt caggcttata acaacctggg ttttccgagt
25321 cctcacttca cttctttctc agggagcttg ctgctagaac ctctatcct ccctcaagcc
25381 ttttctacc tatcactcta cacagtcttc tagaattga atcctcagga atccacagag
25441 cttcagccat ttacactggt tccagagatg tgetggcaaa tgtttaacaa caatcagctc
25501 tcactggttg atataagcca gttccagcat actgctgacc attttttttc ctgccaaactc
25561 ttacctttcc tttatctgaa tcagaaagt ttatcatctc ctcatctatg ttaatgacag
25621 ttatatcacc tcaatttctg atcctaccat gtagtttcat tagtttccac atccattatt
25681 tcatttaacc ctccacaacca ctcggtgagg catataatta tccccattat acagatggag
25741 aaactaacgt ttagagagat ggagaggctt ctctaaggcc ctacaggaag ttcccagggt
25801 ttctgacttt caggccgatg gtattcccat tcttctctc tgctcctaac atccacatca
25861 tggagaggct aagaagctct gctctcagct gggagatgat aaaggaggaa ataagtttag
25921 aaataccatg ggcaagtgc tggaggtcat gagcttgact gctctgtgt gatgatgggc
25981 aagttcctga ccttttctag gtctgtttct atgagcgggg ggagctacac tagaaaactg
26041 agggggctcc tcttaggtct gtaattcctc taggactccc cccgagggtt gagctccaca
26101 tgaggaggct ctatagaggt ggtatctcga tagaacatcc ttttcttag ataggtggtt
26161 agcagtgggt gcaacttctg gactacagga gagataaact gtctattaga aaaataggtc
26221 taggccgggc acgggtggtc acgcctataa tcccagcact ttgggaggcc aaggcagggt
26281 gattacctga ggtcaggagt tcaagaccag cctggccaac atggtgaaac cccgtctcta
26341 ctaaaaatac aaaaattagc cgggcgtggt ggcatacccc tgtaatccca gctactcagg
26401 acgctgaggc aggagaattg cttgagcccg ggaggcagag gttgcagtaa gttgagatca
26461 tgccactgca ctccagcctg gctgacagag cgagactctg tctcaaaaa aaaaaaaga
26521 aatgggtcta gatttcaaaa caccgaaaag aaaacttaga agagtttgag ataacaagga
26581 aggaaagtag tgtttaaaga ggtagacttt ttttttttt tgagacagag ttttctctt
26641 gttgaccagg ctggagtaca gtggtgcat ctcggctcac tgcaaccttt gacttccagt
26701 ttcaagcagat tctcctgctt cggcctcctg agtagctggg attacaggca cccaccacca
26761 caaccagcta atttttgtat ttttaataga gacagggttt caccatgttg gccaggtgg
26821 tctcgaactc ctgacottac gatccacca ccttggctc ccaaagtgtt gggattacag
26881 gtgtagcca ccacacctgg ccaagaggtg gacattttta gggaaactgag cagctcagag
26941 caggtttaga catggagaga gatctagaag gcttagtgac ttactagatg accctgggca
27001 agtccttctg tatctttggt tttgctttcc tgettctacc ataatgggtt atttctctgg

-continued

27061 gtttatttct gatgttctgg tcacgtgtga ttctgctgg aatgccagac tagtagttgg
27121 gttcctgggg ttattgatga agatcaggtc aagggtctac aggtggacca gtagtatcaa
27181 aggaaggaca gcattgggtg ggggtcacag gagagacctg atcctgtgtg gtgcagtttg
27241 cagtggctg gagccaagga cagactgtct cccattgca tgagaatggg aaccagagtt
27301 gggaggcatg atccccgtct gtttccttgc cttttatacc ctcagctctt gtggaataa
27361 accattcatc ctgtgatcat ccacttgaga cctgtgttca tattattctc ttagcctgag
27421 tatcccttcc ctattgagtc tcaactgtca ggctctacct gtccttcaga acccactca
27481 aatttcaact tattcagcaa caacaacaaa tatttattga gcaactaca agtgccagga
27541 actgtgttag aactggaga tacaacagaa aatgaggaaa atgataagag ccctgtgcta
27601 tggagctcac agtctgttca gagaaatggg catcagaaag taacacaaaa tatggccatt
27661 tactgtggct cgtacctgta atcccagcac tttgggaggc ctaggtaggt ggattgcatg
27721 agctcaggag ttcaagacca gcctgggcaa catggcaaaa ccccatctct acaataata
27781 caaaaattag ctgggtgtgg tggcgtgca cgtagtccc agctacttgg gaggtgagg
27841 agggaggatc acttgagccc aggaggtaga agttgcagtg agccaagatt gcgctgttgc
27901 actccagtct ggggtgacaga gcaagacca cgtctcaaaa gaaaaaaaa gtaacaaaa
27961 ataggaaaa aaaattggga tttgtgtgtg tatgtttgtg tgcgtgtgcg tgtatgtgtg
28021 catgtgtgtg ttttagtctc aggtaactgc tttcaatgaa acaactgggt aaaaagagaa
28081 ttatgggaaa tccacattaa atagagtgga cagggaagcc ttctctgaaa aggtgacatt
28141 gagctgagat gtaaggatgg taaggatcca gctatgcatg gaaaaagccg aaaggaaggg
28201 ggtttcagg tggggaaaa gcagtgcagg ccctgaggag gaaagagct ttgtgattg
28261 aggaatgaca ggcctgtgtg agtagaatgg cagagactag gactcaggga tggtaacagg
28321 ttgaaaaagt agacaggagc cagctcctga aggatcttga aggccatggt agggagtagt
28381 gaacacagtg ggaagctgag cacgtagaca aatgttctac ccttacacct tctattgtt
28441 cccacagatt ggggattct tgcctttgca gggctcaca gtctggcaca atgatacata
28501 actacaacat atcacacctg gctcacaagg atgttagaat gatcctgggt gataatgagg
28561 gtgaagatc aaatcatgat acctggcacc taatggatgg atgttcagta aacgtcagct
28621 gaagtaaaat aaagtcgaat tccttttgtc ttcttccctc tgcagaattg ggaagcacgt
28681 ctactgtctg agaggtcaca tgcctgccaag tgcacagaca ttgccacca gctggctggg
28741 actaagaagg tgcagcagga gctaagcagg ccgggcatgc tggagatgtt gctccctggc
28801 cagcctgagg ctgtggccc cctccgccc acctttgtct gctctactc actggatgtg
28861 gtactgtggc agcctgttct tcctaccaca ggctctctag gtggcagaga cctacagccc
28921 aatgtgttgg ggagggtgga gctggcattg tgacaagggg aaggtggagc tggcaaggtt
28981 ggtgatgctc tggagaacct ctagaactct gagcagaagg gcagcctcat aatggaagga
29041 tgggggcttg aatccattgt aagctccctc agcaaaggta gagatgagga tggcaaccag
29101 agggaagggg ctaaggcagg tggcaagaat tgagaagtgt atcaggctgc ctgctgcaga
29161 gccctgagct gttgctaaag aaaggcctgt tctcattgca tcggctgctg cagggggtt
29221 gttgggagtg tcatccagat agtagcatcc tgctgaagg aatttgggc tgttctccct
29281 cctgctcttc ctctgatgt gctctgcata accagctgga cctaagcttc ttgctcttt
29341 agcctttaa cttttgataa ctgcttctg cctcctgcca ggggaagaa ggggaaccag

-continued

29401 ccatacgcga gccccttgct gcccctagcc ggtttgtgct aaagccccag agagaggggtg
29461 gaggtagggtg gatctccctt tgcagggtct ctcaatgaga gggactagca ggctgtggcc
29521 agtgtctcatt ggcacttact ctgggcacag tcccgggcat gggggaaact attggaactg
29581 acacaggcca catgttgac agtgtccct aagacctgt gaccaagtcc gggagcacag
29641 gggaatctga ttaaccagca ttgaagggtt tggacaagt ttacctgagg tgctgtggg
29701 tagattgttg ggaagttag tagggtcata ttaggagact ggagagaata catgtctgtt
29761 ttcctttcta gtttgaact ccttgaggtc aggggtcatg tctgctctc cagaggagag
29821 gattttttta atctttgtct taagaggtgg gttagaattt cccaggtgga aaggaggaag
29881 agtgttccat acaaaaggga caacctcaag ccaaggcacc gggccatgaa agtgtgagat
29941 gtttgagggt taatgagaaa ctggtgagcc tggaggggga gctgggagg gacagggatt
30001 taggctggaa aaatggttg catcctgatt ataaagggcc ttgaatatat actgagaaat
30061 tggattttat cttaaggcca gtgggaagcc attaggagtt ttaagccag gaaggacac
30121 attgatccag gactcaagtg gtttagcagt gtgggaactt gcaaaactta cagtttctgc
30181 attgtagaag atgtcctgga atgaggggag aactggaag cagaaagacc gtggaagagg
30241 ctgatacagt tgttcagaag agcaacgtag aggcctgggc tagggctatg actatggggc
30301 caactggaga gacatgtct agatagttag agggtagtgg aaggaggag ttaaatatga
30361 ctgaggggta ccttttgctt gattgggagt aggaaggtcc agggagggca ggttcaggca
30421 gaagtaataa gttctgcttg gacaagttga gtttgtttgg gggccagtca tatgatgtct
30481 aagcagggg cctgcattaa atatttgaa gtttaacaatt tttttttttt ttttgagacg
30541 gattctcgt ctgtcaccag gctggagtgc agtggcatga tcttggtca ctgcaaccac
30601 tgccctccag gttcaagcga ttctcctgcc tcagcctcct gagtagctgg gactacaggt
30661 gtgcgccacc acaccagct aatttttgta ttttttagtag agatggggtt tcatcatatt
30721 ggccaggatg gtcctaatct cttagacctca tgatctgctt gctcgggctt cccaaagtgc
30781 tgggattaca ggcgtgagcc accatgccc gcccgaagtt aacaattttt agggataga
30841 tggagactca ggaataggag agatctcctt gggaaaatgt acatggggga gagagcaagc
30901 gtggaggacc aattcccctg ggaccccagc atttaagaga aggagccagc aatggagctt
30961 gagaaggaac agctgtagg aggaggagaa ccagggcaga acagttagt ggaagatgtg
31021 ttcactgcat gagtaagggc tctcctgtca aagttagctt cctcctgag aagccagata
31081 tgccctggct tcactgagcg ggtgccagga actgaggctg ctgacttgc catgtggccc
31141 caaaagttag gcatgggat ggaggaggt ggcagaggtt ccagggtgac tggccagttt
31201 cattgcaggt aacaacctat atggggagga aatggtacag gccctgaaac agctgaagga
31261 cagtgaggag agggcctcct acatcctcat ggagaagatc gaacctgagc cttttgagaa
31321 ttgctgcta cggcctgcca gccctgccg agtgggtccag tgcatttcag agctgggcat
31381 ctttggggtc tatgtcaggt gagccaatca ggagaagctc tttccactac ctgcttgcga
31441 gagtgccagc caagttagcc agcctagagg ggaacctgg aaagagttag gaatcctggg
31501 cttcggtgcc agctctgcca atcactagct ttattacctg tttctttatc tattaatga
31561 ggccaaggac ccaagacctg cccacctac cagggtatca gatgaagccc tgatgagaag
31621 tcctttgcaa ccgtgaagga aactccaat agcaccaaga ggactcagaa cacatggttt
31681 gacaacctag gactagaagg agactccaga gagcataga gactctaaaa tcctagcact

-continued

31741 ttcttggtat agacagttac ccaggctactg ctcagctggg tccagggaaag gtctctgggtt
31801 tggggctgag tccaggtgat gtgtgtcccc tgccctccatt tctataggca ggaaaagaca
31861 ctcgtgatga acaagcacgt ggggcatcta cttcgaacca aagccatcga gcatgcagat
31921 ggtgggtgtg cagcgggagt ggcagtcctg gacaaacct accctgtgtg agggcacaac
31981 caggccaacg gaccttctat cctctgtatt tgctattcct ctcctagccc tctgagggg
32041 tatcctccta aagacctcca aggtttttat ggaagggtaa atactggtac cttccccag
32101 cttccatct gaggaccaga aaagtgtgt ctccttaga tgagatctag acgccccaa
32161 atccttgaga tgtgggtata gctcagggta agctgctctg aggtaaaggt ccatgaaccc
32221 tgccccactc ctgtcagccc ctcatcagcc ttttcagcag gttccagtgc ctgacttggg
32281 ataggactga gtggtaggag gagggggagt ggaggggcat agcctttccc taattctgcc
32341 ttaaaaaaaa ctgcattgct gattcagtga tgattcctta cttcgtgcat agaggggagg
32401 cgggagctgt aatctactgt agcccactta agatgtatta gagcagggaa gtgactggtc
32461 tgtaatcagg gtccccctag accagtctct acaggtgaa cctgaagtt tcaatcctta
32521 gccacccact aatgctctta ctggatcaca gggaggaatg agagtcccctg gcaggagccc
32581 aggaggggag gcaaccaaga tgggacatac ataacagtgt tgaactggct tcagtcactt
32641 tctgcttag ctcaggggct tgtcaaagc cctgtcagt aagcctcct cgctctgccc
32701 aaacaaaaag ttctagaagg aagatattgg ggatagtcct aggaaatacc cctcccttc
32761 catctgccac acaaatcaga gccactaatg aatatacagc ctcagggcac agatacctaa
32821 gaaaaacaagt caccactct tgagatcaca ggctttatc ctacaaccac agggcttgag
32881 cctgactggg gcaagaaaac agagtttcat ctgagaatgt cctctatggg ctgggttctg
32941 ttcaggggag ggtgggaaaca gaggacaagg aagacaagct cctctggccc taggaacaaa
33001 acacatttac tcttcaaaag aagcagatga tctgaatacc cctctggagac tgaatctgcc
33061 catacagccc ctggagccaa tgggcagaca gtactggcat ctggcacaaa agggaattca
33121 gaccagaac agaagcagca aaatatttta aaaatagtaa attgttctg gactcacaaa
33181 tcattgtttt taagggcaag tgcatgccc atataagtac tggggcttcc taagagagct
33241 gacataggat tacacagctg ctcctctgct tcagtggagg cctcacatc cctttgaac
33301 acttaacttg gtaggagag gttagccttt cgtctctgt ctgggttctg agagctctgc
33361 agtctggagg cacagcagac tgaggctgac ctgggccctg tctttctgc ctggcagtca
33421 caggatgtt tctctacctg gagacaaagc tggtttccg tcccagacag ctggtcaagg
33481 gagggtagt tgggtaaca ctggccctca gcaactctga gggggcaag aggatgggca
33541 aagtttgag caggaggaat cctaggtaaa ggtcaggatc atgttctctg gatggtcagg
33601 cagcgggtgc tgaagagtg actgatgaca gatgggtcag ccacagtaga catgtccccg
33661 aggtcatggt cattctgagc aatcttccga agcactcgc tcatgattt cctggggaa
33721 ccacagaact ctagtactt ggtgaaagca ctgaccacc ctagccctgc caaaggcttt
33781 catccacgca caccaccaca ccaccaggcc tcagccatc ccaatccatg gaggcctctg
33841 aacatactg agcgggtttt aggcaagcca ggtgcattct ggatgtagtc tgggttgca
33901 atggggccaa tctttctct aactgtaacc aacaaatcat caagcattc ttcagcacc
33961 ttagccagac ttttcaaaaa tcaaagtaga gatggcttg tccccacct gtttctctc
34021 caagtccctg cccacagaga cagcctcagg ttcactgct cctctgctc caacacactt

-continued

34081 gtctctttac tctctcattt tatcttatgg aactcaggct gtagaatgag cctgctagag
 34141 tttaaatgcc acctttctag cagtggtggcc ttgggcaagt gatttaactt ccatgagtct
 34201 cagtttcatc atcttttagca tgaaggtaac aataagatct gtttcatgga ggtgactcta
 34261 gggattaagt ggggtaattc atttaaagca cttagcctag cgggtggcaca aagtattcta
 34321 gaaatgttgg ctattattat taccctagtg ggagactagt ggagac
 //

Human GSS Protein Sequence

[0273]

1 matnwgsl1q dkqgleelar qavdralaeg vllrtsqept ssevvsyapf tlfpslvpsa
 61 lleqayavqm dfnllvdavs qnaafleqtl sstikqddf arlfdihkqv lkegiaqtvf
 121 lglnrsdymf qrsadgspal kqieintisa sfgglasrtp avhrhvlsvl sktkeagkil
 181 snnpskglal giakawelyg spnalvllia qekernifdq raienellar nihvirrtfe
 241 diseksgldq drlrfvdgqe iavvyfrdgy mprqyslqnw earlllersh aakcpdiatq
 301 lagtkkvqge lsrpgleml lpgqpeavar lratfaglys ldvgeegdq aeaalaapsr
 361 fvlkpqregg gnnlygeemv qalkqlkde erasyilmek iepepfenc1 lrpgsparvv
 421 qciselgifg vyvrqektlv mnkhvghllr tkaiehadgg vaagvavldn pypv

Mus musculus glutathione synthetase, mRNA (cDNA clone MGC:6012 IMAGE:3593913), complete cds

1 cccacgcgct cgcagctgga caacgagcga gttgggatgg ctaccagctg gggcagcatc
 61 ttgcaggatg agaagcagct ggaagaactg gcaaagcagg ccatagaccg ggccctggcc
 121 gagggcgctg tgctgaggtc cgcacagcat cccagctcct ccgacgtggt gacatatgcc
 181 ccattcacgc ttttcccctc gccagtagcc agtgctctgc tggagcagcc ctatgctgtg
 241 cagatggact tcaacatact ggtggatgct gtcagccaga acccagcctt cctggagcaa
 301 acactgtcta gcacatcaa aaaggacgac tatactgcc gtctcttga tatctacaaa
 361 caagtctga aagagggcat tgcccagacc gtgttcctgg gcctgaatcg ctcagattac
 421 atgttcagtg gcggcgaga cggctccaaa gccctgaaac agatcgagat caaacctatc
 481 tctgccagct ttgggggctt ggcctcccgg actccagctg tgcaccgaca cgttctcaat
 541 gtctcgaata agaccaaaga agcttccaag atcctgtcca ataaccag caagggactg
 601 gccctgggga tcgcccgaag ctgggagctc tatggctcag ctaatgctg ggtgctactg
 661 attgctcaag agaaggaaa gaacatattt gaccagctg ccgtagagaa cgagctgcta
 721 gacaggaaga tccatgcat ccgtggaaga ttgaagatg tctctgaaag gggttctctg
 781 gacaaaacc gaaggctgtt tatggatgac caggaagtg ctgtggtgta cttccgagat
 841 ggctacatgc ccagtcagta taattcacag aactgggaag cagcctgat gctagagaga
 901 tctctgctg ccaagtgtcc agacattgcc atacagctgg ctgggactaa gaaggtgcag
 961 caggaactga gcagggtggg tctgctggaa gcaactgctc cgggccagcc cgaggctgtg
 1021 gcccgccctc gagccacctt tgctggctc tattcaactgg acatgggtga agaaggggac
 1081 caggccattg ctgagccctt tgctgctcct agccacttg tgctgaagcc ccagagagag
 1141 ggtggaggta acaacttata cggggaagaa atggtacaag ctctggagca gctgaaggac

-continued

1201 agtgaggaga gaggcctccta catcctcatg gagaagattg aacctgagcc ttttaggaat
 1261 tgcttgctac ggcttgccag ccctgcccga gtggtccagt gtatctcgga gctgggtatt
 1321 tttggagtct atgtcagaca gggacaaca ctggtgatga acaagcatgt ggggcacctg
 1381 cttcgaacca aagccgtgga gcatgcagac ggaggtgtgg cggcaggagt ggcagctctg
 1441 gacaaccctt accctgtgtg aaggcgccat ctggacttca ctcaggaggc cttctatccc
 1501 ctgtacttgg cactcctctt ctgaggggtt gccctgtccc ctatcttagg ggagcttgtc
 1561 tcttccatag acctccaaaa cttcagggaa gggaaaacc agggatctt ccctcagcag
 1621 ccttccagcc gaggaccaga aaagctatga ttccattaga agacttctgg aggtccccag
 1681 atctttggag tgtgggaatg gaagctgctt tgaggcaaag gctcataaac cctgcaagtc
 1741 ttcatggtct tctcaccagc ctttcagca ggttctagt ccttgacctg gggtaggacc
 1801 gagtgaagga ggaagagggg aaaagggcac agacttcccc agctctgccc taaataaaat
 1861 aacaatgctg attcaaaaa aaaaaaaaa

Glutathione synthetase (GSS) [*Mus musculus*] Protein
 Sequence

1 matswgsilq dekqleelak qaidralaeg vllrsaqhps ssdvvtyapf tlfpspvpsa
 61 lleqayavqm dfnilvdavs qnpafleqtl sstikkddyt arlfdiykqv lkegiaqtvf
 121 lglnrsdymf qcgadgskal kqieintisa sfgglasrtp avhrhvlvnl nktkeaskil
 181 snnpskglal giakawelyg sanavllia qekernifdq ravenelldr kihvirgrfe
 241 dvsergsldq nrllfmdqge vavvyfrdgy mpsqynsqnw earlmlersr aakcpdiaiq
 301 lagtkkvqqe lsrvgllleal lpgqpeavar lratfaglys ldmgeegdqa iaealaapsh
 361 fvlkpqregg gnnlygeemv qaleqlkdse erasyilmek iepepfrncl lrpgspaqqv
 421 qciselfifg vyvrqgttlv mnkhvghllr tkavehadgg vaagvavldn pyvp

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 16

<210> SEQ ID NO 1

<211> LENGTH: 725

<212> TYPE: PRT

<213> ORGANISM: human

<400> SEQUENCE: 1

Met Gly Pro Arg Ala Ser Leu Ser Arg Leu Arg Glu Leu Cys Gly His
 1 5 10 15

Trp Leu Arg Pro Ala Leu His Thr Lys Lys Gln Ile Leu Glu Leu Leu
 20 25 30

Val Leu Glu Gln Phe Leu Ser Val Leu Pro Pro His Leu Leu Gly Arg
 35 40 45

Leu Gln Gly Gln Pro Leu Arg Asp Gly Glu Glu Val Val Leu Leu Leu
 50 55 60

Glu Gly Ile His Arg Glu Pro Ser His Ala Gly Pro Leu Asp Phe Ser
 65 70 75 80

Cys Asn Ala Gly Lys Ser Cys Pro Arg Ala Asp Val Thr Leu Glu Glu
 85 90 95

-continued

Lys Gly Cys Ala Ser Gln Val Pro Ser His Ser Pro Lys Lys Glu Leu
 100 105 110
 Pro Ala Glu Glu Pro Ser Val Leu Gly Pro Ser Asp Glu Pro Pro Arg
 115 120 125
 Pro Gln Pro Arg Ala Ala Gln Pro Ala Glu Pro Gly Gln Trp Arg Leu
 130 135 140
 Pro Pro Ser Ser Lys Gln Pro Leu Ser Pro Gly Pro Gln Lys Thr Phe
 145 150 155 160
 Gln Ala Leu Gln Glu Ser Ser Pro Gln Gly Pro Ser Pro Trp Pro Glu
 165 170 175
 Glu Ser Ser Arg Asp Gln Glu Leu Ala Ala Val Leu Glu Cys Leu Thr
 180 185 190
 Phe Glu Asp Val Pro Glu Asn Lys Ala Trp Pro Ala His Pro Leu Gly
 195 200 205
 Phe Gly Ser Arg Thr Pro Asp Lys Glu Glu Phe Lys Gln Glu Glu Pro
 210 215 220
 Lys Gly Ala Ala Trp Pro Thr Pro Ile Leu Ala Glu Ser Gln Ala Asp
 225 230 235 240
 Ser Pro Gly Val Pro Gly Glu Pro Cys Ala Gln Ser Leu Gly Arg Gly
 245 250 255
 Ala Ala Ala Ser Gly Pro Gly Glu Asp Gly Ser Leu Leu Gly Ser Ser
 260 265 270
 Glu Ile Leu Glu Val Lys Val Ala Glu Gly Val Pro Glu Pro Asn Pro
 275 280 285
 Glu Leu Gln Phe Ile Cys Ala Asp Cys Gly Val Ser Phe Pro Gln Leu
 290 295 300
 Ser Arg Leu Lys Ala His Gln Leu Arg Ser His Pro Ala Gly Arg Ser
 305 310 315 320
 Phe Leu Cys Leu Cys Cys Gly Lys Ser Phe Gly Arg Ser Ser Ile Leu
 325 330 335
 Lys Leu His Met Arg Thr His Thr Asp Glu Arg Pro His Ala Cys His
 340 345 350
 Leu Cys Gly His Arg Phe Arg Gln Ser Ser His Leu Ser Lys His Leu
 355 360 365
 Leu Thr His Ser Ser Glu Pro Ala Phe Leu Cys Ala Glu Cys Gly Arg
 370 375 380
 Gly Phe Gln Arg Arg Ala Ser Leu Val Gln His Leu Leu Ala His Ala
 385 390 395 400
 Gln Asp Gln Lys Pro Pro Cys Ala Pro Glu Ser Lys Ala Glu Ala Pro
 405 410 415
 Pro Leu Thr Asp Val Leu Cys Ser His Cys Gly Gln Ser Phe Gln Arg
 420 425 430
 Arg Ser Ser Leu Lys Arg His Leu Arg Ile His Ala Arg Asp Lys Asp
 435 440 445
 Arg Arg Ser Ser Glu Gly Ser Gly Ser Arg Arg Arg Asp Ser Asp Arg
 450 455 460
 Arg Pro Phe Val Cys Ser Asp Cys Gly Lys Ala Phe Arg Arg Ser Glu
 465 470 475 480
 His Leu Val Ala His Arg Arg Val His Thr Gly Glu Arg Pro Phe Ser
 485 490 495
 Cys Gln Ala Cys Gly Arg Ser Phe Thr Gln Ser Ser Gln Leu Val Ser

-continued

500	505	510																	
His	Gln	Arg	Val	His	Thr	Gly	Glu	Lys	Pro	Tyr	Ala	Cys	Pro	Gln	Cys				
	515						520					525							
Gly	Lys	Arg	Phe	Val	Arg	Arg	Ala	Ser	Leu	Ala	Arg	His	Leu	Leu	Thr				
	530					535					540								
His	Gly	Gly	Pro	Arg	Pro	His	His	Cys	Thr	Gln	Cys	Gly	Lys	Ser	Phe				
545				550					555						560				
Gly	Gln	Thr	Gln	Asp	Leu	Ala	Arg	His	Gln	Arg	Ser	His	Thr	Gly	Glu				
			565					570						575					
Lys	Pro	Cys	Arg	Cys	Ser	Glu	Cys	Gly	Glu	Gly	Phe	Ser	Gln	Ser	Ala				
			580				585						590						
His	Leu	Ala	Arg	His	Gln	Arg	Ile	His	Thr	Gly	Glu	Lys	Pro	His	Ala				
	595						600					605							
Cys	Asp	Thr	Cys	Gly	His	Arg	Phe	Arg	Asn	Ser	Ser	Asn	Leu	Ala	Arg				
	610				615						620								
His	Arg	Arg	Ser	His	Thr	Gly	Glu	Arg	Pro	Tyr	Ser	Cys	Gln	Thr	Cys				
625				630						635					640				
Gly	Arg	Ser	Phe	Arg	Arg	Asn	Ala	His	Leu	Arg	Arg	His	Leu	Ala	Thr				
			645						650					655					
His	Ala	Glu	Pro	Gly	Gln	Glu	Gln	Ala	Glu	Pro	Pro	Gln	Glu	Cys	Val				
			660					665						670					
Glu	Cys	Gly	Lys	Ser	Phe	Ser	Arg	Ser	Cys	Asn	Leu	Leu	Arg	His	Leu				
		675					680						685						
Leu	Val	His	Thr	Gly	Ala	Arg	Pro	Tyr	Ser	Cys	Thr	Gln	Cys	Gly	Arg				
	690					695						700							
Ser	Phe	Ser	Arg	Asn	Ser	His	Leu	Leu	Arg	His	Leu	Arg	Thr	His	Ala				
705				710						715					720				
Arg	Glu	Thr	Leu	Tyr															
			725																

<210> SEQ ID NO 2
 <211> LENGTH: 2239
 <212> TYPE: DNA
 <213> ORGANISM: human
 <400> SEQUENCE: 2

```

gtacaaaaaa gcagaagggc cgtaaggccc caccatgggg ccacgggcgt ccctgagccg      60
gctccgggag ctctcgggcc actggctgcg gccggctctg cacaccaaga aacagatcct      120
ggagctgctg gtgctggagc agttctctgag tgtgctgcct ccgcacctcc tgggccgcct      180
gcaggggcag ccgctcaggg atggggagga ggtggctgct ctgctcgagg gcatccaacc      240
ggagcccagc cagcgggggc cgctggattt tagttgtaat gctggcaaga gttgtcccgc      300
tgcagacgtc accttgaggg aaaaggggtg tgettcccag gtccccagcc acagcccmaa      360
gaaggaattg cctgcggaag agccttcagt gctgggceca tcggatgagc ctcccagacc      420
ccagccaagg gctgcccagc ctgctgagcc gggacagtgg aggttcccc caagttcaaa      480
gcagccgctg agcccggggc ccagaagac attccaggcc ctgcaagaaa gcagtcccga      540
gggcccctca ccattggccag aggagagttc ccgagatcag gagctggcgg ctgtgctgga      600
gtgctgacc tttgaggatg tgccagagaa taaggcgtgg cctgcacacc ccctgggatt      660
cggaagcaga accccagaca aggaggaatt taaacaagaa gagcccaaag gggctgcctg      720
    
```

- continued

```

gcccactccc atcttagcag agtcccaggc agatagtcct ggggtgcccg gagagccttg 780
cgcccagtcg ctcgacggg gcgctgoggc tagcggccct ggcgaagatg ggtcccttct 840
tggcagcagt gaaattttgg aggtcaaagt ggctgagggc gtccccgagc ccaatccgga 900
gttgagcttc atctgogcgg actgoggggt gagcttcccg cagctgtctc gcctgaaggc 960
gcaccagctg cgctcgacc cggctggggc ctcttctctg tgcctttgct gcgggaagag 1020
cttcggccgc agctccattc tcaagctgca catgcgcact cacacggagc agcggccgca 1080
cgcttgccac ctgtgccc accgcttccg ccagagctcg cacctgagca agcacctgct 1140
gaccactcc tccgaaccgc ccttctctgt cgcagagtgc ggcgcccgtt tccagcgcgc 1200
cgccagcctt gtgcagacc tgetggcgca cgcccaggac cagaagccgc cctgcgctcc 1260
tgagagtaag gccgaagcgc cgccactgac cgatgtcctg tgetcccact gcggccagag 1320
cttcagcgc cgctccagcc tcaagcgcca cctgcggatc cagcccaggc acaaggaccg 1380
ccggtctctc gaaggtctcg gcagccgccc cggggactcc gaccggaggc ccttcgtgtg 1440
cagcgactgc ggcaaggcct tccggcgagc cgagcacctg gtggcccacc ggagggtgca 1500
cacgggagcag cggcccttct cctgccaggc ttgcccgcgc agcttcacgc agagctcgca 1560
gtggtcagc caccaacggg tgcaacggg cgagaagccc tacgctctgc cgcagtgccg 1620
gaagcgttt gtgcccggg ccagccttgc cggccacctg ctgaccacgc gtggccctcg 1680
gcccaccac tgcaccagc gcgggaagag ttctggccag acccaggatc tggcccacca 1740
ccagcgcagc cacacgggag agaagccctg ccgctgcagc gagtgcgggt agggcttcag 1800
ccagagcgc cacctggcgc gccaccagc catccacaca ggggagaagc cccacgcctg 1860
cgacacctgc ggccaccgtt tccgcaatag ctccaacctg gcccgccatc gccgagcca 1920
cacgggagc cggccctaca gctgtcagac gtgcggctgc agcttccggc gcaacgcgca 1980
tctgcccggc cacctggcta cccatgcgga gcccccggc gagcaggccg agccccgca 2040
ggagtgcgtg gagtgcggga agagcttcag ccgagctgc aatctgtgc gacacctgct 2100
ggtgcacagc ggcgccaggc cctactctg cacgcagtgt ggcgcagct tcagccgcaa 2160
ctcccacctg ctgcccacc tgcgaccca cgcccgcgag acgctgtact agggcctcat 2220
ggcccagct ttctgtac 2239

```

```

<210> SEQ ID NO 3
<211> LENGTH: 2178
<212> TYPE: DNA
<213> ORGANISM: human

```

```

<400> SEQUENCE: 3

```

```

atggggccac gggcgtccct gagcccgtc cgggagctct gcggccactg gctgcggccg 60
gctctgcaca ccaagaaca gatcctggag ctgctggtgc tggagcagtt cctgagtgtg 120
ctgcctccgc acctcctggg ccgctgcag gggcagccgc tcagggatgg ggaggaggtg 180
gtgctgtgc tcgaggcat ccaccgggag cccagccacg cggggcccgt ggattttagt 240
tgtaatgctg gcaagagttg tcccctgca gacgtcacct tggaggaaaa ggggtgtgct 300
tcccaggtcc ccagccacag ccccaagaag gaattgectg cgggaagacc ttcagtgtctg 360
ggcccatcgg atgagcctcc ccgaccacc ccaagggctg cccagcctgc tgagccggga 420
cagtgagggc tcccccaag ttcaaagcag ccgctgagcc cggggcccca gaagacattc 480

```


-continued

```

caggccctgc aagaaagcag tcccagggc ccctcaccat ggccagagga gagttcccga 540
gatcaggagc tggcggetgt gctggagtgc ctgacctttg aggatgtgcc agagaataag 600
gcgtggcctg cacaccccct gggattcgga agcagaaccc cagacaagga ggaatttaaa 660
caagaagagc ccaaaggggc tgctggccc actcccatct tagcagagtc ccaggcagat 720
agtctggggg tgccgggaga gccttgcgcc cagtgcctcg gacggggcgc tgcggctagc 780
ggccctggcg aagatgggtc ccttcttgcc agcagtgaaa ttttgaggt caaagtggct 840
gagggcgtec ccgagcccaa tccggagttg cagttcatct gcgaggactg cggggtgagc 900
ttcccgcage tgtctgcct gaaggcgcc cagctgcgct cgcacccggc tgggcgctcc 960
ttctgtgcc tttgtgcgg gaagagcttc ggccgcagct ccattctcaa gctgcacatg 1020
cgcaactaca cggacgagcg gccgcagcc tgcacctgt gcggccaccg cttccgccag 1080
agctcgcaac tgagcaagca cctgtgacc cactcctccg aaccgcctt cctgtgcgca 1140
gagtgcggcc gcgcttcca gcgccgcgc agccttgtgc agcacctget ggcgcagcc 1200
caggaccaga agcccctcg cgtcctgag agtaaggccg aagcgcgcc actgaccgat 1260
gtcctgtgct cccactgcgg ccagagcttc cagcgcgct ccagcctcaa gcgccacctg 1320
cggatccacg ccagggacaa ggaccgccg tcctccgaag gctccggcag ccgccgccg 1380
gactccgacc ggaggccctt cgtgtgcagc gactgcggca aggccttccg gcgcagcgag 1440
cacctggtgg cccaccggag ggtgcacacg ggcgagcggc ccttctcctg ccaggcttgc 1500
ggccgcagct tcacgcagag ctgcagctg gtcagccacc aacgggtgca cacggggcag 1560
aagccctacg cctgtccgca gtgcgggaag cgctttgtgc gccgggccag ccttgcccgc 1620
cacctgctga cccacgggtg ccctcgccc caccactgca cccagtgcgg gaagagttc 1680
ggccagacc aggatctggc ccgccaccag cgcagccaca cgggcgagaa gcctgcccgc 1740
tgcagcgagt gcggtgaggg cttcagccag agcgcgccacc tggcgcgcca ccagcgcac 1800
cacacagggg agaagcccca cgctgcgac acctgcggcc accgtttccg caatagetcc 1860
aacctggccc gccatgcggc cagccacacg ggcgagcggc cctacagctg tcagacgtgc 1920
ggtcgcagct tccggcgcaa cgcgcactg cggcggcacc tggctaccca tgcggagccc 1980
gggcaggagc aggcagacc cccgaggag tgcgtggagt gcgggaagag cttcagccc 2040
agctgcaatc tgctgcgaca cctgtggtg cacacgggcg ccaggcccta ctctgcacg 2100
cagtgtggcc gcagctttag ccgcaactcc cacctgctgc gccactgcg caccacgcc 2160
cgcgagacgc tgtactag 2178

```

```

<210> SEQ ID NO 4
<211> LENGTH: 725
<212> TYPE: PRT
<213> ORGANISM: human

```

```

<400> SEQUENCE: 4

```

```

Met Gly Pro Arg Ala Ser Leu Ser Arg Leu Arg Glu Leu Cys Gly His
1           5           10           15

```

```

Trp Leu Arg Pro Ala Leu His Thr Lys Lys Gln Ile Leu Glu Leu Leu
20           25           30

```

```

Val Leu Glu Gln Phe Leu Ser Val Leu Pro Pro His Leu Leu Gly Arg
35           40           45

```

```

Leu Gln Gly Gln Pro Leu Arg Asp Gly Glu Glu Val Val Leu Leu Leu

```

-continued

50						55										60
Glu	Gly	Ile	His	Arg	Glu	Pro	Ser	His	Ala	Gly	Pro	Leu	Asp	Phe	Ser	
65					70					75					80	
Cys	Asn	Ala	Gly	Lys	Ser	Cys	Pro	Arg	Ala	Asp	Val	Thr	Leu	Glu	Glu	
				85					90					95		
Lys	Gly	Cys	Ala	Ser	Gln	Val	Pro	Ser	His	Ser	Pro	Lys	Lys	Glu	Leu	
			100					105					110			
Pro	Ala	Glu	Glu	Pro	Ser	Val	Leu	Gly	Pro	Ser	Asp	Glu	Pro	Pro	Arg	
		115					120					125				
Pro	Gln	Pro	Arg	Ala	Ala	Gln	Pro	Ala	Glu	Pro	Gly	Gln	Trp	Arg	Leu	
	130					135					140					
Pro	Pro	Ser	Ser	Lys	Gln	Pro	Leu	Ser	Pro	Gly	Pro	Gln	Lys	Thr	Phe	
145				150						155					160	
Gln	Ala	Leu	Gln	Glu	Ser	Ser	Pro	Gln	Gly	Pro	Ser	Pro	Trp	Pro	Glu	
			165						170						175	
Glu	Ser	Ser	Arg	Asp	Gln	Glu	Leu	Ala	Ala	Val	Leu	Glu	Cys	Leu	Thr	
			180					185					190			
Phe	Glu	Asp	Val	Pro	Glu	Asn	Lys	Ala	Trp	Pro	Ala	His	Pro	Leu	Gly	
	195						200					205				
Phe	Gly	Ser	Arg	Thr	Pro	Asp	Lys	Glu	Glu	Phe	Lys	Gln	Glu	Glu	Pro	
	210					215					220					
Lys	Gly	Ala	Ala	Trp	Pro	Thr	Pro	Ile	Leu	Ala	Glu	Ser	Gln	Ala	Asp	
225					230					235					240	
Ser	Pro	Gly	Val	Pro	Gly	Glu	Pro	Cys	Ala	Gln	Ser	Leu	Gly	Arg	Gly	
			245						250					255		
Ala	Ala	Ala	Ser	Gly	Pro	Gly	Glu	Asp	Gly	Ser	Leu	Leu	Gly	Ser	Ser	
			260					265					270			
Glu	Ile	Leu	Glu	Val	Lys	Val	Ala	Glu	Gly	Val	Pro	Glu	Pro	Asn	Pro	
	275						280					285				
Glu	Leu	Gln	Phe	Ile	Cys	Ala	Asp	Cys	Gly	Val	Ser	Phe	Pro	Gln	Leu	
	290					295					300					
Ser	Arg	Leu	Lys	Ala	His	Gln	Leu	Arg	Ser	His	Pro	Ala	Gly	Arg	Ser	
305				310						315					320	
Phe	Leu	Cys	Leu	Cys	Cys	Gly	Lys	Ser	Phe	Gly	Arg	Ser	Ser	Ile	Leu	
			325						330					335		
Lys	Leu	His	Met	Arg	Thr	His	Thr	Asp	Glu	Arg	Pro	His	Ala	Cys	His	
			340					345					350			
Leu	Cys	Gly	His	Arg	Phe	Arg	Gln	Ser	Ser	His	Leu	Ser	Lys	His	Leu	
		355					360					365				
Leu	Thr	His	Ser	Ser	Glu	Pro	Ala	Phe	Leu	Cys	Ala	Glu	Cys	Gly	Arg	
	370					375					380					
Gly	Phe	Gln	Arg	Arg	Ala	Ser	Leu	Val	Gln	His	Leu	Leu	Ala	His	Ala	
385					390					395					400	
Gln	Asp	Gln	Lys	Pro	Pro	Cys	Ala	Pro	Glu	Ser	Lys	Ala	Glu	Ala	Pro	
			405						410					415		
Pro	Leu	Thr	Asp	Val	Leu	Cys	Ser	His	Cys	Gly	Gln	Ser	Phe	Gln	Arg	
			420					425					430			
Arg	Ser	Ser	Leu	Lys	Arg	His	Leu	Arg	Ile	His	Ala	Arg	Asp	Lys	Asp	
		435					440						445			
Arg	Arg	Ser	Ser	Glu	Gly	Ser	Gly	Ser	Arg	Arg	Arg	Asp	Ser	Asp	Arg	
	450					455					460					

-continued

Arg Pro Phe Val Cys Ser Asp Cys Gly Lys Ala Phe Arg Arg Ser Glu
 465 470 475 480
 His Leu Val Ala His Arg Arg Val His Thr Gly Glu Arg Pro Phe Ser
 485 490 495
 Cys Gln Ala Cys Gly Arg Ser Phe Thr Gln Ser Ser Gln Leu Val Ser
 500 505 510
 His Gln Arg Val His Thr Gly Glu Lys Pro Tyr Ala Cys Pro Gln Cys
 515 520 525
 Gly Lys Arg Phe Val Arg Arg Ala Ser Leu Ala Arg His Leu Leu Thr
 530 535 540
 His Gly Gly Pro Arg Pro His His Cys Thr Gln Cys Gly Lys Ser Phe
 545 550 555 560
 Gly Gln Thr Gln Asp Leu Ala Arg His Gln Arg Ser His Thr Gly Glu
 565 570 575
 Lys Pro Cys Arg Cys Ser Glu Cys Gly Glu Gly Phe Ser Gln Ser Ala
 580 585 590
 His Leu Ala Arg His Gln Arg Ile His Thr Gly Glu Lys Pro His Ala
 595 600 605
 Cys Asp Thr Cys Gly His Arg Phe Arg Asn Ser Ser Asn Leu Ala Arg
 610 615 620
 His Arg Arg Ser His Thr Gly Glu Arg Pro Tyr Ser Cys Gln Thr Cys
 625 630 635 640
 Gly Arg Ser Phe Arg Arg Asn Ala His Leu Arg Arg His Leu Ala Thr
 645 650 655
 His Ala Glu Pro Gly Gln Glu Gln Ala Glu Pro Pro Gln Glu Cys Val
 660 665 670
 Glu Cys Gly Lys Ser Phe Ser Arg Ser Cys Asn Leu Leu Arg His Leu
 675 680 685
 Leu Val His Thr Gly Ala Arg Pro Tyr Ser Cys Thr Gln Cys Gly Arg
 690 695 700
 Ser Phe Ser Arg Asn Ser His Leu Leu Arg His Leu Arg Thr His Ala
 705 710 715 720
 Arg Glu Thr Leu Tyr
 725

<210> SEQ ID NO 5
 <211> LENGTH: 782
 <212> TYPE: PRT
 <213> ORGANISM: mouse

<400> SEQUENCE: 5

Met Leu Ala Glu Pro Val Pro Asp Ala Leu Glu Gln Glu His Pro Gly
 1 5 10 15
 Ala Val Lys Leu Glu Glu Asp Glu Val Gly Glu Glu Asp Pro Arg Leu
 20 25 30
 Ala Glu Ser Arg Pro Arg Pro Glu Val Ala His Gln Leu Phe Arg Cys
 35 40 45
 Phe Gln Tyr Gln Glu Asp Met Gly Pro Arg Ala Ser Leu Gly Arg Leu
 50 55 60
 Arg Glu Leu Cys Asn His Trp Leu Arg Pro Ala Leu His Thr Lys Lys
 65 70 75 80
 Gln Ile Leu Glu Leu Leu Val Leu Glu Gln Phe Leu Ser Val Leu Pro

-continued

85					90					95					
Pro	His	Val	Leu	Ser	Arg	Leu	His	Gly	Gln	Pro	Leu	Arg	Asp	Gly	Glu
			100					105					110		
Glu	Val	Val	Gln	Leu	Leu	Glu	Gly	Val	Pro	Arg	Asp	Ile	Ser	His	Met
		115					120					125			
Gly	Pro	Leu	Asp	Phe	Ser	Phe	Ser	Ala	Gly	Lys	Asn	Ala	Pro	Ala	Asp
		130				135					140				
Ile	Ile	Ser	Glu	Glu	Gln	Asn	Ser	Pro	Ser	Gln	Val	Pro	Ser	His	Ser
145					150					155					160
Pro	Gln	Thr	Glu	Leu	Pro	Ser	Glu	Glu	Ile	Pro	Ala	Leu	His	Pro	Leu
			165						170					175	
Asn	Glu	Leu	Pro	Pro	Pro	Gln	Pro	Ala	Pro	Ile	Arg	Pro	Ala	Glu	Pro
			180					185					190		
Glu	Glu	Trp	Arg	Leu	Ala	Pro	Ser	Ser	Asn	Trp	Pro	Met	Ser	Pro	Glu
		195				200						205			
Pro	Gln	Glu	Ile	Leu	Gln	Asp	Pro	Arg	Glu	Ser	Asn	Pro	Ser	Gln	Gly
		210				215					220				
Pro	Ser	Trp	Leu	Glu	Glu	Asn	Ser	Arg	Asp	Gln	Glu	Leu	Ala	Ala	Val
225					230					235					240
Leu	Glu	Ser	Leu	Thr	Phe	Glu	Asp	Thr	Ser	Glu	Lys	Arg	Ala	Trp	Pro
				245					250						255
Ala	Asn	Pro	Leu	Gly	Phe	Gly	Ser	Arg	Met	Pro	Asp	Asn	Glu	Glu	Leu
			260					265					270		
Lys	Val	Glu	Glu	Pro	Lys	Val	Thr	Thr	Trp	Pro	Val	Val	Ile	Gly	Ala
		275					280						285		
Glu	Ser	Gln	Thr	Glu	Lys	Pro	Glu	Val	Ala	Gly	Glu	Pro	Leu	Thr	Gln
		290				295						300			
Thr	Val	Gly	Gln	Glu	Thr	Ser	Ser	Thr	Gly	Trp	Gly	Gly	Thr	Pro	Ala
305					310					315					320
Asp	Gly	Ser	Glu	Val	Val	Lys	Val	Arg	Gly	Ala	Ser	Asp	Ala	Pro	Glu
			325						330					335	
Pro	Gln	Gly	Glu	Met	Gln	Phe	Ile	Cys	Thr	Tyr	Cys	Gly	Val	Asn	Phe
			340					345					350		
Pro	Glu	Met	Ser	His	Leu	Gln	Ala	His	Gln	Leu	Gln	Ser	His	Pro	Asn
		355					360					365			
Leu	Gln	Pro	His	Pro	Ser	Ser	Arg	Ser	Phe	Arg	Cys	Leu	Trp	Cys	Gly
		370				375					380				
Lys	Thr	Phe	Gly	Arg	Ser	Ser	Ile	Leu	Lys	Leu	His	Met	Arg	Thr	His
385					390					395					400
Thr	Asp	Glu	Arg	Pro	His	Ala	Cys	His	Leu	Cys	Asn	Arg	Arg	Phe	Arg
				405					410					415	
Gln	Ser	Ser	His	Leu	Thr	Lys	His	Leu	Leu	Thr	His	Ser	Ser	Glu	Pro
			420					425						430	
Ala	Phe	Arg	Cys	Ala	Glu	Cys	Asn	Gln	Gly	Phe	Gln	Arg	Arg	Ser	Ser
		435					440					445			
Leu	Met	Gln	His	Leu	Leu	Ala	His	Ala	Gln	Gly	Lys	Asn	Leu	Thr	Pro
		450				455						460			
Asn	Pro	Glu	Gly	Lys	Thr	Lys	Val	Pro	Glu	Met	Ala	Ala	Val	Leu	Cys
465					470					475					480
Ser	His	Cys	Gly	Gln	Thr	Phe	Lys	Arg	Arg	Ser	Ser	Leu	Lys	Arg	His
			485						490					495	

-continued

Leu Arg Asn His Ala Lys Asp Lys Asp His Leu Ser Ser Glu Asp Pro
 500 505 510

Gly Ser Leu Ser Ser Ser Gln Glu Ser Asn Pro Tyr Val Cys Ser Asp
 515 520 525

Cys Gly Lys Ala Phe Arg Gln Ser Glu Gln Leu Met Ile His Thr Arg
 530 535 540

Arg Val His Thr Arg Glu Arg Pro Phe Ser Cys Gln Val Cys Gly Arg
 545 550 555 560

Cys Phe Thr Gln Asn Ser Gln Leu Ile Ser His Gln Gln Ile His Thr
 565 570 575

Gly Glu Lys Pro His Ala Cys Pro Gln Cys Ser Lys Arg Phe Val Arg
 580 585 590

Arg Ala Gly Leu Ala Arg His Leu Leu Thr His Gly Ser Leu Arg Pro
 595 600 605

Tyr His Cys Ala Gln Cys Gly Lys Ser Phe Arg Gln Met Arg Asp Leu
 610 615 620

Thr Arg His Val Arg Cys His Thr Gly Glu Lys Pro Cys Arg Cys Asn
 625 630 635 640

Glu Cys Gly Glu Gly Phe Thr Gln Asn Ala His Leu Ala Arg His Gln
 645 650 655

Arg Ile His Thr Gly Glu Lys Pro His Ala Cys Asp Ile Cys Gly His
 660 665 670

Arg Phe Arg Asn Ser Ser Asn Leu Ala Arg His Arg Arg Ser His Thr
 675 680 685

Gly Glu Arg Pro Tyr Ser Cys Pro Thr Cys Gly Arg Ser Phe Arg Arg
 690 695 700

Asn Ala His Leu Gln Arg His Leu Ile Thr His Thr Gly Ser Lys Gln
 705 710 715 720

Glu Lys Glu Val Pro Gln Glu Cys Pro Glu Cys Gly Lys Ser Phe Asn
 725 730 735

Arg Ser Cys Asn Leu Leu Arg His Leu Leu Val His Thr Gly Ala Arg
 740 745 750

Pro Tyr Ser Cys Ala Leu Cys Gly Arg Ser Phe Ser Arg Asn Ser His
 755 760 765

Leu Leu Arg His Leu Arg Thr His Ala Arg Glu Ser Leu Tyr
 770 775 780

<210> SEQ ID NO 6
 <211> LENGTH: 2410
 <212> TYPE: DNA
 <213> ORGANISM: mouse

<400> SEQUENCE: 6

```

gtacaaaaaa gcagaagggc cgtaaggcc caccatgctg gcggaaccag tcctgatgc      60
cctggaacaa gagcatcccg gagcagttaa gttggaggag gatgaagtgg gcgaggagga    120
tcccaggctc gcagagtcca ggccataggcc tgagggtggcc caccagcttt tcagatgctt    180
ccagtatcag gaagatatgg ggccacgggc atccctgggc cggtcccggg aactctgcaa    240
ccactggctg cgaccggctc tgcacaccaa gaagcagatc ctggagctgc tggactactgga    300
gcagttcctg agtgtcctgc ccccgcattg gctgagccgg ctgcacggcc aaccgctccg    360
ggacggagag gaggtggtac agctattgga gggcgtgccc agagacatca gccacatggg    420
    
```

-continued

```

gccactggat tttagcttca gtgctggcaa gaatgccct gcagacatca tctcagagga 480
acaaaatagc ccttcccagg tcccagcca cagccccag acggagtgc cctcagaaga 540
gattccagcc ctacatccac tgaatgagtt acctccacct cagccagcac ccataaggcc 600
tgctgagcct gaggagtgga gactggcccc cagttcaaat tggccaatga gcccagagcc 660
ccaggagata ctccaggacc cagagaaaag caacccttc cagggccctt catggcttga 720
ggaaaattcc agagaccaag agctggcggc tgtgttgag tccctcacct ttgaggatac 780
ctcagagaag agagcttggc ctgcaaacc tcttgattt ggaagcagaa tgctgacaa 840
tgaggaactt aaagtgaag agcctaagt gactacttg cctgtcgtca ttggagcaga 900
gtcccagaca gagaacctg aagttgcagg agagcctctt acgcaaactg tagggcagga 960
gaccagcagc actggttggg gaggtactcc tgetgacggc agtgaagtg tgaaggttag 1020
aggagcttcc gatgccccag agccccagg ggagatgcag ttcatatgta catattgtgg 1080
ggtaaacttc ccagagatgt ctcatctaca ggcccaccag ttacaatctc accccaactt 1140
gcaacctcac ccaagctctc gatccttccg atgtctgtgg tgtgggaaga cttttggacg 1200
cagctcgatc ctcaagctgc acatgcgcac tcacacagac gagcggccgc acgcctgtca 1260
tctctgcaac cgccgcttcc gccagagctc acacctgacg aagcacttgc taacgcattc 1320
ctctgagcct gccttccgat gcgccgagtg taaccagggt tttcagcgtc gctccagcct 1380
catgcagcac ctgtctggcc atgcccagg aaagaatctc acgccaatc cagaaggcaa 1440
gacaaaagtg ccagagatgg cagctgtcct ctgttcccac tgcgggcaga cttcgaagcg 1500
gcgctctagc ttaaagcgtc acctgcgtaa ccatgccaa gacaaggacc atctgtctc 1560
tgaagaccct ggcagcctta gctctagcca ggagagtaac cctatgtgt gtagtgactg 1620
tggaaggcc ttccgacaaa gcgagcaact aatgatccac actaggcgag tccatacccg 1680
tgaacgaccc ttctctgccc aggtctgtgg ccgctgcttt acccaaat cccagctgat 1740
cagccaccag cagattcata cgggtgagaa gcctcacgcc tgtcctcagt gcagcaaacg 1800
ctttgtgaga cgagctggcc ttgctcggca tctgttgacc cacggtagcc tccggcctta 1860
ccactgtgcc caatgtggca aaagctttcg ccaaatgcga gacctaaccc gccacgtacg 1920
ctgccacacg ggggagaagc cctgccgatg caacgaatgt ggagaggggt tcaccagaa 1980
tgcccacctg gcacgccacc aacgcattca cacgggggag aagccccacg cctgtgacat 2040
ctgtggteac cgctttcgta acagctccaa cttggcccgc caccgccga gccacactgg 2100
cgaacggccc tatagctgtc caacctgtgg ccgcagtctt cggcgcaatg cgcacctgca 2160
gcgccacctg atcacacaca cagggtcaaa gcaagaaaag gaagtctctc aggagtgcc 2220
tgagtgtggc aagagcttca atgcagctg caacttctg cgccacctgc tggttcacac 2280
cgggtcaagg ccttactcct gtgcactgtg tggccgcagc ttcagccgta attcacacct 2340
gctgcgccac ctgcgaacct atgcccggga atcgctgtac tagggcctca tgggccccagc 2400
tttctgtac 2410

```

```

<210> SEQ ID NO 7
<211> LENGTH: 2349
<212> TYPE: DNA
<213> ORGANISM: mouse

<400> SEQUENCE: 7

```

-continued

atgctggcgg aaccagtccc tgatgccctg gaacaagagc atccccggagc agtgaagttg	60
gaggaggatg aagttggcga ggaggatccc aggctcgagc agtccaggcc taggcctgag	120
gtggcccacc agcttttcag atgcttcocag taccaggaag atattggggcc acgggcatcc	180
ctgggcccgc tccgggaact ctgcaaccac tggctgcgac cggctctgca caccaagaag	240
cagatcctgg agctgctggt actggagcag ttctctgagtg tcttgcctcc gcattgtgctg	300
agccggctgc acggccaacc gctccgggac ggagaggagg tggtagacgt attggagggc	360
gtgcccagag acatcagcca catggggcca ctggatttta gcttcagtgc tggcaagaat	420
gccccctgag acatcatctc agaggaacaa aatagcctt cccaggctcc cagccacagc	480
ccccagacgg agttgccctc agaagagatt ccagccctac atccactgaa tgagttacct	540
ccacctcagc cagcaccat aaggcctgct gagcctgagg agtggagact ggccccagt	600
tcaaattggc caatgagccc agagccccag gagatactcc aggaccacg agaaagcaac	660
ccttcccagg gcccttcatg gcttgaggaa aattccagag accaagagct ggccgctgtg	720
ttggagtccc tcaccttga ggatacctca gagaagagag cttggcctgc aaaccctctt	780
ggatttggaa gcagaatgcc tgacaatgag gaacttaaag ttgaagagcc taaagtgact	840
acttggcctg tcgtcattgg agcagagtcc cagacagaga aacctgaagt tgcaggagag	900
cctcttacgc aaactgtagg gcaggagacc agcagcactg gttggggagg tactcctgct	960
gacggcagtg aagttgtgaa ggttagagga gcttccgatg cccagagacc ccagggggag	1020
atgcagttca tatgtacata ttgtggggta aacttcccag agatgtctca tctacaggcc	1080
caccagttac aatctcacc caactgcaa cctcaccctc gctctcgatc cttccgatgt	1140
ctgtggtgtg ggaagacttt tggacgcagc tcgatcctca agctgcacat gcgcactcac	1200
acagacgagc gcccgcagc ctgtcatctc tgcaaccgcc gcttcgcca gagtcacac	1260
ctgacgaagc acttctaac gcattcctct gagcctgcct tccgatgcgc cgagtgtaac	1320
cagggttttc agcgtcgctc cagcctcatg cagcacctgc tggcacatgc ccagggaag	1380
aatctcacgc caaatccaga aggcaagaca aaagtgccag agatggcagc tgtcctctgt	1440
tcccactgag ggcagacctt caagcggcgc tctagcttaa agcgtcacct gcgtaacct	1500
gccaaggaca aggacctct gtctctgaa gacctggca gccttagctc tagccaggag	1560
agtaaccctt atgtgtgtag tgactgtggc aaggccttcc gacaaagcga gcaactaatg	1620
atccacacta ggcagtgcca taccctgaa cgacccttct cctgccaggt ctgtggccgc	1680
tgctttacc aaaattccca gctgatcagc caccagcaga ttcatcggg tgagaagcct	1740
cacgcctgct ctcagtgcag caaacgcttt gtgagacgag ctggccttgc tcggcatctg	1800
ttgacccaag gtgacctcag gccttaccac tgtgccaat gtggcaaaa ctttcgcca	1860
atgcgagacc taaccgccca cgtacgctgc cacacggggg agaagccctg ccgatgcaac	1920
gaatgtggag aggggttacc ccagaatgcc cacctggcac gccaccaacg catccacagc	1980
ggggagaagc cccacgcctg tgacatctgt ggteaccgct ttcgtaaacg ctccaacttg	2040
gccccccacc gcgcagcca cactggcgaa cggccctata gctgtccaac ctgtggccgc	2100
agtttccggc gcaatgcgca cctgcagcgc cacctgatca cacacacagg gtcaaagcaa	2160
gaaaaggaag ttctcagga gtgccctgag tgtggcaaga gcttcaatgc cagctgcaac	2220
ttgctgcgcc acctgctggt tcacaccggt gcaaggcctt actcctgtgc actgtgtggc	2280

-continued

cgcagcttca gccgaattc acacctgctg cgccacctgc gaaccatgc cegggaatcg 2340
 ctgtactag 2349

<210> SEQ ID NO 8
 <211> LENGTH: 782
 <212> TYPE: PRT
 <213> ORGANISM: mouse

<400> SEQUENCE: 8

Met Leu Ala Glu Pro Val Pro Asp Ala Leu Glu Gln Glu His Pro Gly
 1 5 10 15
 Ala Val Lys Leu Glu Glu Asp Glu Val Gly Glu Glu Asp Pro Arg Leu
 20 25 30
 Ala Glu Ser Arg Pro Arg Pro Glu Val Ala His Gln Leu Phe Arg Cys
 35 40 45
 Phe Gln Tyr Gln Glu Asp Met Gly Pro Arg Ala Ser Leu Gly Arg Leu
 50 55 60
 Arg Glu Leu Cys Asn His Trp Leu Arg Pro Ala Leu His Thr Lys Lys
 65 70 75 80
 Gln Ile Leu Glu Leu Leu Val Leu Glu Gln Phe Leu Ser Val Leu Pro
 85 90 95
 Pro His Val Leu Ser Arg Leu His Gly Gln Pro Leu Arg Asp Gly Glu
 100 105 110
 Glu Val Val Gln Leu Leu Glu Gly Val Pro Arg Asp Ile Ser His Met
 115 120 125
 Gly Pro Leu Asp Phe Ser Phe Ser Ala Gly Lys Asn Ala Pro Ala Asp
 130 135 140
 Ile Ile Ser Glu Glu Gln Asn Ser Pro Ser Gln Val Pro Ser His Ser
 145 150 155 160
 Pro Gln Thr Glu Leu Pro Ser Glu Glu Ile Pro Ala Leu His Pro Leu
 165 170 175
 Asn Glu Leu Pro Pro Pro Gln Pro Ala Pro Ile Arg Pro Ala Glu Pro
 180 185 190
 Glu Glu Trp Arg Leu Ala Pro Ser Ser Asn Trp Pro Met Ser Pro Glu
 195 200 205
 Pro Gln Glu Ile Leu Gln Asp Pro Arg Glu Ser Asn Pro Ser Gln Gly
 210 215 220
 Pro Ser Trp Leu Glu Glu Asn Ser Arg Asp Gln Glu Leu Ala Ala Val
 225 230 235 240
 Leu Glu Ser Leu Thr Phe Glu Asp Thr Ser Glu Lys Arg Ala Trp Pro
 245 250 255
 Ala Asn Pro Leu Gly Phe Gly Ser Arg Met Pro Asp Asn Glu Glu Leu
 260 265 270
 Lys Val Glu Glu Pro Lys Val Thr Thr Trp Pro Val Val Ile Gly Ala
 275 280 285
 Glu Ser Gln Thr Glu Lys Pro Glu Val Ala Gly Glu Pro Leu Thr Gln
 290 295 300
 Thr Val Gly Gln Glu Thr Ser Ser Thr Gly Trp Gly Gly Thr Pro Ala
 305 310 315 320
 Asp Gly Ser Glu Val Val Lys Val Arg Gly Ala Ser Asp Ala Pro Glu
 325 330 335

-continued

Pro Gln Gly Glu Met Gln Phe Ile Cys Thr Tyr Cys Gly Val Asn Phe
 340 345 350

Pro Glu Met Ser His Leu Gln Ala His Gln Leu Gln Ser His Pro Asn
 355 360 365

Leu Gln Pro His Pro Ser Ser Arg Ser Phe Arg Cys Leu Trp Cys Gly
 370 375 380

Lys Thr Phe Gly Arg Ser Ser Ile Leu Lys Leu His Met Arg Thr His
 385 390 395 400

Thr Asp Glu Arg Pro His Ala Cys His Leu Cys Asn Arg Arg Phe Arg
 405 410 415

Gln Ser Ser His Leu Thr Lys His Leu Leu Thr His Ser Ser Glu Pro
 420 425 430

Ala Phe Arg Cys Ala Glu Cys Asn Gln Gly Phe Gln Arg Arg Ser Ser
 435 440 445

Leu Met Gln His Leu Leu Ala His Ala Gln Gly Lys Asn Leu Thr Pro
 450 455 460

Asn Pro Glu Gly Lys Thr Lys Val Pro Glu Met Ala Ala Val Leu Cys
 465 470 475 480

Ser His Cys Gly Gln Thr Phe Lys Arg Arg Ser Ser Leu Lys Arg His
 485 490 495

Leu Arg Asn His Ala Lys Asp Lys Asp His Leu Ser Ser Glu Asp Pro
 500 505 510

Gly Ser Leu Ser Ser Ser Gln Glu Ser Asn Pro Tyr Val Cys Ser Asp
 515 520 525

Cys Gly Lys Ala Phe Arg Gln Ser Glu Gln Leu Met Ile His Thr Arg
 530 535 540

Arg Val His Thr Arg Glu Arg Pro Phe Ser Cys Gln Val Cys Gly Arg
 545 550 555 560

Cys Phe Thr Gln Asn Ser Gln Leu Ile Ser His Gln Gln Ile His Thr
 565 570 575

Gly Glu Lys Pro His Ala Cys Pro Gln Cys Ser Lys Arg Phe Val Arg
 580 585 590

Arg Ala Gly Leu Ala Arg His Leu Leu Thr His Gly Ser Leu Arg Pro
 595 600 605

Tyr His Cys Ala Gln Cys Gly Lys Ser Phe Arg Gln Met Arg Asp Leu
 610 615 620

Thr Arg His Val Arg Cys His Thr Gly Glu Lys Pro Cys Arg Cys Asn
 625 630 635 640

Glu Cys Gly Glu Gly Phe Thr Gln Asn Ala His Leu Ala Arg His Gln
 645 650 655

Arg Ile His Thr Gly Glu Lys Pro His Ala Cys Asp Ile Cys Gly His
 660 665 670

Arg Phe Arg Asn Ser Ser Asn Leu Ala Arg His Arg Arg Ser His Thr
 675 680 685

Gly Glu Arg Pro Tyr Ser Cys Pro Thr Cys Gly Arg Ser Phe Arg Arg
 690 695 700

Asn Ala His Leu Gln Arg His Leu Ile Thr His Thr Gly Ser Lys Gln
 705 710 715 720

Glu Lys Glu Val Pro Gln Glu Cys Pro Glu Cys Gly Lys Ser Phe Asn
 725 730 735

Arg Ser Cys Asn Leu Leu Arg His Leu Leu Val His Thr Gly Ala Arg

-continued

	740		745		750										
Pro	Tyr	Ser	Cys	Ala	Leu	Cys	Gly	Arg	Ser	Phe	Ser	Arg	Asn	Ser	His
			755				760					765			
Leu	Leu	Arg	His	Leu	Arg	Thr	His	Ala	Arg	Glu	Ser	Leu	Tyr		
	770					775						780			

<210> SEQ ID NO 9
 <211> LENGTH: 1105
 <212> TYPE: DNA
 <213> ORGANISM: human

<400> SEQUENCE: 9

```

ctgtttcaaa cagcacttac aggtggggac ctgtttttgc taagtcatcc tggggatgct    60
caaagctcca ttgtagatc ctttctgtcc tccttctctg etctctcttc ctccccaccc   120
ctctaataag ctcataaagt ggctcaggcc tctctgctgg gctcactctg cgcttcacca   180
tggctttcat tgccaagtc ttctatgacc tcagtgccat cagcctggat ggggagaagg   240
tagatttcaa tacgttccgg ggcaggcccg tgctgattga gaatgtggct tcgctctgag   300
gcacaaccac cggggacttc acccagctca acgagctgca atgccgettt cccaggcgcc   360
tggtggtcct tggcttccct tgcaaccaat ttggacatca ggagaactgt cagaatgagg   420
agatcctgaa cagtctcaag tatgtccgtc ctgggggtgg ataccagccc accttcaccc   480
ttgtccaaaa atgtgagggt aatgggcaga acgagcatcc tgtcttcgcc tacttgaagg   540
acaagctccc ctacccttat gatgacctat tttccctcat gaccgatccc aagctcatca   600
tttgagcccc tgtgcgccgc tcagatgtgg cctggaactt tgagaagtcc ctcatagggc   660
cggagggaga gcccttccga cgetacagcc gcaccttccc aaccatcaac attgagcctg   720
acatcaagcg cctccttaaa gttgccatat agatgtgaac tgctcaacac acagatctcc   780
tactccatcc agtctgagg agccttagga tgcagcatgc cttcaggaga cactgctgga   840
cctcagcatt cccttgatat cagtcccctt cactgcagag ccttgccctt ccctctgccc   900
tgtttccttt tcctctccca acctctgggt tggtgattca acttgggctc caagacttgg   960
gtaagctctg ggccctcaca gaatgatggc accttcctaa acctcatgg gtggtgtctg  1020
agaggcgtga agggcctgga gccactctgc tagaagagac caataaaggg caggtgtgga  1080
aacggccaaa aaaaaaaaaa aaaaaa                                     1105
    
```

<210> SEQ ID NO 10
 <211> LENGTH: 1071
 <212> TYPE: DNA
 <213> ORGANISM: human

<400> SEQUENCE: 10

```

getacagcct tgttcaaaaca gttcacaggt gggtagctgt tttttgctaa gtcateccgg    60
gaatgctcaa aggcctcttg tgaagtcctt tcgggtctct cgggetctct ctttcttccc   120
accggtctaa aggacttaag gaggtcaca gagcagggca gggctcactg ctcttcagca   180
tggcttacat tgccaagctg ttctacgata tcagtgccgt tggcctggat ggggagaaga   240
tagacttcaa tacgttcaga ggcagggtg tgctgattga gaatgtggcg tcaactctgag   300
gaacaactac cggggactac aaccagctca atgagctgca atgtcgcttt cccaggcgcc   360
tggtagttct cggcttccct tgcaaccagt tcggacatca ggagaactgt cagaacgagg   420
    
```

-continued

```

agatcctgaa cagcctcaag tatgtccgac ctgggggtgg gtaccagccc accttagtc 480
ttacccaaaa gtgtgacgtc aatgggcaga acgagcatcc tgtctttgcc tactgaaag 540
acaagctgcc ctacccttat gatgacccgt tctccctcat gaccgatccc aagctcatca 600
tatggagtcc cgtgcgccgc tcagacgtgt cctggaactt tgagaagttc ctcatagggc 660
cagaagggga gcccttccgt cgctacagcc gcagcttcca gaccatcaac atcgagcctg 720
acatcaaacg gctcctcaaa gttgccatct agatgagagc tgctcagccc aggaatctcc 780
cactgtttcc cctgagcagt ctccctcagg gctcagtgtc cctcggggag acctggggag 840
accaaggcat tcctgaata tcgtcccctt gccttcccta ccggccattt cctttagctc 900
cctcaaggct cttggggagt ttgctggggg ctctaagtct ggggtaggtt ctgggccttc 960
acagaatgat ggcattctcc taaaccttc tgggagatgt ctgagaagtt gtgaagggtc 1020
cagagccagt ctgctttaga gtccaataaa gtgtaggtgt ggcaatgaaa a 1071

```

```

<210> SEQ ID NO 11
<211> LENGTH: 1491
<212> TYPE: DNA
<213> ORGANISM: human

```

```

<400> SEQUENCE: 11

```

```

atggggacac agaaggctac ccagctctg atatttgcca tcacagttgc tacaatcggc 60
tctttccaat ttggctacaa cactggggtc atcaatgctc ctgagaagat cataaaggaa 120
tttatcaata aaactttgac ggacaaggga aatgcccac cctctgaggt gctgctcacg 180
tctctctggt cctgtctgt ggccatattt tccgtcgggg gtatgatcgg ctccctttcc 240
gtcggactct tcgtcaaccg ctttggcagg cgcaattcaa tgctgattgt caacctgttg 300
gctgtcactg gtggctgctt tatgggactg tgtaaagtag ctaagtcggt tgaatgctg 360
atcctgggtc gcttggttat tggcctcttc tgcggactct gcacaggttt tgtgcccctg 420
tacattggag agatctcacc tactgccctg cgggggtcct ttggcactct caaccagctg 480
ggcatcgttg ttggaattct ggtggcccag atctttggtc tgggaattcat ccttgggtct 540
gaagagctat ggcctgctct actgggtttt accatccttc ctgctatcct acaaagtgca 600
gcccttccat tttgccctga aagtcccaga tttttgctca ttaacagaaa agaagaggag 660
aatgctaagc agatctccca gcggtgtggt ggcacccagg atgtatccca agacatccag 720
gagatgaaag atgagagtgc aaggatgtca caagaaaagc aagtcaccgt gctagagctc 780
tttagagtgt ccagctaccg acagcccacc atcatttcca ttgtgctcca gctctctcag 840
cagctctctg ggateaatgc tgtgttctat tactcaacag gaatcttcaa ggatgcaggt 900
gttcaagagc ccactatgac caccatcggc gcgggtgtgg ttaatactat cttcactgta 960
gtttctctat ttctggtgga aagggcagga agaaggactc tgcataatgat aggccttgga 1020
gggatggctt tttgttccac gctcatgact gtttctttgt tattaagga taactataat 1080
gggatgagct ttgtctgtat tggggctatc ttggtctttg tagccttctt tgaatttgga 1140
ccaggcccga ttccctgggt tattgtggcc gaactcttca gccaggggccc ccgcccagct 1200
gogatggcag tggccggctg ctccaactgg acctccaact tectagtcgg attgctcttc 1260
cctccctctg ctactatatt aggagcctac gtttttatta tcttcaccgg cttcctcatt 1320
accttcttgg cttttacctt ctccaagtc cctgagaccc gtggcaggac ttttgaggat 1380

```

-continued

atcacacggg cctttgaagg gcaggcacac ggtgcagata gatctggaaa ggacggcgtc 1440
 atggagatga acagcatcga gcctgctaag gagaccacca ccaatgtcta a 1491

<210> SEQ ID NO 12
 <211> LENGTH: 1482
 <212> TYPE: DNA
 <213> ORGANISM: mouse

<400> SEQUENCE: 12

atggggacaa cgaaggtagc cccatctctg gtgttcgccc tgactgttc cagcagcggc 60
 tctttccagt ttggctacaa cactggagtc atcaatgcac ctgagacaat cctaaaggac 120
 tttcttaact acactttgga agagcgggta gaagacctac caagtgaggg actgctgact 180
 gccctctggt ccttatgtgt ggccatcttc tctgttggtg gcatgattgg ctctttttct 240
 gttggactct ttgtcaaccg ctttggcaga cgcaactcta tgcttctagt caacttgctg 300
 gccatcattg cgggctgcct tatgggattc gccaaagatag cggagtctgt tgaatgctg 360
 atcctgggcc gcttactcat tggcatttcc tgtggcctgt gcaecggcctt tgtgcctatg 420
 tacattggag aggtgtctcc cactgccctt cgggggtgcat ttggcacact aaaccagctg 480
 ggcatcgttg ttgggattct ggtagctcag atctttgggt tggactttat tctgggctct 540
 gaagaactgt ggccctgggt ccttggccta accatcattc cagctatcct gcaaagcgca 600
 gcccttccat ttgcccctga gactccaaga ttcttctca ttaacaaaaa ggaggaagac 660
 caagctacag agatcctgca gcgcttgggg ggcacctcgg acgtgggtcca ggagatccag 720
 gagatgaagg atgagagtgt tcggatgtca caggagaagc aggtgactgt gctggagctc 780
 ttcaggctac ccaactacgt ccagccgctt ctcatctcca ttgtctctca gctgtctcag 840
 cagctctctg ggatcaatgc tgtgttctat tactcaacag gaatcttcaa ggacgagggt 900
 gtccaggaac cgatctatgc cagcattgga gcaggcgtgg tcaatactat cttcactgta 960
 gtttctctgt tctcgttggg gagggcaggg aggagaacct tgcatatgat aggcctggga 1020
 ggcatggctg tttgctccgt ttctcagcag atttcgctgt tactaaagga tgactatgaa 1080
 gccatgagct ttgtctgtat tgtggctatc ttgatctacg tagccttctt tgagattgga 1140
 cctggcccca ttccctggtt tatttgggct gagctcttca gccagggcc cgcgccagct 1200
 gccattgctg ttgctggctg ttgtaactgg acctccaact ttctggctcg aatgctcttc 1260
 ccctcagctg cagcctactt aggagcctac gtttttatac tcttcgctgc cttcctcacc 1320
 ttcttctaa tcttcacctt cttcaaagtc ccggagacca aaggcaggac tttcaggac 1380
 attgcccggg ccttcgaggg gcaggcgcac tctggaaaag gccctgcccg tgtggagttg 1440
 aacagcatgc agccggtcaa ggagaccctt ggcaacgcct ga 1482

<210> SEQ ID NO 13
 <211> LENGTH: 474
 <212> TYPE: PRT
 <213> ORGANISM: human

<400> SEQUENCE: 13

Met Ala Thr Asn Trp Gly Ser Leu Leu Gln Asp Lys Gln Gln Leu Glu
 1 5 10 15
 Glu Leu Ala Arg Gln Ala Val Asp Arg Ala Leu Ala Glu Gly Val Leu
 20 25 30

-continued

Leu	Arg	Thr	Ser	Gln	Glu	Pro	Thr	Ser	Ser	Glu	Val	Val	Ser	Tyr	Ala
	35						40					45			
Pro	Phe	Thr	Leu	Phe	Pro	Ser	Leu	Val	Pro	Ser	Ala	Leu	Leu	Glu	Gln
	50					55					60				
Ala	Tyr	Ala	Val	Gln	Met	Asp	Phe	Asn	Leu	Leu	Val	Asp	Ala	Val	Ser
65					70					75					80
Gln	Asn	Ala	Ala	Phe	Leu	Glu	Gln	Thr	Leu	Ser	Ser	Thr	Ile	Lys	Gln
				85					90					95	
Asp	Asp	Phe	Thr	Ala	Arg	Leu	Phe	Asp	Ile	His	Lys	Gln	Val	Leu	Lys
			100					105					110		
Glu	Gly	Ile	Ala	Gln	Thr	Val	Phe	Leu	Gly	Leu	Asn	Arg	Ser	Asp	Tyr
		115					120					125			
Met	Phe	Gln	Arg	Ser	Ala	Asp	Gly	Ser	Pro	Ala	Leu	Lys	Gln	Ile	Glu
	130					135					140				
Ile	Asn	Thr	Ile	Ser	Ala	Ser	Phe	Gly	Gly	Leu	Ala	Ser	Arg	Thr	Pro
145					150					155					160
Ala	Val	His	Arg	His	Val	Leu	Ser	Val	Leu	Ser	Lys	Thr	Lys	Glu	Ala
				165					170					175	
Gly	Lys	Ile	Leu	Ser	Asn	Asn	Pro	Ser	Lys	Gly	Leu	Ala	Leu	Gly	Ile
			180					185					190		
Ala	Lys	Ala	Trp	Glu	Leu	Tyr	Gly	Ser	Pro	Asn	Ala	Leu	Val	Leu	Leu
		195					200					205			
Ile	Ala	Gln	Glu	Lys	Glu	Arg	Asn	Ile	Phe	Asp	Gln	Arg	Ala	Ile	Glu
	210					215					220				
Asn	Glu	Leu	Leu	Ala	Arg	Asn	Ile	His	Val	Ile	Arg	Arg	Thr	Phe	Glu
225					230					235					240
Asp	Ile	Ser	Glu	Lys	Gly	Ser	Leu	Asp	Gln	Asp	Arg	Arg	Leu	Phe	Val
			245						250					255	
Asp	Gly	Gln	Glu	Ile	Ala	Val	Val	Tyr	Phe	Arg	Asp	Gly	Tyr	Met	Pro
			260					265					270		
Arg	Gln	Tyr	Ser	Leu	Gln	Asn	Trp	Glu	Ala	Arg	Leu	Leu	Leu	Glu	Arg
		275					280					285			
Ser	His	Ala	Ala	Lys	Cys	Pro	Asp	Ile	Ala	Thr	Gln	Leu	Ala	Gly	Thr
	290					295					300				
Lys	Lys	Val	Gln	Gln	Glu	Leu	Ser	Arg	Pro	Gly	Met	Leu	Glu	Met	Leu
305					310					315					320
Leu	Pro	Gly	Gln	Pro	Glu	Ala	Val	Ala	Arg	Leu	Arg	Ala	Thr	Phe	Ala
			325						330					335	
Gly	Leu	Tyr	Ser	Leu	Asp	Val	Gly	Glu	Glu	Gly	Asp	Gln	Ala	Ile	Ala
			340				345					350			
Glu	Ala	Leu	Ala	Ala	Pro	Ser	Arg	Phe	Val	Leu	Lys	Pro	Gln	Arg	Glu
	355						360					365			
Gly	Gly	Gly	Asn	Asn	Leu	Tyr	Gly	Glu	Glu	Met	Val	Gln	Ala	Leu	Lys
	370					375					380				
Gln	Leu	Lys	Asp	Ser	Glu	Glu	Arg	Ala	Ser	Tyr	Ile	Leu	Met	Glu	Lys
385					390					395					400
Ile	Glu	Pro	Glu	Pro	Phe	Glu	Asn	Cys	Leu	Leu	Arg	Pro	Gly	Ser	Pro
			405						410					415	
Ala	Arg	Val	Val	Gln	Cys	Ile	Ser	Glu	Leu	Gly	Ile	Phe	Gly	Val	Tyr
			420					425					430		
Val	Arg	Gln	Glu	Lys	Thr	Leu	Val	Met	Asn	Lys	His	Val	Gly	His	Leu

-continued

435	440	445	
Leu Arg Thr Lys Ala Ile Glu His Ala Asp Gly Gly Val Ala Ala Gly			
450	455	460	
Val Ala Val Leu Asp Asn Pro Tyr Pro Val			
465	470		

<210> SEQ ID NO 14
 <211> LENGTH: 34366
 <212> TYPE: DNA
 <213> ORGANISM: human

<400> SEQUENCE: 14

```

tcctcacttt gattccacag gcatttctcg agcagcaatg ctggcccagg cctgtgctag    60
gggctggaag acagaggaat tccactctga atggccaaag cagtggcccc cagccagggtg   120
gggagatggc ctcataaaca acagtatgag gcaggggtgat atcactgcta aaaagagaca   180
gtagccatgt gcacagatgc agaccatgtg tgatgcagac cctggggctg acagagatgt   240
tccaatcaaa aggcacagtc cagtggctgg gtgcggtggc tccgcctgt aatcccagca   300
ctttgggagg ctgaggcggg tggatcacia ggtcaggaga tcgagacat cctggctaac   360
acggtgaaac cccatctcta ctaaaaatag aaaaaatag gcgggcgtgg tggcaggcgc   420
ctgtagtccc agctactcgg gaggtctagg taggagaatg gcatgaacac gggaggcggg   480
gcttgcatgt agccaagatg gcgccactgc actctagcct gggctacaaa gcaagactcc   540
atctcaaaaa acaaaaaaca aaaaaaaccc acagtccaga cttggagaga ggcctcgcg   600
gggagaaaag caagacacaa aattaaggga ttggcctcca ttcacagtga agtacatccc   660
tgcatacctt ttttcaceta attcagaccc aaatgttccc acaaacccca agaacagagg   720
atgaaattga ttcaacagtt agctttggga agtctgagcc catggcatgt cccaaggtag   780
atatgtggga acaccatggc tgacactgct gctgtgatct ttggcaagtc aggatacctc   840
ttcaagcctt cctttccccc gctgtaaaat ggaggctata aagatactga tgtgataggg   900
aggtaaggga aagttagata acgactgtaa agtcattagc caagtacctg acacttagcg   960
accagatcaa taaagggtag ttattgttag gaaaaaacag atttcacttt gaaagtgagg  1020
aaagccaggc gcggtggctc acacctgtaa tcccagcact ttgggaggct gaggcaggca  1080
gatcacgagg tcaggagttc gagaccagcc tggacagcaa ggtgaaaccc tgtctccact  1140
aaaaatacaa aaaattagct gggcatggtg gcatgtgcct gtaatccag ctactcggga  1200
gactgaggca ggagaattgc ctgaacccgg gaggcagagg ttgcagtgag ccaagatcgt  1260
gccactgcac tccagcctgg gtgacagaga gagactccat ctcaaaaaaa aaaaaagaa  1320
agaaagaaaa aaaataaaat gaggaaagtg ggattcggag aggtgagatg acttctgcac  1380
agtcaggatt caaacctcagg tctgagacac cagaggctca gggcaaatca tctccctctg  1440
ctccggaatc ttcagcaggt tccctacagt ccaactacatg gactccatcc ttgccaggga  1500
gtgaggatcc agcaaaaggc tggggccaaa aagaccctgg gcaagttccc caatcctatg  1560
tgtcttgatc tgatagcccc aagttagcct gagaaggtct gtgaattcct ccacgtagct  1620
gatgcaaaat tttatactaa tggatctcag acgagcttat agcctcaaaa gtaacaaacc  1680
acagacttga cctgaactag catggtttct tattcaccca atggagatag gatttctacc  1740
ttgaaaggct gtgaagggat taaatgaggt aatttgtgag aagtacttga aacatcctca  1800
    
```

-continued

gctttcatta aatggtgggt tcttctctt tctctctccc caaactatctt ccatcagtta	1860
gcaaatatta ttgagcatct gccacgtggc aggcaccagt caggtcctgg gggtaaagtg	1920
gtgaacaaga cagacatggc ccattttcat ggggctcaca ttctagcaga gggaaacagc	1980
aaacaataa aagcaacaat ttcagatctg aataactgct atgaagaaaa tacaaggccg	2040
ggcacggtgg ctccagcctg taatcccagc actttgagag gcagaggcgg acggatcaca	2100
aggtcaggag tttgagacca gctgatcaa catggtgaaa cctgtctct cctaaaaata	2160
caaaaattag cgggcatgg tggcacgtgc ctgtaatccc agctactcag gagactgagg	2220
caggagaatt gtttgaacc aggagacaga ggtgacgtg agccaagatc gcaccactgc	2280
actccagcct gggcaacaga gtgagactcc atctcaaaaa aaagaaaagg ataactgat	2340
agacttatag ggtggggcag cctccaggga tgaaacatct gaatgaccaa aggagccagt	2400
catgccagga ttttgaggga aagcaccag gcagagagtg cagaagggc aaacgtccc	2460
tgaaagatt cttagtcaag agtccttcac tcccagtcct accacaaaact gggtcacctt	2520
gaacaagtca cgtaactctt gaggtcagc tgccacatct acaaaatggg aataaagaca	2580
tcttacctgc cacattgtga gaggtttcaa ccaaagggt gttaaggctt gggatcctcc	2640
ccaaaatcga ccatagacac ctgataactca tcaactggca cccgtcttg aagaggggaa	2700
cctgcacaga gaacctggg tcatgctttt gatttttaat ttcagctgc actagaaata	2760
gcttctttg tctctgggtg acccaggagc ctcttctgc cacctggggc ctattctagt	2820
taacagctgc ttatcccctc aggtacaaaa gccaacgagg aaaggacatc aggaaacatt	2880
gttctgggaa taaccagaca cctatctgcc accatctccc cccatcccgt gaccacacac	2940
gggagactgg aggactcagc ctgtctgtga gtcagataat gtacatggtt tatttaaaga	3000
gtcaaaaggg gccgggcgca gtggctaacg cctgtaatcc tagcactctg ggaggctggg	3060
gcggtgggat cacctgagct caagagtctc agaccaatct gcccaacatg gtgaaaccct	3120
gtctctacca aaaatacaaa aattagccgg gtgtggtggt ggacgcctgt aatcccagct	3180
acttgggagg ctgaggcagg agaattgctt gaacctggga agtgagggtt gcagtgagct	3240
gagatcgtgc cactgcactc cagcctgggc aacaacaacg aaaactccgt ctcaaaaaa	3300
aaaaaaaaa aaaagagtca aaaggatctt ggtccctggg ttgggcccact gatttacgat	3360
cactaggagt tctcaactct aaatttctt gatctgttcg ctctcctcca tctccacagc	3420
tgctgcactg gctacagcct catgatctca catcttaact ctctctgctt tctctggccc	3480
atctccccac ttccaacca tttgtcacgc tgtaaccagt gcctaacaca caaaactaac	3540
catgtcctc cctgcttaa agcccttagc tctgttgcct cagtggaaact ggcgtctgag	3600
gctacctctc caagcctaag cgcctaagtc ctgttgcaac cctcaggccc tctctatta	3660
tccacaccaa actcctcagt gtctgtaaaa caagccgagc aacctcaga attatatgcc	3720
ttcgtgctc gtttgtttt tttttaggac aggtctctcac gctgtcacc aggcaggagt	3780
gctgcagcgt gatctcagct cacagcagcc tccgtctccg gggctcaaga attctcacgc	3840
cgcagcctcc cgagtagctg ggattacagg cacgggcca cacacccggc taattctgt	3900
atctctagta gagacgggtt ttcgcatgt tgcccagcct ggtctccac tctgagctc	3960
aagtaatcca cctgcctcgg cctctcaag tgctgggatt acaggtctga gccactgcac	4020
ccagccagcc tttgctgctt ttgttctgc aatttgaac actgtcccca tcccagcctc	4080

-continued

tcaactctac cctacctcc tteactaect ataecttccct atccatecct caagacccca	4140
aaaaccatcc ctgattcctt cagaaaggca gtttattgcc tatcttatca gactgaaagc	4200
agtggctgtg tcttatttat ggttaattcc ctagaagctg gactgataca ttccatttaa	4260
ctaaaattcg taccaggtgc ttcggactgc agacaagcct atcacacccc agaaggaaga	4320
aacaggaag gcaacctggg gctgccaagc aatgaggtgg ggggtaggaa tcatgaatcc	4380
gcatattttt aaaaactgcc ccagatcctg atgtaaacgg tacaagagag tctgagaaac	4440
acagggtccc cctcaaacag tccctgacttc agcattcctg gaaaaatgaa aatcctttcc	4500
ttttgctctc aatgctttcc ctgctgggat cccaggtaa aaaaaatag ataaatcag	4560
ggggattttt ctgggacttg gctgggctgg gaaacaagcc tgggttctaa tacaggctca	4620
gcccctgacg tactatgggc cctgcccct cctgggggc tccattacca cggccacccc	4680
caccttacc aattgtgtgc cctgaggta gtgactgtcc cgctctgagc attagtttcc	4740
ccatcttcca ctagtctgc tcagctctga cgctctatga gctatgcata cccgtagctc	4800
cccgccgacc ccgatgttcc cctcccctcc ttcccaggc ccatecgcca ggggtcgagc	4860
gacgcactcc taatgctaag gccgccctct catcgaccgc ccttccctgg cctcgactca	4920
gcccgaagg tatgggtctc tgcccgcct gctctttaag cctagccggg gcggtcagcg	4980
caagcgact gggctgcac gaggccccgc cccctgagcc tgggtagcgg cgcgagggcc	5040
gggagaaccg ttccgggagg aaaggcgaac tagtaggttg gggcgccacc ggcggccgpc	5100
atgggtcacg tttcctcggg aggaacgatg tgaggggagg gtctggcaag agattggaat	5160
tccggaggcc gggagacctt gtggctgaaa cccttcgtag gagcggggca actagtgtct	5220
agtgaggggg ttgggtggc gcgcaactgat cccagacttt ccggaatctc tgcctttaga	5280
tccggccggg gtcggggcat gtaggccagt gagactggag ccagttagag ctacaacggg	5340
gagcgattag ggcacaactt tgtccagggt ggaagcgagc gggcccgtga agtggggcca	5400
gcccgggag ccgaccctgt cgttgccctc gggcctttcc aggcactggc ctaagtcctg	5460
gagataaagt gcgaccgat tccctgtggg cgttttgagg ctttcgggta tctgaccctg	5520
ctgtcattca ttctcattc attcatgtga tgaatgaata cagtactaag cgcggctaata	5580
tactaggtag agaagtgatc aagacaaaca ctgttccctac ggtacagga aaagtgatgg	5640
gctgtagaat gtagaagccc gggcgggaga acagggacag cttccggaac gaaatcgca	5700
gcccagatca ggagtggtgg cgagagttcc aaagagaaga cagcacgtgc caagtcctgg	5760
aagggggaca gaggccaaca tatcctggtc actgaagaca cctgactctg aatctgtttc	5820
acgccaggg aagagatgac agtggccggg gctaggctac aaactctgga aatggagata	5880
aataaaggaa ttcaaatgac tatatactta ggcagcaaaa tccataggat ttggggagag	5940
tgagatgtag gaaacaagta ctcaaggctt gggcacctgg gtgggttca tcagagaaga	6000
agcagatttg tgggagacaa caacaaatc tattctgggt gtatggagac tgcagggaaa	6060
aaattggata ttctagtttg aaggtaggaa agtattgctg tgaagatgta gatttgaatg	6120
tcatcagcaa aacataaata aagccaaggg agggttgagg ctgtagaatg agaaaaacaa	6180
agggcccact tagcaccttc atctgatttc ttttctttct tttttttttt cttttttttt	6240
ttttttgaca gagctttgct cttgttccc aggctggagt gcaatggcac gatctcggct	6300
cactacaacc tccacctcct gggttcaagc tattctcctg cctcagcctc ccaagtagct	6360

-continued

cggattacag gcatgcgcca ccaggcccgg ctaattttgt attttttagta gagatgggg	6420
ttctccatgt tggtaggct ggtctcgaac tcccacctc gggtagtccg cctgcctcgg	6480
cctcacaag tgctgggatt acacgagtga gccaccacac ctggcccagtg gtgattatct	6540
ttatgtctta tcctctcca tatcccagtg acctagtcaa gggagtggca ttaaatgcaa	6600
atcagtgttt gccactaaa taaaagccca acagcaaaaca gatgttgaa tttcagagtt	6660
gtggaacgat gggggctcat ggagggttct attactctaa tgtcaaggta atgggttctt	6720
gtcctggctc tgccactagg cttctgtgtg acctctgaca agtctcctcc tacctataaa	6780
gagagtacag ccaaaaaatg gtctcatgta tagagcttca aacctgctg ataaatttca	6840
cactgatttt tctcttttaa tccacacagc aatcttactt gaaagggaag tggctgggc	6900
ggggtggctc acgctgtaa tcccagcact ttgggaggcc gagagtgggg gatcacgaga	6960
tcgagacat cctggctaac acggtgaaac cccgtctcta ctaaaaatc aaaaaattag	7020
ccgggcatgg tggcaggctc ctgtagtccc agctactcgg gaggctgagg caggagaatg	7080
gcatgaaccc aggaggcggg gcttgcatgt agccgagatc gtgcggctgc actccagcct	7140
gggcgacaga gccagactcc gtcaaaaaa aaaaaaaga aagaaaggagg gagggagaga	7200
gagagaaaga aagaaaaaga aggaaggaaag gaaggaaaga aggagggaag ggaagggaa	7260
agggaaaagg aaggaaaggaa agaagggaag gggagaagtc gtattatatt ggactcaaac	7320
ccaggctgt ctgtctgtct gacttgaacc ttgttcttta ctatgattgc cctcatgtat	7380
gtctcactca acaggggat tatcaggacc ctcttgagat cacatgcgca ttctttcaa	7440
gcatgtgct gaggtggca gactttcata attggcctgg cactggctct gtcattggga	7500
cagggggaca gagctgaatg tgatggaggt ttctattat tctctaaact ccttctggg	7560
gaccactgag ttggcaacc atgttctgtt aaatggcaac agggcagaac aaaattagtg	7620
actgtgttct cagattttta cccagatctt aaactcctga ggcctgctga aaaatgaatg	7680
agtatcaggg tgtgagtttg tacacctctg tatgtctctg ggcaaccaat cagacaactt	7740
ctcctattac attggacact tgggtttcag caatttccat cttgctaatg tgatttctca	7800
aaaatatttt ctgtcttttg gtgctttgat gataaatgct catatatgga atgtagtcat	7860
ttctgtctac taagattctt tctggtttgt ataaggagg agttcactt attcgcattt	7920
catggtattc cacaagagc tcctcctccc ttcccagta atttattga gatctgctga	7980
catgagttgt tggagcttga agggaattaa taatgtactg cagtgaactc tatcccagga	8040
aaacttgta aaaatacaaa gcctcggtg ggtgtgatgg ctacgcctg taatcccagt	8100
actttgggag gtcgaggcgt gtggatcaca aggtcagaag atcaagatca tctggctaa	8160
cacggtgaaa cccctctct actaaaatac aaaaaattag ccaggcgtgg tgggtgtgtc	8220
ctgtaatccc agctactcag ggaggctgag gcgggagaat tacttgaacc caggaggcgg	8280
aggttgcatg gagccaagat cgagccactg aactccagcc taggcgactg agtgagactc	8340
catatcaaaa aaaaaaaaa acaaaagcctc aaccctcct tcccacagc cctcttgc	8400
cagagtctct gggatggggc ccaggaatct gtattcttct ccagctcccc agaatgttca	8460
gccaggtttg gaaactgatc tatccgatc ttcttgttct acagttaggg aatctgtagc	8520
tctgggaagg gaaggaactt gccccagtc catctgatat tagtgcttct ttctccaatg	8580
aagagccttt aggcgtggag tccagagaca tgggttcaag tccaggctat accagtcac	8640

-continued

acctcgggca agtcatttca cctctccaag cctctgcttc cttactgtga gaataatgcc	8700
atttgtttgg gaatcaaaag agagagtggc aatggaaatg ctttgtcaag ctttctattt	8760
tgtgcacatg gaagtgttta agagtagtaa ccagccagtg ttcactcctg tataccacgc	8820
tgttcccttc caacagaggt cagggctcctg ctgtgttggg ggtggccgcc agccagtttc	8880
ggtggttgct gggcctcagg ccatctgtta ccaactctct tctctccate ttttgtaggt	8940
gttgggatgg ccaccaactg ggggagcctc ttgcaggata aacagcagct agaggagctg	9000
gcacggcagg ccgtggaccg ggcctggct gagggagtat tgctgaggac ctcacaggag	9060
cccacttctc cggaggtaag cccctagctc ctccccacag cattcaccat ggcccactgt	9120
ctggccccgg ccaggtctgag ggctactcct ttgcatcagg gaccatatct cttttgcctt	9180
atTTTTTcca gtaactaaaa ttgatctcta gaagtagaaa ataaaaaggc agtgtcctgg	9240
agtaatcaaa tttaaatag gggtttgaag tgtgacttag gcaaatctact taaccgctct	9300
cagctgcagt ttcttcagggt gtaaaaatgg gataataata ggacctacct cactggtttg	9360
gtaagagaat tacaggatga ttcatgtgaa gcactttgcc cagtgtgacta ttactgaaaa	9420
ccccataatc actctacctt ctctgtaact ggtttgtgat atatgctttc aagcctttct	9480
ctgtgcattt atatacatag ataggtatat atagaaatac gtctttttta aaaaacaaat	9540
tgtatcatat atattattct atgatatgtt tttggttttt tatttgtctg tcttagaact	9600
ttctaagcc ttctattagg gtcatcttca ttctgaggca tagtattcca gatgtgggtg	9660
tatcacagtt tagcttccct ctactcatgt ctatttaggt gatttctcat tattttatga	9720
ccataaatag cattataggg aacatccatg catatgtctg ttggggcacc tatgtgagtg	9780
ttctccagg ttcaatacgt aaaaagtagaa ctgctgagtc caaaccacac ctttttaaaa	9840
cctcatcctt agggaagaaa aaaaaataaa aaaataaaat cttttttaat ttggtgacta	9900
ggtaagacat tttcatggtt caaattcaaa tggtaacaaga gtttacccta atgcagcttg	9960
tgttttggtt tcttgttgat cctttcagat ggcttattca taacaagtaa ctaataacaa	10020
gtaaatatat tctctggggc ctctctctgt tgcccaggct ggagtgtagt ggcacaatct	10080
tggtcactg caacctccgc ctctggggtt caagcaattc tcccacctca gcctcccaag	10140
tagctgggac tacaggcatg tgccactacg cctggctaat tttttttttt tttttgtag	10200
ggacagggtt tcaccatggt gtccaggctg gtctcaaact cctgacttca agtgatccac	10260
tggcctctgc cccccaaaa tgctgggatt acaggtgtga accaccgtgc ccagcctcct	10320
tttgcccact ttttttctt taacttaaca gtacacctta agaccatatt ggtgactaaa	10380
gagctgccaa catctctctt ttttttagcc agaccattc tttttgtct ctgtgtgccc	10440
agaacctaca caggcctgat ggagtccaca ctgagtaatt gtttctaaag gcccaagtaa	10500
atgacaatgt ctgtcaccta aggcaggctg atggtatgga atagaattgc ttgggctgtg	10560
aacctagatt ttgtgaatta cttgtatgaa tctaaaatga agcattttct cttccacgct	10620
tttgtttctt ctgttaatca ataggtacca tgtgaagatc caacacttg tctttctggg	10680
aggttatgga gcctagaaaa ggcgtaatcc acaatgagat ttctaatacca gaaaaaaagt	10740
cagaaagtgt acgtgtgtgt gtatgtgtgt gtgtgtgtgt gtgtgagaga gagagagaga	10800
gaatgatttt actccaaatc ttaccaaat gcctgctcta tgccgggcca ttgtaggcac	10860
tgaggacaga gaggtgagtc agccagagcc ctgacctctg gggctcctgg tctagttaga	10920

-continued

gaacatacca	caaaacaaaa	ttaaataaca	tcagctctat	gaggaaacac	aggcagtctg	10980
ctacacaaag	ttaactatca	tttattgagt	athtagtatg	tgccaggcat	tattctaaac	11040
actttggaat	cactgactcc	tcaccacaac	agagataagg	aaaccgaagc	ccagagaggc	11100
taagtaacct	acotgaggtt	atftaaatgg	taaaataatt	ggcagagcca	ggatgtgaac	11160
ccaaggaatt	tggctcctga	gtccatgctc	tgaacatcca	tgcttttttt	cctctcccaa	11220
gatactatat	aggacagctg	gaagaaagag	tagttcatta	tgattagatg	attgagatgg	11280
ggggtgggat	ttgaactaga	ccttaaaaga	caaataggga	aaaggaacag	catagcaagg	11340
acccaaaagt	agggaaaggc	aaaaaaaaaa	aaaaatgttc	aagagaatgc	agctgaaatg	11400
cagggcgcat	aagtgatgat	agtgggaaag	aaggcaggcc	agcgtcagac	agccgcgggg	11460
ccttagctac	tgggtggagg	aggagatgta	actttatcct	gtagatcaga	gctgcaaact	11520
agccatatct	aggctgagta	tttggctcct	gcagtgtttg	gggagttaat	ttgtttttta	11580
caataagtaa	tacgttcaaa	tacatttgaa	cagggcgcaa	aattcaaaag	ggtattcagt	11640
acagagtaag	tccccttctc	ccagccactg	ttccctgac	caggggcaag	cattgttaac	11700
agttgttttc	accagagtat	ttttaaaaag	tcagagccaa	catttaaaaa	aaaaaatcat	11760
gaaattaaaa	caaaaaatct	agcaacccaa	cttgtcttga	aaaattatat	catctggcaa	11820
ctctggccta	ctttctcgca	tggcaacaat	tggctagagc	agagttctgg	ctgccccctt	11880
tagagaagat	gcaagtactt	ctttttgcca	caattcctat	cactccctgt	tgettctctg	11940
ctacaaaagca	gaattttgtc	atgcacgtgc	tataggtttt	tttaaatagt	agaaaaatgt	12000
ttcttttttt	ttttttgaga	cagagtctca	ctctgtcgcc	aggctggagt	gcagtggcac	12060
gatctcagct	cactgcaaac	tctgcctcct	gggttcaage	gattctcctg	cctcagcctc	12120
cagagcagct	gggactacgg	gtgtgtgcca	ccacgcccag	ctaatttttg	tatttttagt	12180
agagatgggg	tttcaccatg	ttggccagga	tggctctgat	ctcttgatct	tgtgatctgc	12240
ccgcctcggc	ctccc aaagt	gctgggatta	caggcatgag	ccaccgtgcc	cggccagtaa	12300
tgtcatttta	tgttaatgtc	tctatcaaaa	gtgagaagac	tgtgtgtttc	agccttttagc	12360
ctgtagatag	cagagaacag	ctataaacta	ttgatcctaa	atcaggagg	gcataatgag	12420
ccctgggaca	gaggcagagg	gatgtcttag	cagaaaaact	ctgagttttt	gaggccaaga	12480
tgagacttgt	tgggggcagc	agagctctat	gtgttcaagc	caaggaaatg	ctcctgtagt	12540
catcacatag	ctactcaggg	tattagggtca	ccccttatgt	aatctgcagt	cattcccatt	12600
ctaactcata	aaggcttcag	actgaataaa	ccttattctc	acaaatagcc	ttcctcagtt	12660
ttatcttaga	tgtctgagcc	agggcagtg	tacacacctg	cagctctcagc	tactggggag	12720
gctgagacag	gaggattgct	tgagcccagg	aatttgaggc	tatagtgcac	tatgatggca	12780
cctatgaata	gccactgtat	tccagctctg	gcaacatagt	aagaccccac	tccaaaaaaa	12840
aaaaaaaaag	atgctgagaa	gggtaattta	gaaattatct	accaaaaatt	aaaatagatt	12900
tacctgaatt	acttgatatt	ttactttta	gaaatttaga	atgatggac	tttctcatat	12960
atgaaaatat	ctagaatgta	tattctagga	taccattgta	aacattaatg	gtaaataggaa	13020
aataaagaaa	ccacctatat	actagattca	ataaattatg	gtatatccta	agagtagaat	13080
aatatacagc	aattaaat	aatgaaatg	ctctatttga	acataaagg	aaatatttaa	13140
aaagcacaat	gtagtatagt	ttgctatggg	ggtgaaaaaa	agagaaaata	tatgtgtata	13200

-continued

catatatatc aatacaaaaga tgactggaag gatgtgtgag acactagtct gtcatttgcc	13260
tctggggagg agaactgggt ggctggggcc cagtcctttc cccaggagac tggaatgaga	13320
gtgagacata cttctcacta tatattctta tgtctctttt gaattttgta tcatgtattt	13380
gtattacctg ttaaaaaaat aataaatattt tggctgggca tgggtgctca tgctgtaat	13440
cccaacactt tgggaggctg aggcaggcag atcacttgag gccagggtgt tgagaccagc	13500
ctggacaaca cagtgaacc ccatctctac taaaaataca aaaattacct ggggtgtggtg	13560
gcacacacct gtagtctcag ctacttggga ggctgaggca ggagaattgc ttgaaccag	13620
gagatggagg ttgcagttag ccgagattgt accactgcac tccagcctgg gcaacagagt	13680
gagactctac ctcaaaaaaa aaaatagtag tttaaaaata aatatctaaa tacciaagttc	13740
taacaccgta aacttatacc accataatga caaactgata ttaactcaaa ggttaaacctc	13800
aggaatgctt tataatacaa gtcaacaagat tttcttttca tctcttacc aagttctagt	13860
tcagttggtg gcagggatct cagaatgcac tttcccttc tagaatcagt gtccttgatg	13920
gtatttgggt ttctcgteta tgataaagtc caaagaatgc ggaatgcagc tgaactctag	13980
gcctgttaac ctgagtcacc atcactaaca ttggtggaaa aaacactcct ggcttctact	14040
aagggaaaca gagttcactt gtctaccaca gtaaccaaat caaaatcaaa aggcaaggaa	14100
actggagtggt gagctcctga tgcattggaag ggctgggct tgaacatcaa ccagcaagga	14160
gcaggcttcc atgtatgtat gtgtgtggtg tgtttagtaa ccatcctggt tcaaatccca	14220
gcaccccggt actagctgaa tataattttg gatctgttaa ctgttctggt tcaaatccca	14280
gcaccagttc cttagctgat ataattttgg atctgttaac ctctctttct caggteccgt	14340
ctctgttaag tgtggataat aatagtatct tcctcacagg gctgaatgat gaatctatgt	14400
aaagtattta aaatagtacc ttgcacatag taagtgtca ataacttggt ggtttctttt	14460
tgttatttgc attttctttt ttgtctctc tctcttcaat acgtagagat aaactatcac	14520
agaatctgga agctctctgg gttccactct ccccttcca ctctcccaag gtaaccacta	14580
atctacagtt ggtgtgtctc cagtaaatat aggcagact ttccatggga ttccatttgc	14640
aggaagacaa cccgttcaca ggtgccctac ccctgtcca ttctctcttc ttgatcacag	14700
gtggtgagct atgccccatt cagctctctc ccctcactgg tcccagtgcc cctgctggag	14760
caagcctatg ctgtgcagat ggaactcaac ctgctagtgg atgctgtcag ccagaacgct	14820
gccttctgg agcaaaactc ttccaggtag gggacagtga agcattgggg ggccaggagc	14880
tgccagagcc aaggaactgg aagattgcag agccgtgagg tgttactgtg tcagctgact	14940
tgggtgggata gaggaaaggt acctccaaag aacaaaaagt cataggagtc aggaaagctg	15000
gcttctaate ctggctcgac cagttattta tatggcctca agccactccc tttcttctc	15060
tgggcctaag gtttctctat ctgaaaaatg aagagactgg cttaaatcca agatcccttt	15120
attgttgaca ttctgtaate cgtgacaccc tactttgaag actgatattt ccatttggaa	15180
ttaggggaag tcagcctggt tttggaggaa aacagaggta gggaaagtta ttgggttaaa	15240
gtcagatttt ctacttctcc taagcagcga cactttcttg tcacctcagg cctctcatct	15300
ttggatggga tggggtacag actggggccc actcagggca tgaggaaagca acctctgaaa	15360
tggttcagcc catccgccc tctctgtctc tttcccttga tctttttttt tttttcttca	15420
gattctgggg caatttctta aaatttcttt atttatttta gaattaaata tatataggct	15480

-continued

```

gggcgcggtg gctcaggcct gtaatcccag cactttggga ggccgaggtg ggtggatcac 15540
ttaaggctcag gagtttgaga ccagcctggc caacatggtg aaaccccgctc tctactaaaa 15600
atataaaaaa attagctggg tgtgggtggcg ggtgcctata atcccagcta cttgggaggc 15660
tgaggcagga gaatcgcttg aaccaggag gcagaggctg cagtaagcca agatcacgac 15720
actgtactcc agcctgggcy acagagcgag actccatctc aaaaaaaaaa aaataataat 15780
acatatatat atgtatatat attcattgta gaattaaata tctagaaata ttatgtattt 15840
acatatacat gctagatgty tatatactgt acaggttgag catccctaat ccaaaaatcc 15900
aaaagctgaa atgtccaaa attcaaaact tgttgaacac cacatgactc taccagtggg 15960
aaacgccacy cctgatgtca tgtgacaggt gcagtcaaaa cacagtcaa agtttgttc 16020
atgcacaaaa ttaattaaaa tattgtataa aataatcttc aggetatgag tataaggtgt 16080
atatgaaaca aatgaatatt gtgtttagac ttgagtccea tcccgaagat gtctcattac 16140
gtatatgcaa atcttccaaa atccgaaaga cttctggtcc caagcatttc ggataagggg 16200
tatccaaact gtaattgcat gtctttgatt aatttttcaa cagaaattag acttttgtyg 16260
gagacaaaat cttttaaaaa tgtgtgggtg aatatgagaa ggggtcataa tggaagaag 16320
cttgaaacc attgacttgt agccaaaaac ccaatgagtc atgaatgtat gaatctgccc 16380
accaccttgc cctgagctg tttcttgaa tgggccagc tttgtacctg caatcctgga 16440
ttgtgggaaa catgagcagc ctggcttata accctaatga tgcaattatg aaggagactt 16500
gcagctcacc tttgcaacc ctgctctctc tgttctctc tctctcaca cacatataaa 16560
cctagttcc taaggagaa gagcccccta caaacatga aggggagcac ctcttcagaa 16620
aaaggaaagt gtgtctcaac tctctggag gctgaagccc agctgggact ctctcctaa 16680
ccaagggtg gcatgagaga gctcaccctt gggagagagc tggctgagga gcagaggaac 16740
ttcagggcag gcctgggcta cttggcttcc ccccactggt ctgctgtgac gtttctgtaa 16800
caaggtgatt caggcttgag cagggtgtgca gaatccacc tgaatctcaa agggcagtaa 16860
gtgtgatgtt aatcacctgt ggattccttc ttaactgtgc tcttgttgag acttcagaaa 16920
accatactgg ataggccct aacacatgct acatgtcatg gcagtacact gagctgtgac 16980
gatgagcctg catagacaca gccattacct tcatgaggtt tatagtcaa caggagagat 17040
gacactaatc atcacacaaa gaaaatgtaa aattgcaact gcagtcagty ctgtaaagga 17100
gtggttctta gttctatgag aacacatagt aggggatct gactcagata ggaaggctt 17160
cctgaggaa atcacatcat atgaggacta gttgaagaag aaacaaaca aaaaaaaaaa 17220
cccaggatat ttgcttggg tcagaaaaat cttattgtyg cacagggcat aactgctgtc 17280
ttctaactc caagggtgc tgtggaggag gaggagaag ctaccctgg gagtgcgag 17340
agggtaggaa aagctatgga gagttatgat taggtcaacc agaaggcttg ccaaccatca 17400
gagctattca agtagaatag atacatcatg tcattttcta gctcttctc ggtgcagtat 17460
gttcaattct ttgaatgtaa tatcttattg gctttttacc acaactctat gatataaata 17520
taattatatt ctccatttta aagatcagca aactgagaca cagagaggtg aatgattcc 17580
ctgaggttgc ctactagtga gtggtagagc taggattga acccaggtct agagttggat 17640
tcttagccac tgttctctac cacattggg cygacattca agttttggcc agtagactca 17700
gagaggattc aggagtcaat gactgaggat gggactcctt gaaattttag gtccaattaa 17760

```

-continued

gectgcaaaa	tgttctctgt	ttcttctctc	agcaccatca	aacaggatga	ctttaccgct	17820	
cgtctctttg	acatccacaa	gcaagtccca	aaagagggca	tgcccagggt	aaccattccc	17880	
agccctactc	cagtctgtaa	cctgtccctc	ccatctctgt	ttgtttctg	ttttgcttga	17940	
agaatttggg	ccaggccctc	agctcatggg	aatctgcctc	tcaactggcc	tcaactgggt	18000	
tatcccagtg	accaattcta	ggatgaccag	aagaatgatt	ccactgggct	tgggagtgtt	18060	
tgctggtacc	tctaactctc	gtgtagagtt	catggtacct	gtgtgctctg	tggttaggtc	18120	
ctcagagtea	gtcccctggg	aggtactgtc	agccttcagt	tttccccaca	gactgtgttc	18180	
ctgggectga	atcgctcaga	ctacatgttc	cagcgcagcg	cagatggctc	cccagccctg	18240	
aaacagatcg	aaatcaaac	catctctgcc	agctttgggg	gcctgggctc	ccggacccca	18300	
gctgtgcacc	ggtgggtccc	ctgggcagcc	cccggcatac	ctgtgggggtg	acatgctgat	18360	
gggtgtacag	tcaactggta	ggccagggaa	ctccagctat	gattgtgctt	tcctgggccc	18420	
cgggtcacat	gttgccctg	gccaccocga	cagcagtttc	cacttgaat	gagatccttg	18480	
gtatgtcagg	gagaaaaagg	acctcatagc	tcactctagc	ctgtccctcc	attgtacagg	18540	
cagaggggaa	aatatcttga	gagccccaga	gagaggaatg	cagggaacttc	tgtctggggg	18600	
ctgggctctg	tagcatccat	ttctagccag	cagtgatgct	ccaggttga	atgattttag	18660	
atggtctgca	gcaggatccc	agacagcacc	tggaggccca	gagtaagggg	ctccagctca	18720	
ctgggacact	agggtagggt	gggggtggga	cagaggctct	caggtctctc	ccaggcatat	18780	
acaccagggg	ccaagggttag	ggcagcccag	catattocaa	cctgaagtgg	atcttacagg	18840	
aatgtgatgg	gaggatgctt	tttagtgctc	agctgattct	cagagtcag	ttgctgtata	18900	
tatgaggtea	tgggcagagg	ggtcttccag	gtccatccaa	ttactgaaca	gccatctctc	18960	
ttccaacaga	catgttctca	gtgtcctgag	taagaccaa	gaagctggca	agatcctctc	19020	
taataatccc	agcaagggac	tggccctggg	aattgccaaa	gcctgggagc	tctacggctc	19080	
acccaagtaa	gggtgtgaaa	aggtagcagg	aggatcctgc	tttagtttca	gcattcatgg	19140	
gtttagcaac	ttcttttctt	gccagccatc	attagagaat	aaggggattt	ttctaggaat	19200	
agaaacttat	acctttacat	gccaaaatta	ttttaagggt	tccttcttaa	ataacagatg	19260	
ctgactatga	tttaactttt	tcttattgag	tggagggtcat	cattatgact	gtcaacaatt	19320	
gcagcttctc	gtaatacag	agtgtacct	agggttagag	aggcacgcaa	ggctgtttgc	19380	
ctgcgcta	aat	agctctgact	gctaggcttt	aagttcttag	tcatttctct	tttttttttt	19440
ttttgagaca	gagtctcact	ctctcacc	ggctggagt	cagtggtaca	atcttgctt	19500	
acttcaacct	ccacctccc	ggttcaagca	attcttctgc	ctcagcctcc	tgagtactg	19560	
ggatttcagg	cgcatgctgc	cacacctggc	taatttttgt	attttttagta	gagacgggg	19620	
ttcccatgt	tggatcatgct	ggtctcgaac	tcctgaacctc	gtgatccgcc	caacctggcc	19680	
tcccaaatg	ctgggattac	aggcatgagc	cactgcaccc	ggcctctcat	tcattttctt	19740	
catagtttct	ttgtctgttt	cccattctc	agctcttact	ttgactgct	gttggtatgc	19800	
ttgaatttgg	aatcctccac	ccccatgcc	catgcctccc	ttctgatttg	ctgtggtttg	19860	
ggaaaacaaa	tgatccagat	tggtatgatt	gggtctgaag	agtgtagggg	cctcttgat	19920	
gagtaaatgc	ataagcttct	actacgaaat	tttatggtat	cctttttaa	tgcttagagg	19980	
cattttttgc	tttcttccca	tttctcaagt	gaagatgtta	ggtaagtgat	tttcagatca	20040	

-continued

tcgaggggcc	gctatactaa	cagttattgc	aatgttaata	tagcattaat	agtccttaat	20100
gtacacttac	tagtgetaca	ccttgtgcta	agctctgtac	atacaggatc	tcattgaatt	20160
ctcataataa	gctctctgag	gtcaactactg	ttcaactccc	tcattttaca	gatgaggaaa	20220
ctgaggttct	gagaaacgaa	gtgaattggt	aaggctaagt	gatgagtgg	tggcagatcc	20280
caaagtctac	ctccctctaa	aacctccact	cttaatcatg	ctcttacctc	caaggagacc	20340
tctctgtcct	tgtaagcct	cactaagccc	aaagaaacct	cagactgtaa	gcatttagaa	20400
gtcatcagac	aaatattctt	tcaagtatat	tggctagggt	gtattttaag	agagtgaagc	20460
caggggatgg	gtcagctggg	gaactgctga	cagacaaatg	ctgcagaggg	ttttgctctc	20520
cagcctgtca	gtaactgtga	cagaaaaatac	ttgtgtgtcc	aaaattaggc	actggtaggt	20580
aggagttagt	tggcacctga	gccagaactg	gcttccccca	ttgtgagagt	gagataggtt	20640
cttctgctga	catagcacat	gacctgggca	agttagtctt	tctctgagct	tcagtttcct	20700
catttgtaaa	ataggagtaa	taataatacc	taaaggggtg	ttagtgagaa	ttaaagaga	20760
tcattgatct	gaaaaatggt	tttaaaaatc	tgtgtggatc	attatgtggt	actttcaata	20820
ataataatag	gocgggtgca	gtggctcaca	cctctaatacc	cagcactttg	ggagaccgag	20880
gocgggtgat	catcagaggt	caggagtcca	aggccagcct	ggccaacatg	gtgaaacctt	20940
gtctctaata	aaaaatacaa	aaattagcca	ggcatggtgg	caggcacctg	tagtcccagc	21000
tacttgggat	gctgaggcag	gagaatcact	tgaacccggg	aggtggaagt	tgcagtggcc	21060
aagatcacc	cactgcactc	cagcctgggc	gacagagcga	gactccatct	caaaaaaaaa	21120
aaaaacaaaa	aacaaccca	aataataata	ataatagcta	tcatttgaca	agtattagtt	21180
ttaattcata	caacagcaaa	ctgaggctaa	gagagttaga	ataacttgcc	caaagttaca	21240
caaccggtaa	gtatagaatt	catctgcctc	taaagcctat	gttctctcta	cttccctatt	21300
ctgccttaa	gagatattgt	tccacagtat	tgactgaaaa	actgcattgg	tagagcagat	21360
taattttcgt	caattattct	atgattttta	aaatttctta	aaaatggaag	cctgcaaaat	21420
gacttacaat	ttcaatttag	acaaactctc	aaagcatagg	gectgtggtt	agaatgagta	21480
gaataagaaa	aggggactac	tggtgataaa	agtttgggaa	ctgtgatctt	ttaacacca	21540
atTTTTTct	TTTTTTTga	gacagagttt	cgTTTTTgt	gcccagctg	gagtgcattg	21600
gcacgatctc	ggctcactac	atcctccacc	ttccaggttc	aagggatTTT	cctgccttag	21660
cctcccaagt	aactgggatt	acagggtgcc	accaccacgc	ctggctaatt	ttgtattttt	21720
agtagaaaag	gggtttctcc	atgttggta	ggctggtctc	aaactcccga	cctcaggcaa	21780
tccgcccccc	tggcctctt	aaagtgtctg	gactataggc	gtgagctacc	atgcccagcc	21840
ataacactct	tattttatag	atgggaaaac	cagggcccaa	ggaacgaaat	tgcttacc	21900
aagtcaatta	ccaagacaca	ctacaagtca	ctggcagagc	ctggactacc	tacgactcag	21960
gggtctctac	ccccagccc	catgctctct	tagctgacaa	ctttctact	aggaaacaga	22020
ctgctgagaa	ctgctcagaa	ctgaaggcag	gagaggtcaa	atatgttttc	tgagcccagc	22080
tctgattggt	tagcagttgg	caggctgact	taattagctg	ggcgctgacg	tctctcttta	22140
acctccagct	gocagccttc	ctcctccgcc	tctttttgga	ggtgggcccag	cctgggccaa	22200
ctgcctcct	cccacacaca	ccctcacc	tgagcgggac	agtttaggct	gcaaagttaa	22260
gagcaaaagc	attggccctt	aggactctct	cagggcaaga	tgacttgtga	gagcaccact	22320

-continued

tttagtttgt	ctctcaggca	cccaactcaa	agccaagact	cagcttaaca	tcacatctga	22380
cctcatgaga	tttcaggcaa	accaggagag	gggacttact	aagacctata	ttttggctaa	22440
gcagaaagga	gtcaggcaaa	cagagtttag	actaagaggt	tcagccaagg	tcaggagaag	22500
cagagataga	caagagaggc	taagcagagg	aggtcaggga	atacacactt	agaatcctaa	22560
gccaagcct	agggttccat	gggtctcagg	aagaagccac	agacacaaag	cagtacagtc	22620
acagcaaaaa	tggagtttgg	aggctgagcg	cagtggctca	cacctgtaat	gctaacactt	22680
tgggaggccg	aggcgggag	atcacctgag	gtcaggagtt	cgagcccagc	ctggccaaca	22740
tgggtgaaacc	ccatctctac	tcaactaca	aaaattagcc	ggcgggggtg	gtgcacacct	22800
gaaatcccag	ctaccggga	ggctgaagca	ggagaatcgc	tggaaccag	ggggtggagg	22860
ttgcagtgag	cctagattgt	gccactgca	tccagcctgg	gcaacagggg	gagactccgt	22920
ctcaaaaaa	taataaaaa	aaaatgtaa	agaaaaaaa	tgcagtttgg	tactgctgag	22980
cattagccct	aggaatctct	taggggactg	gacctatctt	tgacaacgga	aatatgtag	23040
ctggcagcca	aacagatagt	tcctggcat	aagcttttcc	ctgagccctc	aagccctgc	23100
ctctttaaga	aatacatgaa	taatcagaga	ggaagaagcc	acataagccc	tagtgatctc	23160
attaacta	tgagatcaaa	tgtggccctg	tgtacattat	aggaatcttg	ggaggccca	23220
ggagataatg	tcgtgtttg	tagttggccc	tgtgggttcc	tgtagggttc	catcttgtgt	23280
aagaaccaca	ttcctttatt	gtatccttta	caatctagta	atagagccat	tagccccgga	23340
ccccctgcat	tgttctttta	caaatgttc	ctcaatactc	ccactgtttt	attcttcag	23400
aaagatttta	gaattatggt	aagttctaag	aaaaagtcct	cttgggtttt	tgagatggtt	23460
ttaaatctaa	attttaattt	gcacagaaat	tcacaaacce	atgacatcat	tacaatattt	23520
catctgcccc	ctggagaagg	gtcagaggca	tcttcatttt	tgaagttttc	tattttcagg	23580
aaatcatatg	tgatagcacc	agggtgtctat	gcctgaggta	atctcaaggt	tctgagaga	23640
gggaacatct	gttctttcag	ggaagcgggtg	ttcttattct	tattccagga	ggtggggcgg	23700
tatggggggt	gagggggaga	acaaaagaag	aacaagtctc	atagtagcct	cgggccacct	23760
gtgctctttc	cccagtgctc	tgggtgctact	gattgctcaa	gagaaggaaa	gaaacatatt	23820
tgaccagcgt	gccatagaga	atgagctact	ggccaggtaa	gtaaagggaag	ggggacttct	23880
agggtggtct	ccaggattag	gggtggggca	ctcagaacat	agcatccatt	ccctctggct	23940
cttgcccatt	tttcccagga	acatccatgt	gatccgacga	acatttgaag	atatctctga	24000
aaaggggtct	ctggaccaag	accgaaggct	gtttgtgtaa	gcattcccaa	gaatccagtg	24060
gaaggctggt	ttatgaaact	catcctgcca	ccctcttccc	caaatgatt	ctttctctg	24120
ggagatgtga	tggcttgctt	ccttctctca	taattctctga	aatatctcat	cctcccagga	24180
aattttggag	aaagccagcc	acgctgtgct	tctatcagag	ctggtgacat	tctggatcag	24240
ggctctctta	gagatcatct	tagttttcat	atgccctaag	ttccccaaaag	ttttcttgc	24300
tctctagta	aggtagagtc	aggcctgaga	agctgagctg	ggcagtcagg	gaggaagagg	24360
agcagctggc	tcagtctgtg	attggtctgg	atgccactgt	ctgagctcga	gcctggattt	24420
gtgttccaag	ccaagcctta	tccttttctc	taggggccac	caccaggtag	atttgggtct	24480
acatatttgg	gtagcattgc	agcacatata	tttagaccta	gacctttgtg	attgttaaaa	24540
ttaaaactgt	ccatggaatt	tcacaatacc	actcaactgtt	tttcaaatg	tgtttttatc	24600

-continued

ataactaac	aaagtagtta	atctactttt	cagataaact	agacaatate	aaataggtea	24660
aagaaaagga	aaagacattt	aaaaagcctg	tgtcttaate	agactcatca	ttttacatgt	24720
ttgcgttttc	accttcaccc	ctgccattaa	aaatTTTTTt	attctggttt	cagctgcttt	24780
aagcagtgga	aatataaagt	gtgttttact	acacatggca	gtatgattct	gctgctcggg	24840
aatttcgagc	caacatttgt	atgcatttac	caaatttgat	tctagtgacc	ttcttgttcc	24900
ttctggcctt	cttagaatga	ctctaaatct	ggcatattct	aaagtattct	gtatggcaca	24960
cctccctggt	ttcagtgaa	gccttggtag	tgtggatate	tactttcact	ggttccagtg	25020
aaccctgac	caggctccca	ctgtgggctg	aatTTTgaaa	aagccaaatt	catcttgatg	25080
cacctgaaa	tagattgaac	cactgaacaa	atcagttata	atTTaacaca	gcagccttct	25140
ccatcctgtg	ttccagggat	ggccaggaaa	ttgctgtggt	ttacttccgg	gatggctaca	25200
tgccctgca	gtacagteta	caggTtggtg	TTTTctgtga	gaccattctt	tgccctcctg	25260
gaccacaag	agctccacag	agaccaatt	caggcttata	acaacctggg	TTTTccgagt	25320
cctcacttca	cttctttctc	agggagcttg	ctgctagaac	ctcctatect	ccctcaagcc	25380
TTTTgtacc	tatcactcta	cacagtcttc	tagaatttga	atcctcagga	atccacagag	25440
cttcagccat	ttacactggt	ttccagagatg	tgctggcaaa	tgTTtaacaa	caatcagctc	25500
tcactggttg	atataagcca	gttccagcat	actgctgacc	atTTTTtttc	ctgccaaactc	25560
ttaccTTTcc	TTtatctgaa	tcagaaagt	ttatcatctc	ctcattcatg	TTaatgacag	25620
ttatatcacc	tcattttgct	atcctaccat	gtagtTtcat	tagTttccac	atccattatt	25680
tcattTaaacc	ctcacaaacca	ctcggTgagg	catataatta	ttccattat	acagatggag	25740
aaactaacgt	ttagagagat	ggagaggctt	ctctaaggcc	ctacaggaag	ttccaggtt	25800
ttctgacttt	caggccgatg	gtattcccat	tcttctctc	tgctctaac	atccacatca	25860
tggagaggct	aagaagctct	gctctcagct	gggagatgat	aaaggaggaa	ataagTttag	25920
aaatccoatg	ggcagtgagc	tggaggtcat	gagcttgact	gcctctgtgt	gatgatgggc	25980
aagTtctga	ccctttctag	gtctgtttct	atgagcgggg	ggagctacac	tagaaaaactg	26040
agggggctcc	ttctaggtct	gtaattcact	taggactccc	cccaggggt	gagctccaca	26100
tgaggaggct	ctatagaggt	ggTatctcga	tagaacatcc	TTTTcttag	ataggtggtt	26160
agcagTggtg	gcaacttgct	gactacagga	gagataaact	gtctattaga	aaaataggTc	26220
taggccgggc	acggTggttc	acgcctataa	tcccagcact	ttgggaggcc	aaggcaggtg	26280
gattacctga	ggtcaggagt	tcaagaccag	cctggccaac	atggtgaaac	cccgtctcta	26340
ctaaaaatac	aaaaattagc	cgggcgtggt	ggcatacccc	tgtaatccca	gctactcagg	26400
acgctgaggc	aggagaattg	cttgagcccg	ggaggcagag	gttgagTaa	gTtgagatca	26460
tgccactgca	ctccagcctg	gctgacagag	cgagactctg	tctcaaaaa	aaaaaaaaaga	26520
aatgggteta	gatttcaaaa	cacgacaaa	aaaacttaga	agagTttgag	ataacaagga	26580
aggaaagtag	tgTTtaaa	ggtagacttt	TTTTTTTTTt	tgagacagag	TTTTgctctt	26640
gTtgaccagg	ctggagtaca	gtggtgogat	ctcggctcac	tgcaaccttt	gacttccagt	26700
ttcaagcgat	tctcctgct	cggcctcctg	agtagctggg	attacaggca	cccaccacca	26760
caccagcta	atTTTTgtat	TTttaataga	gacagggTtt	caccatgttg	gccaggtg	26820
tctcgaactc	ctgaccttac	gatccacca	ccttggcctc	ccaaagtgct	gggattacag	26880

-continued

gtgtagcca ccacacctgg ccaagggtta gacattttta gggaaactgag cagctcagag	26940
caggtttaga catggagaga gatctagaag gcttagtgac ttactagatg accctgggca	27000
agtccttgct tatccttggg tttgctttcc tgcttctacc ataatggggg atttctctgg	27060
gtttatttct gatgttctg tcaogtgtga ttctgctggg aatgccagac tagtagttgg	27120
gttctcgggg ttattgatga agatcaggtc aagggtctac aggtggacca gtagtataca	27180
aggaaggaca gcattgggtg ggggtcacag gagagacctg atcctgctgt gtgcagtttg	27240
cagtggctcg gagccaagga cagactgtct ccccatgca tgagaatggg aaccagagtt	27300
gggaggcatg atccccctgt gtttctctgc cttttatacc ctgactctt gtggaataa	27360
accattcctc ctgtgatcat ccacttgaga cctgtgttca tattattctc ttagcctgag	27420
tatcccttcc ctattgagtc tcaactgtca ggctctacct gtccttcaga accccactca	27480
aatttcaact tattcagcaa caacaacaaa tatttattga gcaactaca agtgccagga	27540
actgtgttag acactggaga tacaacagaa aatgaggaaa atgataagag ccctgtgcta	27600
tggagctcac agtctgttca gagaaatggg catcagaaag taacacaaaa tatggccatt	27660
tactgtggct cgtacctgta atcccagcac tttgggaggc ctaggtaggt ggattgcatg	27720
agctcaggag ttcaagacca gcctgggcaa catggcaaaa ccccatctct acaataata	27780
caaaaattag ctgggtgtg tggcgtgcac ctgtagtccc agctacttg gaggtgagg	27840
agggagatc acttgagccc aggaggtaga agttgcagtg agccaagatt gcgctgttc	27900
actccagctc ggggtacaga gcaagaccca cgtctcaaaa gaaaaaaaa gtaaacaaaa	27960
ataggaaaa aaaattggga tttgtgtgtg tatgtttgtg tgctgtgctg tgtatgtgtg	28020
catgtgtgtg ttttagtctc aggtaactgc tttcaatgaa acaactgggt aaaaagagaa	28080
ttatgggaaa tccacattaa atagagtgga cagggaagcc ttctctgaaa aggtgacatt	28140
gagctgagat gtaaggatgg taaggatcca gctatgcatg ggaaaagccg aaaggaaggg	28200
ggtttcaggt tgagggaaaa gcagtgacag ccctgaggag gaaagagct ttgtgatttg	28260
aggaatgaca ggcctgtgtg agtagaatgg cagagactag gagtcaggga tggtaacagg	28320
ttgaaaaagt agacaggagc cagctcctga aggatcttga aggccatggt agggagtatg	28380
gaacacagtg ggaagctgag cactgtagaca aatgttctac ccttacacct tctattgttt	28440
cccacagatt ggggattctc tgcccttgca ggggtcaca gtctggcaca atgatacata	28500
actacaacat atcacacctg gctcacaagg atgttagaat gatcctgggt gataatgagg	28560
gtgaagatac aaatcatgat acctggcacc taatggatgg atgttcagta aacgtcagct	28620
gaagtaaaat aaagtcgaat tccttttgtc ttcttccctc tgcagaattg ggaagcagct	28680
ctactgctgg agaggtcaca tgctgccaag tgcccagaca ttgccacca gctggctggg	28740
actaagaagg tgcagcagga gctaagcagg ccgggcatgc tggagatgtt gctccctgpc	28800
cagcctgagg ctgtggcccg cctccgccc acctttgctg gctctactc actggatgtg	28860
gtactgtggc agcctgttcc tctaccaca ggcctcctag gtggcagaga cctacagccc	28920
aatgtgttgg ggaggggtga gctggcattg tgacaagggg aagggtggagc tggcaaggtt	28980
ggtgatgctc tggagaacct ctagaactct gagcagaagg gcagcctcat aatggaagga	29040
tggggcttgg aatccattgt aagctccctc agcaaaggta gagatgagga tggcaaccag	29100
aggaagggga ctaaggcagg tggcaagaat tgagaagtgt atcaggctgc ctgctgcaga	29160

- continued

gccttgagct gttgctaaag aaaggcctgt tctcattgca teggetgctg cagggggttt	29220
gttgggagtg tcatccagat agtagcatcc tgcctgaagg aatttgtggc tgttctccct	29280
cctgctcttc ctctgatgct gctctgcata accagctgga cctaagcttc ttgcctcttt	29340
agcctttaa cttttgataa ctgctttctg cctcctgcca gggggaagaa ggggaccagg	29400
ccatcgccga ggccttgct gcccctagcc ggtttgctct aaagccccag agagagggtg	29460
gaggtaggtg gatctccct tgcagggtc ctcaatgaga gggactagca ggctgtggcc	29520
agtgtcatt ggcacttact ctgggcacag tcccgggcat gggggaaact attggaactg	29580
acacaggcca catgttgagc agtgtcccct aagaccctgt gaccaagtc gggagcacag	29640
gggaatcga ttaaccagca ttgaagggtt tggacaagtt ttacctgagg tgctgtggg	29700
tagattgttg ggaagtagag tagggcata ttaggagact ggagagaata catgtctgtt	29760
ttcctttcta gtttgaaact ccttgaggtc aggggtcatg tctgctctc cagaggagag	29820
gattttttta atctttgtct taagaggtgg gttagaatth cccaggtgga aaggaggaag	29880
agtgttccat acaaaaggga caacctcaag ccaaggcacc gggccatgaa agtgtgagat	29940
gtttggaggt taatgagaaa ctggtgaggc tggaggggga gctgggaggg gacagggatt	30000
tagctgga aatgggttg catcctgatt ataagggcc ttgaatatat actgagaaat	30060
tggatthtat cttaaggcca gtgggaagcc attagggagt tttaagccag gaaggacac	30120
attgatccag gactcaagtg gttagcagtg gtgggaact gcaaaactta cagtttctgc	30180
attgtagaag atgtcctgga atgaggggag aactggaag cagaaagacc gtggaagagg	30240
ctgatacagt tgttcagaag agcaacgtag aggcctgggc tagggctatg actatggggc	30300
caactggaga gacatgtcct agatagtgag agggtagtgg aaggaggag ttaaatatga	30360
ctcaggggta ccttttgctt gattgggagt aggaaggtcc aggaggggca ggttcaggca	30420
gaagtaataa gttctgcttg gacaagttga gtttgtttg gggccagtc tatgatgtct	30480
aagcagggag cctgcattaa atatttgaa gttacaact ttttttttt ttttgagacg	30540
gattctcctc ctgtcaccag gctggagtg agtggcatga tcttggtca ctgcaaccac	30600
tgcctcccag gttcaagcga ttctcctgcc tcagcctcct gactagctgg gactacaggt	30660
gtgcccacc acaccagct aatttttgta tttttagtag agatggggtt tcatcatatt	30720
ggccaggatg gtctcaatct cttgacctca tgatctgctt gcctcgccct cccaaagtgc	30780
tgggattaca ggcgtgagcc accatgccc gcccgaagtt aacaattttt agggataga	30840
tggagactca ggaataggag agatctcctt gggaaaatgt acatggggga gagagcaagc	30900
gtggaggacc aattcccctg ggaccccagc atttaagaga aggagccagc aatggagctt	30960
gagaaggaac agctgtaggt aggaggagaa ccagggcaga acagttagt ggaagatgtg	31020
ttcactgcat gagtaaggcc tctcctgca aagttagctt cctcctgag aagccagata	31080
tgcctggct tcaactgagc ggtgcccagga actgaggctg ctgacttgcc catgtggccc	31140
caaaagtgag ggcattggat ggaggaggta ggcagaggtt ccagggtgac tggccagttt	31200
cattgcaggt acaaacctat atggggagga aatggtacag gccctgaaac agctgaagga	31260
cagtgaggag agggcctcct acatcctcat ggagaagatc gaacctgagc cttttgagaa	31320
ttgctgcta cggcctgcca gccctgccc agtgggtccag tgcatttcag agctgggcat	31380
ctttggggtc tatgtcaggt gagccaatca ggagaagctc tttccactac ctgcttgcaa	31440

-continued

gagtgccagc caagtgagcc agcctagagg ggaacactgg aaagagtacg gaatcctggg	31500
cttcggtgcc agctctgcca atcactagct ttattacctg tttctttatc tattaatga	31560
ggccaaggac ccaagacctg cccaccttac cagggatca gatgaagccc tgatgagaag	31620
tcctttgcaa ccgtgaagga aactccaaat agcaccaaga ggactcagaa cacatggttt	31680
gacaacctag gactagaagg agactccaga gaggcataga gactctaaaa tcctagcact	31740
ttcttggtat agacagttac ccaggtactg ctcagctggg tccagggaaag gtctctgggt	31800
tggggctgag tccaggatgat gtgtgtcccc tgcctccatt tctataggca ggaaaagaca	31860
ctcgtgatga acaagcacgt ggggcatcta cttcgaacca aagccatcga gcatgcagat	31920
ggtggtgtgg cagcgggagt ggcagtcctg gacaacccat accctgtgtg agggcacaac	31980
caggccacgg gaccttctat cctctgtatt tgcattcct ctccctagccc tctgagggg	32040
tatcctccta aagacctcca aagtttttat ggaagggtaa atactggtag cttccccag	32100
ctttccatct gaggaccaga aaagttgtgt ctcccttaga tgagatctag acgccccaa	32160
atccttgaga tgtgggtata gctcagggta agctgctctg aggtaaaggt ccatgaaccc	32220
tgccccactc ctgtcagccc ctcatcagcc ttttcagcag gttccagtgc ctgacttggg	32280
ataggactga gtggtaggag gagggggagt ggaggggcat agcctttccc taattctgcc	32340
ttaataaaaa ctgcattgtct gattcagtga tgattcctta cttcgtgcat agaggggagg	32400
cgggagctgt aatctacgtt agcccactta agatgtatta gagcagggaa gtgactggtc	32460
tgtaatcagg gtccccctag accagtctct acaggtggaa cccctgaagtt tcaatcctta	32520
gcccccactc aatgctctta ctggatcaca gggaggaatg agagtccctg gcaggagccc	32580
aggagggaaag gcaaccaaga tgggacatac ataacagttg tgaactggct tcagtcaact	32640
tctgcttag ctacggggct tgtcaaaggc cctgtcagtg aagcctcctt cgctctgccc	32700
aaacccaaag ttctagaagg aagatattgg ggatagtcct aggaaatacc cctcccttc	32760
catctgccac acaaatcaga gccactaatg aatatacagc ctcagggcac agatacctaa	32820
gaaaaaagtc caccactctt tgagatcaca ggctttatc ctacaaccac agggcttgag	32880
cctgactggg gcaagaaaac agagtttcat ctgagaatgt ctcttatggg ctgggtctg	32940
ttcaggggag ggtgggaaca gaggacaagg aagacaagct cctctggccc taggaacaaa	33000
acacatttac tcctcaaag aagcagatga tctgaatacc ctctggagac tgaatctgcc	33060
catacagccc ctggagccaa tgggcagaca gtactggcat ctggcacaaa agggaattca	33120
gaccagaac agaagcagca aaatatttta aaaatagtaa attgttctct gactcacaaa	33180
tcattgtttt taagggcaag tgcctgccc atataagtagc tggggcttcc taagagagct	33240
gacataggat tacacagctg cctccctgct tcagtgaggg cctccatc ccctttgaac	33300
acttaacttg ggtaggagag gttagccttt cgtctctggt ctgggttctg agagctctgc	33360
agtctggagg cacagcagac tgaggctgac ctgggcccctg tctttctgc ctggcagtea	33420
caggatgttg tctctacctg gagacaaaagc tggtttccgg tcccagacag ctggccaagg	33480
gagggtagtg tgggtcaaca ctggcccctca gcactcctga gggggcaaaag aggatgggca	33540
aagtttgagg caggaggaat cctaggtaaa ggtcaggatc atgttcaactg gatggtcagg	33600
cagcgggtgc tgaagaggtg actgatgaca gatgggtcag ccacagtaga catgtcccgc	33660
aggtcatggt cattctgagc aatcttccga agcactcgcc tcatgatttt cctggggaa	33720

-continued

```

ccacagacct ctagtactt ggtgaaagca ctgacceacc ctagecctgc caaaggcttt 33780
catccacgca caccaccaca ccaccaggcc tcagcccatc ccaatccatg gaggcctctg 33840
aacatacctg agcgggtttt aggcaagcca ggtgcattct ggatgtagtc tgggtggca 33900
atggggccaa tcttttctct aactgtaacc aacaaatcat caagcatttc ttcagcacc 33960
ttagccagac ttttcaaaaa tcaaagtaga gatggctttg ttccccacct gtttctctct 34020
caagtcctctg cccacagaga cagcctcagg ttcactgctt ctcttgctct caacacactt 34080
gtctctttac tctctcattt tatcttatgg aactcaggct gtagaatgag cctgctagag 34140
tttaaatgcc acctttctag cagtgtggcc ttgggcaagt gatttaactt ccatgagtct 34200
cagtttcate atcttttagca tgaaggtaac aataagatct gtttcatgga ggtgactcta 34260
gggattaagt ggggtaattc atttaaagca cttagcctag cgggtggcaca aagtattcta 34320
gaaatgttgg ctattattat taccctagtg ggagactagt ggagac 34366

```

```

<210> SEQ ID NO 15
<211> LENGTH: 1889
<212> TYPE: DNA
<213> ORGANISM: mouse

```

```

<400> SEQUENCE: 15

```

```

ccccagcgtc cgcagctgga caacgagcga gttgggatgg ctaccagctg gggcagcatc 60
ttgcaggatg agaagcagct ggaagaactg gcaaagcagg ccatagaccg ggccttgccc 120
gagggcggtg tgctgaggtc cgcacagcat cccagctcct ccgacgtggt gacatagccc 180
ccattcaagc ttttcccctc gccagtaccg agtgctctgc tggagcaggc ctatgctgtg 240
cagatggact tcaacatact ggtggatgct gtcagccaga acccagcctt cctggagcaa 300
acactgtcta gcaccatcaa aaaggacgac tatactgccc gtctctttga tatctacaaa 360
caagtctcta aagagggcat tgcccagacc gtgttctctg gctgaatcg ctcagattac 420
atgttccagt ggggcgcaga cggctccaaa gccctgaaac agatcgagat caacactatc 480
tctgccagct ttgggggctt ggcctcccgg actccagctg tgcaccgaca cgttctcaat 540
gtcctgaata agaccaaaag agcttccaag atcctgtcca ataaccaccg caagggactg 600
gccctgggga tcgccaaagc ctgggagctc tatggctcag ctaatgcggt ggtgctactg 660
attgctcaag agaaggaaag gaacatattt gaccagcgtg ccgtagagaa cgagctgcta 720
gacaggaaga tccatgtcat ccgtggaaga tttgaagatg tctctgaaa gggttctctg 780
gacaaaacc gaagctggtt tatggatgac caggaagtgt ctgtggtgta cttccgagat 840
ggctacatgc ccagtcagta taattcacag aactgggaag cagcctgat gctagagaga 900
tctcgtgctg ccaagtgtcc agacattgcc atacagctgg ctgggactaa gaaggtgcag 960
caggaactga gcaggggtgg tctgctgtaa gcactgctcc cgggccagcc cgagctgtg 1020
gcccgcctcc gagccacctt tgctggcctc tattcaactg acatgggtga agaaggggac 1080
cagggcattg ctgaggccct tgctgctcct agccactttg tgctgaagcc ccagagagag 1140
ggtggaggta acaacttata cggggaagaa atggtacaag ctctggagca gctgaaggac 1200
agtgaggaga gagcctccta catcctcatg gagaagattg aacctgagcc ttttaggaat 1260
tgcttcttac ggctggcag cctgcacca gtggtccagt gtatctcgga gctgggtatt 1320
tttgagtct atgtcagaca gggaacaaca ctggtgatga acaagcatgt ggggcacctg 1380

```

-continued

```

cttcgaacca aagcctggga gcatgcagac ggaggtgtgg eggcaggagt ggcagtcctg 1440
gacaaccctt accctgtgtg aaggcgcct ctggacttca ctcaggaggc cttctatccc 1500
ctgtacttgg cactcctctt ctgaggggtt gccctgtcc ctatcttagg ggagcttgtc 1560
tcttccatag acotccaaaa cttcagggaa gggaaaacc aggtatctt ccctcagcag 1620
ccttccagcc gaggaccaga aaagctatga ttccattaga agacttctgg aggtcccccag 1680
atctttggag tgtgggaatg gaagctgctt tgaggcaaag gctcataaac cctgcaagtc 1740
ttcatggtct tctcaccagc ctttccagca ggttctagtg ccttgacctg gggtaggacc 1800
gagtgaagga ggaaggggtt aaaagggcac agacttcccc agctctgccc taaataaaat 1860
aacaatgctg attcaaaaa aaaaaaaaa 1889

```

```

<210> SEQ ID NO 16
<211> LENGTH: 474
<212> TYPE: PRT
<213> ORGANISM: mouse

```

```

<400> SEQUENCE: 16

```

```

Met Ala Thr Ser Trp Gly Ser Ile Leu Gln Asp Glu Lys Gln Leu Glu
1          5          10          15
Glu Leu Ala Lys Gln Ala Ile Asp Arg Ala Leu Ala Glu Gly Val Leu
20          25          30
Leu Arg Ser Ala Gln His Pro Ser Ser Ser Asp Val Val Thr Tyr Ala
35          40          45
Pro Phe Thr Leu Phe Pro Ser Pro Val Pro Ser Ala Leu Leu Glu Gln
50          55          60
Ala Tyr Ala Val Gln Met Asp Phe Asn Ile Leu Val Asp Ala Val Ser
65          70          75          80
Gln Asn Pro Ala Phe Leu Glu Gln Thr Leu Ser Ser Thr Ile Lys Lys
85          90          95
Asp Asp Tyr Thr Ala Arg Leu Phe Asp Ile Tyr Lys Gln Val Leu Lys
100         105         110
Glu Gly Ile Ala Gln Thr Val Phe Leu Gly Leu Asn Arg Ser Asp Tyr
115         120         125
Met Phe Gln Cys Gly Ala Asp Gly Ser Lys Ala Leu Lys Gln Ile Glu
130         135         140
Ile Asn Thr Ile Ser Ala Ser Phe Gly Gly Leu Ala Ser Arg Thr Pro
145         150         155         160
Ala Val His Arg His Val Leu Asn Val Leu Asn Lys Thr Lys Glu Ala
165         170         175
Ser Lys Ile Leu Ser Asn Asn Pro Ser Lys Gly Leu Ala Leu Gly Ile
180         185         190
Ala Lys Ala Trp Glu Leu Tyr Gly Ser Ala Asn Ala Val Val Leu Leu
195         200         205
Ile Ala Gln Glu Lys Glu Arg Asn Ile Phe Asp Gln Arg Ala Val Glu
210         215         220
Asn Glu Leu Leu Asp Arg Lys Ile His Val Ile Arg Gly Arg Phe Glu
225         230         235         240
Asp Val Ser Glu Arg Gly Ser Leu Asp Gln Asn Arg Arg Leu Phe Met
245         250         255
Asp Asp Gln Glu Val Ala Val Val Tyr Phe Arg Asp Gly Tyr Met Pro
260         265         270

```

-continued

Ser Gln Tyr Asn Ser Gln Asn Trp Glu Ala Arg Leu Met Leu Glu Arg
 275 280 285
 Ser Arg Ala Ala Lys Cys Pro Asp Ile Ala Ile Gln Leu Ala Gly Thr
 290 295 300
 Lys Lys Val Gln Gln Glu Leu Ser Arg Val Gly Leu Leu Glu Ala Leu
 305 310 315 320
 Leu Pro Gly Gln Pro Glu Ala Val Ala Arg Leu Arg Ala Thr Phe Ala
 325 330 335
 Gly Leu Tyr Ser Leu Asp Met Gly Glu Glu Gly Asp Gln Ala Ile Ala
 340 345 350
 Glu Ala Leu Ala Ala Pro Ser His Phe Val Leu Lys Pro Gln Arg Glu
 355 360 365
 Gly Gly Gly Asn Asn Leu Tyr Gly Glu Glu Met Val Gln Ala Leu Glu
 370 375 380
 Gln Leu Lys Asp Ser Glu Glu Arg Ala Ser Tyr Ile Leu Met Glu Lys
 385 390 395 400
 Ile Glu Pro Glu Pro Phe Arg Asn Cys Leu Leu Arg Pro Gly Ser Pro
 405 410 415
 Ala Gln Val Val Gln Cys Ile Ser Glu Leu Gly Ile Phe Gly Val Tyr
 420 425 430
 Val Arg Gln Gly Thr Thr Leu Val Met Asn Lys His Val Gly His Leu
 435 440 445
 Leu Arg Thr Lys Ala Val Glu His Ala Asp Gly Gly Val Ala Ala Gly
 450 455 460
 Val Ala Val Leu Asp Asn Pro Tyr Pro Val
 465 470

1. A method for producing induced pluripotent stem cells generated from aged donors (A-iPSCs) from mammalian non-pluripotent cells, the method comprising: supplementing non-pluripotent cells prior to the initiation of reprogramming, during reprogramming, and/or after reprogramming of the non-pluripotent cells with an effective amount of at least one of: (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter 3 (GLUT3); and (iii) an exosome subunit, thereby producing A-iPSCs with at least one of DNA damage response, apoptosis response, glucose metabolism, and genomic stability levels approximating those of induced pluripotent stem cells from young donors (Y-iPSCs).

2. The method of claim 1, further comprising reducing expression of A-iPSC glutathione peroxidase 2 (GPX2) or glutathione synthase (GSS) by at least one of the following:

supplementing the A-iPSC with an effective amount of ZSCAN10; and/or

supplementing the A-iPSC with an effective amount of GLUT3; and

supplementing the A-iPSC with an effective amount of the exosome subunit,

thereby rescuing one or more of DNA damage response, apoptosis, and genomic stability in the A-iPSC.

3. The method of claim 1, wherein the supplementation: is carried out by adding ZSCAN10 and/or GLUT3 and/or an exosome subunit to a culture medium in which the A-iPSC are maintained;

is carried out by increasing the expression of ZSCAN10, and/or GLUT3, and/or an exosome subunit in the A-iPSCs;

is carried out by increasing the expression of ZSCAN10, and/or GLUT3, and/or an exosome subunit in the A-iPSCs, wherein the expression of ZSCAN10, and/or GLUT3, and/or an exosome subunit in the A-iPSCs is increased by transfecting the A-iPSCs with a vector harboring a nucleic acid sequence encoding the ZSCAN10, and/or GLUT3, and/or an exosome subunit;

is carried out by increasing the expression of ZSCAN10, wherein the expression of ZSCAN10 is increased by transfecting the A-iPSCs with a vector harboring nucleic acid sequence encoding the ZSCAN10, wherein expression of the nucleic acid sequence encoding ZSCAN10 is transient;

is sufficient to restore ZSCAN10, and/or GLUT3, and/or exosome subunit levels in the A-iPSCs to about 50% or more of the respective levels of embryonic stem cells (ESCs);

is sufficient to reduce oxidation capacity of glutathione in the A-iPSCs to about 80% to about 120% of that of ESCs;

is sufficient to restore genomic stability of the A-iPSCs to approximately that of Y-iPSCs;

is sufficient to restore apoptosis rate of the A-iPSCs to approximately that of Y-iPSCs;

is sufficient to restore DNA damage response of the A-iPSCs to approximately that of Y-iPSCs;

is sufficient to reduce oxidation capacity of glutathione in the A-iPSCs to approximately that of Y-iPSCs; and/or is sufficient to reduce GPX2 levels in the A-iPSCs to approximately those of Y-iPSCs.

4.-7. (canceled)

8. The method of claim 3, wherein the genomic stability is measured by incidence of aneuploid clones; the apoptosis rate is measured by DNA fragmentation assay in response to a DNA damaging agent and the DNA damage response is measured by ATM or H2AX phosphorylation in response to a DNA damaging agent.

9.-18. (canceled)

19. A method for reducing the oncogenic potential of induced pluripotent stem cells (iPSCs) or A-iPSCs, the cells having one or more of genomic instability, a defect in apoptosis, a defect in DNA damage response, and a defect in glucose metabolism, and exhibiting excessive glutathione-mediated H₂O₂ scavenging activity compared to embryonic stem cells (ESCs) or induced pluripotent stem cells from young donors (Y-iPSCs), the method comprising:

- (a) supplementing iPSCs or A-iPSCs with at least one of (i) pluripotency factor ZSCAN10; (ii) pluripotent stem cell-specific glucose transporter GLUT3; and (iii) an exosome subunit, each as an adjunct to reprogramming to substantially restore the at least one of DNA damage response, apoptosis response, glucose metabolism and genomic stability to levels substantially the same as those of Y-iPSC or ESC; and/or
- (b) inhibiting glutathione-mediated H₂O₂ scavenging activity in the iPSCs or A-iPSCs to partially or totally restore homeostasis in the iPSCs or A-iPSCs by directly and/or indirectly inhibiting excessive expression of glutathione peroxidase 2 (GPX2) in the iPSCs or A-iPSCs.

20. The method of claim 19, wherein the supplementation:

- is carried out by adding ZSCAN10, and/or GLUT3, and/or an exosome subunit to a culture medium in which the iPSCs or A-iPSCs are maintained;
- is carried out by increasing the expression of ZSCAN10, and/or GLUT3, and/or exosome subunit expression in the iPSCs or A-iPSCs;
- is sufficient to restore ZSCAN10, and/or GLUT3, and/or exosome subunit levels in the iPSCs or A-iPSCs to about 50% or more of the respective levels of embryonic stem cells (ESCs);
- is sufficient to reduce oxidation capacity of glutathione in the iPSCs or A-iPSCs to about 80% to about 120% of that of ESCs;
- is sufficient to restore genomic stability of the iPSCs or A-iPSCs to approximately that of Y-iPSCs;
- is sufficient to restore apoptosis rate of the iPSCs or A-iPSCs to approximately that of Y-iPSCs; and/or
- is sufficient to restore DNA damage response of the iPSCs or A-iPSCs to approximately that of Y-iPSCs.

21.-24. (canceled)

25. The method of claim 20, wherein the genomic stability is measured by incidence of aneuploid clones; the apoptosis rate is measured by DNA fragmentation assay in response to a DNA damaging agent; and the DNA damage response is measured by ATM or H2AX phosphorylation in response to a DNA damaging agent.

26.-28. (canceled)

29. The method of claim 1, wherein the reprogramming of the non-pluripotent cells is carried out with Yamanaka factors OCT4, SOX2, KLF4, and MYC.

30.-31. (canceled)

32. The method of claim 1, wherein the reprogramming of the non-pluripotent cells is carried out with pluripotency factors selected from the group of those of Yamanaka wherein one or more of OCT4, SOX2, KLF4 and MYC are replaced as follows: Nanog and Lin28 replace Klf4 and MYC; esrb replaces Klf4; SV40 LT (T) replaces Klf4, MYC lin28 and Nanog; BIX-01294 replaces SOX2, OCT4; VPA replaces Klf4 and MYC.

33. The method of claim 1, wherein the supplementation is with an exosome subunit, the exosome subunit being one or more of the following EXOSC1, EXOSC2, EXOSC3, EXOSC4, EXOSC5, EXOSC6, EXOSC7, EXOSC8, EXOSC9, EXOSC10, and hDis3.

34. (canceled)

35. An iPSC derived from a somatic cell of an aged donor where the iPSC has been engineered to express ZSCAN10 at levels comparable to an iPSC derived from a healthy young donor (Y-iPSC) or an embryonic stem cell (ESC).

36. The iPSC of claim 35, wherein the iPSC originally displayed one or more of (i) reduced ZSCAN 10 expression level, (ii) increased oncogenic potential, (iii) reduced GLUT3 expression level; (iv) reduced exosome subunit level; and (v) increased GPX2 or increased GSS expression level, compared to a Y-iPSC or ESC control, wherein the iPSC has been supplemented with ZSCAN10 to restore the one or more reduced or increased levels to levels comparable to those encountered in the control.

37. The iPSC of claim 35, wherein the iPSC in the absence of ZSCAN10 supplementation would be deficient in ZSCAN10 expression, expressing either no ZSCAN10 or a level of ZSCAN 10 substantially lower than that of a control iPSC derived from a healthy young donor (Y-iPSC) or embryo (ESC).

38.-39. (canceled)

40. The method of claim 1, wherein the mammalian non-pluripotent cells are somatic cells.

41. An A-iPSC produced by the method of claim 1, wherein the A-iPSC expresses ZSCAN10 at levels comparable to a Y-iPSC.

42. An A-iPSC produced by the method of claim 1, wherein the A-iPSC is characterized by ZSCAN10 expression levels, oncogenic potential, GLUT3 expression levels, exosome subunit levels, GPX2 expression levels, and/or GSS expression levels comparable to those of a control Y-iPSC or embryonic stem cell (ESC).

43. An iPSC or A-iPSC produced by the method of claim 19, wherein the iPSC or A-iPSC exhibits one or more of the following:

- decreased GPX2 expression;
- increased ZSCAN10 expression;
- increased GLUT3 expression; and
- increased exosome subunit expression;

relative to an untreated control iPSC or A-iPSC.

* * * * *